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Chapter 1 
General introduction 
Rhesus (Rh) is the most complex of the blood group systems. In this gen-
eral introduction several aspects of Rh are described. The immunogenicity 
is responsible for its discovery and establishes its clinical importance. Sub-
sequently the following characteristics of the Rh complex are described: the 
molecular basis of the Rh blood group system, the membrane organisation 
of the Rh proteins, Rh-complex formation, association of the Rh complex 
to the membrane skeleton, and the development and distribution of the Rh 
polypeptides. With regard to this thesis, much emphasis is given to the 
variation in expression of Rh. This variation in expression of Rh is not only 
between the different phenotypes (qualitative versus quantitative), but also 
between ethnic groups (prevalence of certain phenotypes). To understand 
the development of a protein like Rh, processing from DNA to membrane 
protein is described. And a transfection model, mimicking the RBC, was 
used to follow this process. Insight in the function of Rh proteins might 
also be informative for the complexity of the Rh blood group system (and 
vice versa). 
1.1 Immunogenicity 
The Rh blood group was discovered in 1939 because of its high immuno-
genicity. At that time, Levine and Stetson (Levine et al., 1939) inves-
tigated a haemolytic reaction resulting from the transfusion of a woman 
with blood from her husband, after she had given birth to a stillborn baby. 
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An antibody in the mother's serum agglutinated her husband's red blood 
cells (RBCs) and those of 80% of ABO-compatible blood donors. Levine 
and Stetson showed that this new antigen, which they did not name, was 
independent of the then known blood groups ABO, MN and P. They sug-
gested that the mother had been immunised by a foetal antigen of paternal 
origin, and that the haemolytic episode was caused by a maternal anti-
body reacting with that antigen on the transfused husband's RBCs. One 
year later, Wiener and Peters (Wiener et al., 1940) were able to identify 
the same antibody in the serum of individuals showing transfusion reac-
tions after receiving ABO-compatible blood transfusions. In 1941, Levine 
et al. reported that the antibody responsible for this reaction had the same 
specificity as the antibody obtained by Landsteiner and Wiener (Land-
steiner et al., 1940) after injecting rabbits and guinea pigs with RBCs of 
rhesus monkeys. However, in the course of further investigations, it be-
came obvious that the human antibodies responsible for the haemolytic 
disease of the newborn and the 'anti-rhesus' antibody produced in animals 
by Landsteiner and Wiener recognise different antigens (Fisk et al., 1942). 
Therefore, the term anti-Rh was chosen to designate the clinically signifi-
cant human alloantibody RhD, whereas the hetero-antibody was renamed 
anti- 'LW', in honour of its discoverers Landsteiner and Wiener. The other 
major antigens of the Rh system (C, c, E and e) were discovered shortly 
afterwards (Race et al., 1944), (Fisher, 1944). 
More than 45 different Rh antigens have been described till now, but 
very few are of clinical importance. The major Rh antigen is RhD. Depend-
ing on the presence or absence of this antigen, human RBCs are divided into 
RhD-positive or RhD-negative cells. After the ABO blood group system, 
RhD is the most important RBC antigen (Mollison et al., 1997). Eighty 
percent of RhD-negative individuals who receive RhD-positive blood will 
produce anti-D antibodies after their first blood transfusion (Pollack et al., 
1971), (Urbaniak et al., 1981). Only 7 to 8% of the RhD-negative individ-
uals remain complete non-responders (Issitt, 1994). RhD antibodies can 
cause haemolytic transfusion reactions, autoimmune haemolytic anaemia 
and, despite the introduction of anti-D prophylaxis in 1969 (in the Nether-
lands), anti-D is still the major cause of haemolytic disease of the newborn 
(HDN). 
Rhc is clinically the most important Rh antigen after RhD. Between 
1.1. IMMUNOGENICITY 3 
14 and 21 % of Rhc-positive babies born to women with anti-c required 
exchange transfusion (Astrup et al., 1977), (Hardy et al., 1981), (Kozlowski 
et al., 1995). Anti-C, -E, -e and -G can all cause HDN, but the occurrence 
is rare and the outcome seldom severe (Mollison et al., 1997). 
1.1.1 Haemolytic disease of the newborn 
In the Netherlands, maternal antibodies against foetal RBCs threaten the 
infant's health in about 200 cases per year, of which 170 cases are due 
to RhD antagonism (Klumper et al., 2000). Maternal antibodies may be 
produced after exposure to an antigen that is not present on maternal 
RBCs, e.g. by foetal-maternal transfusion, after blood transfusion or after 
organ transplantation. In the foetus, RBCs covered by maternal antibodies 
will be degraded, mainly extravascularly by phagocytosis and antibody-
dependent cellular cytotoxicity (ADCC), leading to hyperbilirubinaemia 
and anaemia. Destruction of foetal RBCs is recognised by signs of anaemia 
(oedema), increased levels of bilirubin in amniotic fluid and extramedulary 
hematopoiesis (resulting in hepatosplenomegaly). Foetal anaemia may lead 
to foetal hydrops and death. After birth, hyperbilirubinaemia may lead to 
kernicterus. 
To prevent immunisation, anti-D is given within 48 hours after expo-
sure to RhD-positive RBCs, for example as a consequence of chorion villi 
biopsy, abortion or ectopic pregnancy and, of course, as a result of birth. 
The precise mechanism for this antibody-mediated immune suppression is 
not known, but probably depends on interactions with the IgG Fc1 receptor 
type lib on B lymphocytes (Kumpel et al., 2001). Routine postnatal pro-
phylaxis with 1000 IE anti-D has reduced the immunisation from 14.7% to 
1.6% of the RhD-negative women with an RhD-positive child (Crowther et 
al., 2000). If a massive foetal-maternal transfusion (>20 mL RhD-positive 
blood) is expected, e.g. after caesarean section, manual placenta removal 
or multiple pregnancy, the dosis of anti-D has to be adjusted according to 
the volume of foeto-maternal transfusion. 
In the Netherlands, antenatal prophylaxis (1000 IE anti-D) is given since 
July 1998 to all RhD-negative mothers in the 30th week of gestation, which 
is expected to decrease RhD immunisation from 1.5% to 0.2% (Crowther et 
al., 2000). Moreover, all pregnant women are screened early in pregnancy 
for the presence of irregular antibodies against RBCs. This will be repeated 
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in all RhD-negative pregnant women in the 30th week of gestation, before 
administration of antenatal RhD prophylaxis. If irregular antibodies are 
present, their specificity, concentration and haemolytic activity (by ADCC 
test) will be determined, as well as the blood group of the father. If the 
ADCC is above the critical value (>50% for anti-D), echoscopic monitoring 
of foetal anaemia is performed once a week. Echoscopically, foetal anaemia 
is characterised by increased flow velocity in the fetal arteria cerebri media, 
vena umbilicalis and aorta decendens, and by cardiomegaly and spleno-
or hepatomegaly. When indications for foetal anaemia are present, foetal 
blood sampling by cordocentesis for haemoglobin determination and by 
amniocentesis for bilirubin determination has to be performed. 
Early treatment of severe foetal anaemia consists of intra-uterine trans-
fusion, performed between the 17th and 35th week of gestation. In the 
37-38th week of gestation, labour will be induced, because the intra-uterine 
disadvantages (continuing haemolysis, severe anaemia) are greater than the 
advantages, and the diagnostic tools will have less predictive value. Directly 
after birth, in the neonatal period, jaundice may be expected. Therefore, 
the foetal blood group, the direct antiglobulin test and the haemoglobin 
concentration have to be determined from cord blood directly after birth. 
Also the concentration of bilirubin has to be monitored during the first 
days after birth. 
1.1.2 Transfusion reactions by red blood cell antibodies 
Transfusion reactions caused by alloimmunisation can occur when the donor 
blood group is not compatible with that of the recipient. 
Mild transfusion reactions include fever, chills and anaemia due to the 
shortened lifespan of the transfused RBCs. Breakdown of these RBCs 
causes increased levels of bilirubin and lactate dehydrogenase. 
Major haemolytic transfusion reactions may cause hypotension, shock, 
disseminated intravascular coagulation, renal failure and death. 
Haemolytic transfusion reactions due to incompatibility of Rh occur 
especially when matching of the Rh blood group is not a routine procedure, 
for example in China, where 99.5% of the population is RhD-positive (Guo 
et al., 1994). 
However, the most common alloantibody problem is not due to typ-
ing neglectance but to an antibody present in such a low titer that it is 
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not detected by the antibody screen or crossmatch. After transfusion, the 
patient has a rise in antibody titer, usually in 5 to 10 days, a rapid fall 
in haemoglobin and a rise in bilirubin and lactate dehydrogenase. This is 
termed a delayed haemolytic transfusion reaction. 
1.1.3 Autoimmune haemolytic anaemia 
Autoimmune haemolytic anaemia (AIHA) comprises a diverse group of dis-
orders that have in common the presence of an RBC autoantibody result-
ing in a shortened RBC lifespan as the major mechanism of the cause of 
anaemia. Warm autoantibodies with a broad "Rh" specificity are typically 
found in the serum and can be eluted from the patients' RBCs. They are 
usually of the IgG class, with or without fixed complement. A relative 
specificity of the autoantibody for anti-e is sometimes observed, but also 
anti-c, -E, -D and -C autoantibodies can occur, roughly in that order of 
prevalence. Cold autoantibodies are usually of the complement-activating 
IgM class, and autoanti-D has been described (Longster et al., 1988). 
Clinical signs and symptoms of AIHA can be insidious. A gradual emer-
gence of symptoms of anaemia is often associated with fever and jaundice. 
If the onset is sudden, it can present with pain in the abdomen and back, 
general malaise and manifestations of rapidly increasing anaemia. A history 
of dark urine is common as the result of the presence of bile pigments or 
hemoglobinuria. Only 25% of the patients have no enlargement of spleen, 
liver or lymph nodes. There is a positive direct antiglobulin test and signs of 
haemolysis, but although anaemia can be severe, platelet count and white 
blood cell count are usually normal. 
The incidence of AIHA in the Netherlands is 1-3 per 100,000 per year, of 
which 70-84% due to warm autoantibodies. Therapy of AIHA due to IgG 
and/ or IgA warm autoantibodies consists of corticosteroids, splenectomy 
and intravenous immunoglobulin, whereas AIHA due to IgM cold autoan-
tibodies are more benificially treated with alpha-interferon. The prognosis 
is unpredictable. A minority of the patients has a complete resolution of 
their disease, and others have chronic but manageable courses (Petz, 1992). 
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Figure 1.1: Location of RHD and RHCE on chromosome 1. 
Genomic organisation of the RH genes in typical RhD-positive (above) and RhD-negative 
(below) haplotypes, showing RHD, the two homologous Rh boxes and SMP1 in 5' to 3' 
orientation, and RHCE in 3' to 5' orientation. In the RhD-negative haplotype, there is 
a deletion of RHD and a part of each Rh box (Wagner et al., 2000-II). 
1.2 Rh blood group system 
1.2.1 Molecular basis 
The Rh blood group system is encoded by two highly homologous genes, 
RHD and RHCE, located on chromosome 1 (p34.3-p36.1) (CMrif-Zahar et 
al., 1991), (MacGeoch et al., 1992). Each gene is composed of 10 exons and 
produces transcripts of 1251 base pairs (bp ), resulting in a protein of 417 
amino acids (aa) (CMrif-Zahar et al., 1994), (CMrif-Zahar et al., 1997). 
The whole RHD and RHCE genes consist of 57295 and 57831 bp, respec-
tively (exons and introns together) (Okuda et al., 2000) and are separated 
by approximately 30 kb, in which the coding sequence of SMP1 (Small 
Membrane Protein 1) is located (Wagner et al., 2000-II). RHD and RHCE 
are located in opposite direction on the chromosome (5'RHD3'-3'RHCE5'), 
with RHD centromeric of RHCE. The RHD sequence is flanked by two 
highly homologous (98.6%) regions, termed the upstream and the down-
stream Rh box (Figure 1.1). 
The RHCE gene encodes the CcEe polypeptides and the RHD gene 
gives rise to the D polypeptide. Forty nucleotide ( nt) differences are found 
between the RHD gene and the RHCE gene, resulting in 35 amino acid 
substitutions (Figure 1.2) (Mouro et al., 1993), (Simsek et al., 1994). 
In Caucasians the deletion of both RHD genes results in the RhD-
negative phenotype, leaving a hybrid Rh box originating from the upstream 
and downstream box. In non-Caucasians, mutated genes have been found 
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Figure 1.2: RH transcripts. 
The positions of nucleotide mutations that lead to amino acid substitutions are indicated 
by bars. Compared to the RHcE transcript, which was the first to be described, the 
RHD transcript reveals 35 amino acid substitutions. Exon 1 of the RHcE, RHce and 
RHD transcripts are identicaL All RH transcripts share identical cxons 8 and 10. Exons 
1 and 2 of RHCE gene show four amino acid substitutions, which are responsible for the 
Cjc antigenic switch. At position 226 in exon 5 of the RHCE gene proline to alanine 
substitution is responsible for the E/e polymorphism. The Alanine 226 is also present in 
the RHD gene. RHD intron 4 is smaller than that of RHCE. 
to result in the RhD-negative phenotype. 
The RHCE gene has four alleles: RHCE, RHCe, RHcE and RHce. 
Nucleotide substitutions of the RHCE gene in exon 1 (nt48 G-+C, aa16 
Cys-+Trp) and exon 2 (nt150 T-+C, silent mutation; nt178 A-+T, aa60 
Ile-+Leu; nt201 G-+A & nt203 G-+A, aa68 Ser-+Asn; nt307 T-+C, aa103 
Ser-+Pro) account for the C/c polymorphism. One nucleotide substitution 
in exon 5 (nt676 C-+G, aa226 Pro-+ Ala) of the RHCE gene is responsible 
for the E/e antigenic difference (Figure 1.2) (Faas et al., 1995). 
Exons 1 of the RH ce and RH cE alleles are identical to the RHD gene. 
Exons 2 of the RHCe and RHCE alleles are identical to exon 2 of the RHD 
gene. 
Knowledge about the molecular background of Rh is of essential impor-
tance for genotyping in case RBCs are not available, for example in prenatal 
diagnostics, after massive transfusions and in severe cases of AIHA. 
1.2.2 Membrane organisation 
The two Rh polypeptides, RhD and RhCcEe, have an almost identical orga-
nization. Both share 12 transmembrane spanning domains, with the NH2-
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Location of Cc or Ee polymorphism. 
Location of amino acid residues difference between D and CE. 
Probable sites for palmitoylation (Cys-Leu-Pro motifs), 
(in grey) palmitoylation site only present on the CcEe polypeptide. 
Border between the different exons. 
Figure 1.3: Model of the RhD and RhCcEe polypeptides in the red blood 
cell membrane. 
The Rh polypeptides have 12 membrane spanning domains with cytoplasmatic N- and 
C- termini. The regions encoded by the 10 exons (numbered 1 to 10) are alternately 
represented in black and grey . The zig-zag lines represent possible sites of palmitoylation. 
The circles represent sites where the amino acid residues of the D, Cc and Ee may differ. 
and the COOH-terminal parts intracellulary (Avent et al., 1990), ( Kajii et 
al., 1993). Three of the cysteine residues in the RhCcEe polypeptide and 
two in the RhD polypeptide form Cys-Leu-Pro motifs at the point of entry 
of the polypeptide into the cytoplasmic leaflet of the lipid bilayer and prob-
ably represent the major sites for attachment of palmitic acid (De Vetten 
et al., 1998), (Hartel-Schenk et al.,1992). The extracellular parts, against 
which the immune responses are directed, are very small and comprise no 
more than 25% of the polypeptide (Figure 1.3). 
It is assumed that the RhD protein monomer has a diameter of about 
50A (Liu et al., 1999). 
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1.2.3 Rh complex 
The molecular mass of the Rh complex in non-ionic detergent-solubilized 
membranes has been estimated to be 170 kDa, after correction for bound de-
tergent. This size is consistent with the complex being a a2,62-type tetramer 
(Hartel-Schenk et al., 1992). Most probably, therefore, the Rh polypeptides 
exist in a macromolecular complex, comprising two Rh polypeptides and 
two RhAg polypeptides (Rh-associated glycoprotein, also known as GP50, 
Rh50 or CD241) These four peptides interact through their N-terminal 
domains, as was shown by proteolysis studies. After treatment with S. au-
reus V8 protease (cleaving RhAg specifically at Glu34 and Lys196) a 28.5-
kDa RhAg peptide was co-precipitated with RhD /RhCcEe, suggesting that 
RhAg interacts with RhD /RhCcEe between Glu34 and Lys196 (Eyers et 
al., 1994), (Avent et al., 1996). Several membrane glycoproteins, such as 
LW, CD47 and glycophorin B (GPB), are associated with the tetrameric 
Rh complex (Figure 1.4) (Cartron et al., 1994). 
The RHAG gene is located on chromosome 6 (q21-qter). RhAg has a 
homology of about 36% with the Rh polypeptides, but there is no indication 
of polymorphisms in RhAg (Ridgwell et al., 1992). For that reason RhAg 
is not immunogenic. Hydropathy analysis suggests that RhAg closely re-
sembles Rh polypeptides, with 12 transmembrane spanning domains and 
the NH2- and COOH- terminal parts also located intracellularly (Ridgwell 
et al., 1992), (Matassi et al., 1998), (Huang et al., 1998). In contrast to 
the Rh polypeptides, RhAg possesses one extracellular N-glycosylation site 
(Asn37, on the first extracellular loop) (Eyers et al., 1994) and no sites for 
palmitoylation. 
The involvement in the Rh complex of other proteins (such as LW, 
GPB, CD47) has been deduced from their simultaneous absence or extreme 
reduction in the Rhnull phenotype, a phenotype completely deficient in RhD 
and RhCE (see below). 
LW antigens have a higher expression in RhD-positive than in RhD-
negative RBCs; this convergence has probably led to confounding of Rh 
with LW in 1940. In addition, monoclonal anti-LW co-precipitates LW 
glycoprotein and Rh polypeptide (Bloy et al., 1989). 
The Fy5 antigen of the Duffy system is also totally absent in Rhnull 
RBCs and weakly expressed in D-- RBCs, suggesting an association in the 
membrane of this protein with the Rh proteins or with the Rh-associated 
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RhD/CcEe RhAg GPB CD47 LW 
Figure 1.4: The RhD complex. 
The Rh complex consists of a tetrameric core of two RhAg proteins and two RhD /RhCcEe 
proteins, accompanied by GPB, CD47 and LW. 
glycoprotein. However, there is no evidence of reduced expression of the 
Duffy glycoprotein or other Duffy antigens (Daniels, 2002). This implies 
that the involvement of the Duffy system in the Rh complex is still unclear. 
Rhnull RBCs (regulator and amorph type) have a 60-70% reduction in 
GPB (Dahr et al., 1987), reflected as reduced levels of S, sand U antigens. 
The association of GPB with the Rh complex was confirmed by the co-
precipitation of GPB with anti-RhAg MoAb 2D10 (Von dem Borne et al., 
1990). RhAg of GPB-deficient RBCs is more heavily glycosylated than in 
normal RBCs. GPB might facilitate transport of RhAg to the cell surface 
membrane, which, in the absence of GPB, remains longer in the intracellular 
compartment, permitting more glycosylation (Ridgwell et al., 1994) 
CD4 7 or integrin-associated protein (IAP) is a widely distributed 
heavily N-glycosylated glycoprotein in RBC membranes (Avent et al., 
1988). It is present in reduced quantity (75% of normal) on Rhnull RBCs 
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(Avent et al., 1988), (Lindberg et al., 1994), (Miller et al., 1987). It may 
function as a marker of self by binding signal regulatory protein a ( SIRP a) 
on macrophages, generating a negative signal that prevents phagocytosis 
of RBCs (Oldenborg et al., 2000). 
The presence in the Rh complex of the Diego system is not clear. There 
is no evidence that antigens of the Diego system show altered expression on 
Rhnull cells, but an association of band 3 (the Diego antigen) with Rh has 
been demonstrated by co-transfection experiments. K562 cells transfected 
with RHD or RHcE eDNA express RhD or RhcE antigens, respectively. 
When those cells are subsequently co-transfected with eDNA encoding band 
3, the levels of RhD or RhcE and of endogenously produced RhAg are in-
creased (Beckmann et al., 2001). This suggests that an interaction between 
band 3 and the Rh-RhAg complex either enhances their translocation to 
the cell surface or affects their conformation in the plasma membrane. 
1.2.4 Association of the Rh complex with the membrane 
skeleton 
The Rh complex represents a major attachment between the lipid bilayer 
and the erythroid skeleton, as was concluded from the following observa-
tions; i) Rhnull cells are characterized by abnormalities of the RBC shape, 
cation transport and phospholipid organization (Cartron, 1999), (Huang et 
al., 2000); ii) The major members of the Rh complex (RhD, RhCcEe, RhAg 
and CD47) are partly resistant to membrane solubilization by the non-ionic 
detergent Triton X100, indicating an association with the membrane skele-
tal matrix (Gahmberg et al., 1984), (Ridgwell et al., 1984), (Paradis et 
al., 1986). And iii) fluorescence-imaged microdeformation, a method which 
quantifies redistribution in situ of fiuorescently labelled RBC membrane 
proteins during mechanically induced membrane deformation following cell 
aspiration into a micropipette, showed that the behaviour of RhD, RhCcEe 
and CD4 7 proteins is intermediate between that of actin (a component of 
the membrane skeleton) and that of band 3 (a membrane glycoprotein that 
is firmly attached to the skeleton), whereas the behaviour of RhAg is sim-
ilar to that of actin (Gimm et al., 2000), (Dahl et al., 2003). These results 
imply that the Rh complex is firmly linked to the actin-spectrin-based RBC 
membrane skeleton, presumably via RhD/RhCcEe, RhAg and/or CD47. 
From the study of RBCs from hereditary spherocytosis patients, asso-
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Figure 1.5: Association of the Rh complex with the membrane skeleton. 
Tetramers of band 3 are attached to the spectrin cytoskeleton via ankyrin. Protein 4.2 
binds anl:yrin, band 3, and CD47, providing a link between the Rh complex and the 
band-3 complex. 
ciated with the complete lack of protein 4.2, it has been suggested that 
protein 4.2 through interaction with CD4 7 is involved in the linkage of the 
Rh complex to the RBC skeleton and/ or its translocation through the cell 
membrane (Mouro-Chanteloup et al., 2003). Band 3 is also playing a major 
role in the association of Rh to the membrane skeleton, as was suggested 
by the reduced expression of the Rh complex in band-3 deficient RBCs and 
by a similar number of tetrameric Rh complexes and band-3 tetramers. 
Direct evidence that Rh and band 3 are associated was obtained by co-
precipitation of band 3 with the Rh-protein complexes (Bruce et al., 2003). 
Band 3 in tetrameric form binds ankyrin and protein 4.2 and is the ma-
jor attachment site of the RBC membrane to cytoskeleton (Rybicki et al., 
1996). A proposed model for the band-3 macrocomplex is shown in Figure 
1.5. 
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1.2.5 Development and distribution of Rh antigens 
RhD, RhCcEe and RhAg appear to be specific for RBCs. There is no ev-
idence that these antigens, also referred to as erythroid Rh homologues, 
are expressed on other tissue types. RhAg is detected early in the ery-
thropoiesis on erythroid blast-forming units (BFU-E), after glycophorin C 
and Kell glycoprotein, but before glycophorin A and band 3. The Rh anti-
gens appear substantially later, after glycophorin A and band 3 (Southcott 
et al., 1999), (Bony et al., 2000). Their expression increases during ery-
throid differentiation and erythroid ageing (Rearden et al., 1977). Besides 
the erythroid Rh homologues, closely related non-erythroid Rh homologues 
have been described, located in liver, skin, proximal tubules of the kidney 
(RhBG) (Liu et al., 2000) and the testis, and in the collecting tubules of 
the kidney (RhCG= RhGK) (Liu et al., 2001). 
1.3 Expression of RhD 
1.3.1 Qualitative variations 
Qualitative variations of RhD were discovered when individuals who where 
typed RhD-positive had produced alloanti-D after exposure to RhD-
positive blood. The RhD antigen harbours a number of epitopes; therefore, 
individuals who lack one or more epitopes (partial D) may be alloimmu-
nized to the missing epitopes. 
Tippett and Sanger divided partial-D antigens into six catagories (I-
VI), based on reaction patterns of RBCs with antibodies of RhD-positive 
individuals who made anti-D. The introduction of monoclonal antibodies 
enabled the classification of partial-D antigens to different patterns of reac-
tions, considered to represent different epitopes of the RhD antigen. Lomas 
et al. (1989) defined seven reaction patterns by testing 29 monoclonal anti-
D, representing most of the partial-D antigens, and two more were added 
later. However, the more different partial-D RBCs were identified, the more 
subsplits in the original reaction pattern were created. The latest pattern 
of reactions between partial D and monoclonal antibodies includes 30 epi-
topes, with a terminology consisting of the original 9 epitopes, followed by 
numbers representing subdivisions of these epitopes (Fourth International 
Workshop on Monoclonal Antibodies to Red Cell Surface Antigens, Paris, 
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Figure 1.6: Hairpin formation resulting in RHD-CE-D or RHCE-D-CE 
hybrids. Probable mechanism for RH gene conversion, with pairing between 
RHD and RHCE, in cis. 
France, 2001). 
Gene rearrangements and point mutations form the molecular basis for 
partial-D variants. That many RHD and RHCE hybrids are formed is 
probably due to the high homology and opposite orientation of these two 
genes. Gene conversion, resulting in RHD-CE-D or RHCE-D-CEhybrids or 
amino acid substitutions, can easily occur after hairpin formation, pairing 
RHD and RHCE in cis (Figure 1.6) (Wagner et al., 2000-II), (Suto et al., 
2000). 
An overview of all known partial Ds is shown in Table 1.1, together 
with the molecular basis (amino acid substitutions or hybrid genes), nu-
cleotide changes, protein sequence, exon and membrane localisation, anti-
gen density, similarity index (if known) and whether alloantibodies have 
been observed in this phenotype. 
1.3.2 Quantitative variations 
The number of RhD antigens expressed on the RBC membrane has been 
determined by Scatchard plot analysis with 1251-labelled monoclonal anti-
bodies. A continuum of RhD-antigen expression was found in the following 
increasing order: Rlr, R2r, R1R1, R1R2, R2R2 (Appendix, Table 2), rang-
ing from 15,000 to 33,000 sites per cell (Hughes-Jones et al., 1988), (Van 
Bockstaele et al., 1986), (Nicholson et al., 1991). 
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mean RhO 
Trivial Name Molecular basis Nucleotide Protein membrane antigen Similarity allo~ 
(allele) chango sequence localization density Index anti-D 
D II RHD (A354D) C->Gat 1060 AlatoAspat354 EC 3200 
'" C->Aat 1061 EC 
D lila RHD (N152T, T201R, F223V) A->Cat455 Asn toThr.:.t 152 TM 12300 
'" C->G at 602, Thrto Arg at 201 IC 
T->G <lt 667, PhetoV<Jiat 223 TM 
D lllb RHO -CE {exon2) -D T->Cat90 no change yes 
A->Cot 180 lletolcuat 60 TM 
G->Aat 201 Serto Asn at 68, TM 
T->C at 307 Scr to Pro at 103 EC 
D lllc RHD -CE (exon3) -D T->A ot 361, LoutoMetot 121 TM 22300 0.69 yos 
T->C at 380, VnltoAia 127 TM 
A->G at 383, AsptoGiyat 128 TM 
A->Cot455 AsntoThrat 152 TM 
DIll type IV RHD (L62F, A137V, N152T) G >CIT <lt 186 LoutoPhe<Jt62 TM 33255 0.45 yes 
C->T at410 Ala to Vol at 137, IC 
A->CJt455 A~n to Thr at 152 TM 
DIVa RHO (L62F, N152T, D350H) G->CIT at 186 LeutoPheot62 TM 9300 0.21 yo:; 
A->Cot455 A:>ntoThrat 152 TM 
G->Cat 1048 
"' 
to Hbot 350 EC 
OIVb RHO CE (axon?, 8 ,9) -0 G->Cat 1048 Asp to His at 350 EC 4000 yes 
C->T at 1053 no change 
G->Tot 1057 Gly to T~p at 353 EC 
A->G at 1059 
G->Aat 1060 AlatoAsn at354 EC 
C->Aat 1061 
T->Cat 1170 no change 
A->T at 1193 GlutoValat398 IC 
D IV typo Ill RHD -CE (exon6, 7, 8, 9) -0 G->A at 916, Voltolleat306 IC 607 
A->Gat 931 Tyrto Cys at 311 IC 
& all nt ofD lvb & all aa of D lvb 7 8 9 EC/IC 
D IV type IV RHO (0350H, G353W, A354N) G->C at 1048, AsptoHisat350 7 EC 
G->T ut 1057, GlytoTrp <it 353 
A->G at 1059, 
G->A ot 1060, Ala toAsn ot354 EC 
C->Aat 1061 
DVo RHO -CE (oxon5) -0 T->G at 667, Photo Val at223 TM 9400 yes 
G->Cat 676, Ala to Pro at 226 EC 
G->Cat 697, GlutoGin at233 EC 
G->A at 712, ValtoMetat238 TM 
G->Cat 733, ValtoLouat245 TM 
G->A at 787, Glyto Arg at 263 IC 
A->T at 800 L stoMetat 267 IC 
OVI type I RHO -CE (exon4, 5) -0 A->C at 505, Motto Lou at 169 EC 300 yos 
T->G at 509, MettoArg at 170 EC 
A->T at 514, llotoPhoat172 EC 
T->A at 544, 5ertoThr at 182 TM 
G->A at 577, Gluto Lysat 193 IC 
A->T at 594, LystoAsnat 198 IC 
C->G ot 602, ThrtoArg <lt201 IC 
&<lll ntofOVa &all oo of OVa 5 EC/IC/TM 
0 VI type II RHO -CE (exon4, 5, 6) -0 all ntofOVI type I, nil ail of OVI type I, 4, 5 EC/IC/TM 1600 yo':> 
G->A <lt 916, Valtolleat306 6 IC 
A->Gat 931 T rto C snt 311 IC 
D VI type Ill RHO -CE (exon3, 4, 5, 6) -0 T->A at 361, LeutoMetat 121 TM 14502 
T->Cat 380, Val to Ala 127 TM 
A->G at 383, Asp to Glyat 128 TM 
A->Cat455 AsntoThrat 152 3 TM 
& all nt ofD VI typo II & oil aa ofO VI type II 4 5 6 EC/IC/TM 
OVII RHO (L110Pl T->Cat 329 LeutoProat110 2 EC 3600 0.48 yes 
DAR RHO (T201R, F223V, 1342T) C->G at 602, ThrtoArg at 201 IC 
' 
yes 
T->G <lt 667, PhetoValat 223 TM 
T->Cat 1025 lie toThrat342 TM 
OBTtype I RHD -CE (exon5, 6. 7) -0 <lll ntofO Va <lll a<lofOVa EC/IC/TM 4300 ya':> 
G->A at 916, Val toile at 306 IC 
A->Gat 931 Tyrto Cys at 311 IC 
G->C at 1048 Asp to His at 350 EC 
C->T at 1053 no chango 
G->Tat 1057 GlytoTrpat 353 EC 
A->G at 1059 
G->Aot 1060 AlotoAsn at354 EC 
C->Aat 1061 7 
DBTtype II RHO -CE (exon5, 6, 7, 8, 9) -0 oil ntof OBTtypol all of OBTtypa I 5,6,7 EC/ICfTM 
T->C<lt 1170 no change 9 
A->T at 1193 GlutoVol at398 IC 
OFR RHO (M169L, M170R, 1172F) A->C <lt 505, MottoleU<lt169 EC 5300 
T->G at 509, MettoArg at 170 EC 
A-> Tat 514 lie to Pheot 172 EC 
DFW RHD (H166Pl A->Cnt 497 HI~ to Pro at 166 EC 
OHAR RHCE -D {exon5) -GE 
'" 
OHK (DYO) RHO fE233K) G->Aat 697 Glutolvsat 233 EC 
DHMI RHO fT2831l C->T at 848 Thrto lie at 283 TM 2400 0.12 yes 
DHD RHO (K235Tl A->Cat 704 L stoThr:~t 235 1300 7 
OHR RHO (R229KJ G->Ant 686 Ac tolsat229 3800 
' RHO (C285YJ G->Aat 854 Cys to Tyr at 285 192 
OMH RHO (L54Pl T->Cat 161 LoutoProat 54 
DNB RHO (G3555} G->A at 1063 Gl toSarat355 7 
DOL RHO (M170T, F223V) T->G at 509, MettoArgat 170 EC 4700 
'" T->G at 667 PhatoValat 223 
Table 1.1: All partial Ds 
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RBCs expressing quantitative variations can be divided into those with 
enhanced expression (e.g. D-- ) and those with decreased expression (weak 
D). 
Enhanced expression of RhD 
The Rh phenotypes D-- and related complexes, which lack expression of 
RhE and Rhe and sometimes also of the RhC and Rhc antigens, show 
elevated expression of the RhD antigen (between 50,000 and 100,000 sites 
per cell) (Van Bockstaele et al., 1986), (Nicholson G et al., 1991), (Issitt, 
1985) Most of the D-- haplotypes consist of a complete, or almost com-
plete, RHD, paired with a hybrid gene containing a substantial portion of 
RHD (Figure 1.7). This may provide an explanation for the enhanced RhD 
expression. The D-- haplotype has a frequency of 0.0005 in Sweden, 0.0047 
in Iceland and 0.001 in Japan (Rasmuson et al., 1966), (Olafsdottir et al., 
1983), (Okubo et al., 1983). 
Weak expression of RhD 
In 1946, a phenotype was described in which the RhD antigen could only 
be detected by some of the anti-RhD reagents available at that time or 
when an antiglobulin reagent was added (Stratton, 1946), (Stratton et al., 
1948). This antigen was first called nu, later weak D. 
A fraction of the weak-D phenotype is caused by the suppressive effects 
of the Cde haplotypes in trans position. When the haplotype producing the 
weakly expressed D is partnered by a haplotype expressing neither C nor D 
(thus cde or cdE) in another family member, the Dis expressed normally. 
The mechanism for this phenomenon is unknown (Ceppellini et al., 1955). 
This weak-D phenotype, formerly called high-grade nu, likely possesses the 
normal RHD allele, because the parents and children of individuals with this 
phenotype often express a normal RhD density. This weak-D phenotype 
is characterised by a minor reduction of RhD-antigen expression and is 
nowadays often typed as normal RhD, because of the increased sensitivity 
of monoclonal anti-D. 
The majority of weak-D phenotypes, is caused by variations either at 
the Rh gene locus itself or in its proximity, because the weak expression is 
inherited along with the RhD phenotype. Besides the mere quantitative re-
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Figure 1. 7: Genomic arrangement of D-- and related phenotypes. 
17 
Representation of the 10 exons of RHD (black) and RHCcEe (grey) of D-- and related 
phenotypes. D-- indicated with a * are the proposed haplotypes in one D-- propositus. 
White triangle in exon 1 encodes Arg41 characteristic of cw. 
duction, no qualitative differences have been discerned in the RhD antigen 
of this group. Since 1997 (Avent et al., 1997), (Legler et al., 1998), evidence 
has been accumulating that the underlying molecular basis of these weak-
D phenotypes might be heterogenous, and that some weak-D individuals 
may carry structurally abnormal RHD alleles. Wagner et al. (1999, 2000-I) 
revealed 20 different molecular causes of these weak-D phenotypes. The 
amino-acid substitutions of the weak-D phenotypes were located in intra-
cellular and transmembrane protein segments and clustered in four regions 
of the protein (amino acid positions 2 to 13, around 149, 179 to 225, and 
267 to 397) (See Table 1.2). The weak-D types display type-specific anti-
gen densities between 70 and 5200 RhD antigens per celL Each weak-D 
type expresses a particular epitope density profile, which was established 
by flowcytometry with 59 IgG anti-D MoAbs. An Rh similarity index, the 
ratio of the lOth percentile and the 90th percentile of the epitope densities, 
was devised to indicate qualitative differences of RhD phenotypes. Ideally, 
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normal RhD antigens would have an index of 1 (all MoAbs recognize the 
same epitope density, the epitope density profile is a single narrow peak), 
grossly aberrant partial RhD would have an index of 0. 
A very weak form of RhD expression in the Far East is called DEL ( orig-
inally Del). This phenotype can only be detected reliably by adsorption-
elution tests and is characterised by several genotypes. In Taiwan, DEL 
is associated with a 1013bp deletion of RHD extending from intron 8 to 
intron 9 and encompassing the whole of exon 9 (Chang et al., 1998). Two 
types of RNA mutations with the potential to disrupt RNA splicing were 
found. The first is a G to A substitution on the first nucleotide of intron 1, 
which leads to the loss of exon 1 in most mRNA molecules. The second is 
a G to A substitution on nt 1227 (exon 9), which might lead to abnormal 
splicing of exon 9 (Singleton et al., 2001). 
1.3.3 Rh-deficiency phenotypes 
Rhnull RBCs are completely deficient in RhD and RhCE (Avent et al., 1988) 
Rhnull RBCs of the regulator type have a molecular defect in the RHAG 
gene (Cherif-Zahar et al., 1996) resulting in the lack of expression of the 
complete Rh complex. Rhnull RBCs of the amorph type have a molecular 
change in the RHCE gene in tandem with a deleted RHD gene (Cherif-
Zahar et al., 1998), (Huang et al., 1998) resulting in the lack of expression 
of RhD and RhCE; however, RhAg is still expressed in reduced amounts. 
Some mutations in the RHAG gene give rise to low-level expression of 
Rh antigens, a phenotype called Rhmod (Chown et al., 1972). Molecular 
analysis of three individuals with the Rhmod phenotype revealed missense 
mutations in RHAG (aa1 Met--+Ile, aa79 Ser--+Asn and aa399 Asp--+Tyr). 
This indicates that the expression of RhAg is essential for the expression 
of the Rh polypeptides. 
Rhnull RBCs are morphologically and functionally abnormal (Schmidt et 
al., 1967), (Schmidt et al., 1969). Most Rhnull and Rhmod individuals have 
some degree of haemolytic anaemia. Typical signs of Rh-deficiency syn-
drome are the presence of stomatocytes and some spherocytes, increased 
red cell osmotic fragility and increased reticulocyte count. Rhnull RBCs 
have an abnormal organisation of their membrane phospholipids (Kuypers 
et al., 1984) and increased cation permeability, compensated by an in-
creased number of sodium-potassium pumps (Lauf et al., 1976). 
mean RhD f-..< 
Trivial Name Molecular basis Nucleotide Protein membrane %of antigen Similarity w (allele) change sequence exon localization no. weak RhD density Index 
Weak RhO type 1 RHO (V270G) T->G at 809 Val to Gly at 270 6 TM 95 70.29 1285 0.57 ~ Weak RhO type 2 RHO (G385A) G->C at 1154 Gly to Ala at 385 9 TM 43 18.01 489 0.68 
Weak RhO type 3 RHO (S3C) C->G at 8 Ser to Cys at3 1 IC 7 5.19 1932 0.77 i Weak RhO type 4 RHO (T201 R, F223V) C->G at 602, Thr to Arg at 201, 4 IC 6 1.30 2288 0.36 T->G at 667, Phe to Val at 223 5 TM G->A at 819 no change 6 
Weak RhO type 4.1 RHO (W16T, T201 R, F223V) G->C at 48, Trp to Cys at 16 1 TM 3811 0.48 ~ C->G at 602, Thr to Arg at 201, 4 IC ~ T->G at 667, Phe to Val at 223 5 TM G->A at 819 no change 6 
weak RhO type 4.2 RHO (T201 R, F223V, 1342T) C->G at 602, Thr to Arg at 201, 4 IC 1650 0.21 ~ ~DAR T->G at 667, Phe to Val at 223 5 TM 
T->C at 1025, lie to Thr at 342 7 TM ~ ~ Weak RhO type 4.2.1 RHO (T201 R, F223V, 1342T) C->G at 602, Thr to Arg at 201, 4 IC 
0" T->G at 667, Phe to Val at 223 5 TM 8 >--' G->A at 957 no change 6 ('[) T->C at 1025, lie to Thr at 342 7 TM 
f-' Weak RhO type 4.2.2 RHO (T201 R, F223V, 1342T) C->G at 602, Thr to Arg at 201, 4 IC 
~." T->G at 667, Phe to Val at 223 5 TM 
C->T at 744, no change 5 
> G->A at 957 no change 6 >--' T->C at 1025, lie to Thr at 342 7 TM >--' 
~ Weak RhO type 5 RHO (A149D) C->A at 446 Ala to Asp at 149 3 TM 2 0.84 296 0.39 Weak RhO type 6 RHO (R10Q) G->A at 29 Arg to Gin at 1 0 1 IC 1 0.74 1053 0.79 
~ Weak RhO type 7 RHO (G339E) G->A at 1016 Gly to Glu at 339 7 TM 1 0.74 2409 0.03 Weak RhO type 8 RHO (G307R) G->Aat919 Gly to Arg at 307 6 IC 1 0.74 972 0.75 
t:J Weak RhO type 9 RHO (A294P) G->C at 880 Ala to Pro at 294 6 TM 1 0.42 248 0.43 
UJ Weak RhO type 1 0 RHO (W393R) T->C at 1177 Trp to Arg at 393 9 IC 1 0.42 1186 0.34 
Weak RhO type 11 RHO (M2951) G->T at 885 Met to lie at 295 6 TM 1 0.22 183 0.53 
Weak RhO type 12 RHO (G277E) G->A at 830 Gly to Glu at 277 6 TM 0 <2.22 96 nc 
Weak RhO type 13 RHO (A276P) G->C at 826 Ala to Pro 276 6 TM 0 <2.22 946 0.33 
Weak RhO type 14 RHO (S182T, K198N, T201 R) T->A at 544, Ser to Thr at 182, 4 TM 0 <2.22 
A->T at 594, Lys to Ans at 198, 4 IC 
C->G at 602 Thr to Arg at 201 4 IC 
Weak RhO type 15 RHO (G282D) G->A at 84S Gly to Asp at 282 6 TM 0 <1.26 297 0.21 
Weak RhO type 16 RHO (W220R) T->C at 658 Trp to Arg at 220 5 TM 0 <1.26 235 0.44 
Weak RhO type 17 RHO (R114W) C->T at 340 Arg to Trp at 114 3 TM 66 nc 
Weak RhO type 18 RHO (R7W) C->T at 19 Arg to Trp at 7 1 IC 
Weak RhO type 21 RHO (P313L) C->T at 938 Pro to Leu at 313 6 IC 5200 
Weak RhO type 22 RHO (W408C) G->C at 1224 Trp to Cys at 408 9 IC 
Weak RhO type 23 RHO (G212C) G->T at 634 Gly to Cys at 212 4 TM 
Weak RhO type 24 RHO (L338P) T->C at 1013 Leu to Pro at 338 7 IC 
nc:=::not calculated, because 90th percentile is less than 200 antigens per cell f-' (,0 
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1.3.4 Ethnic diversity 
The Rh blood group is very polymorphic and frequencies of the Rh haplo-
types can differ markedly between different ethnic groups. About 15% of 
Europeans and North-American Caucasians have the RhD-negative pheno-
type. Of the black population, less than 5% has the RhD-negative pheno-
type, whereas in the Asian population the frequency of RhD-negativity can 
even be lower (Mourant et al., 1976), (Tills et al., 1983). As described 
before, RhD negativity in Caucasians is mainly caused by homozygos-
ity for a deletion of RHD. In blacks, the RhD-negative phenotype can 
also be caused by the RHD pseudo (RHDiJ!) gene, in which a 37bp se-
quence duplication of the last 19 nucleotides of intron 3 and the first 18 
nucleotides of exon 4 results in a reading-frame shift and introduces a pre-
mature translation stop codon. RHDiJ! has also a nonsense mutation in 
exon 6 (269Tyr---+stop), which ensures that no RhD protein is present on 
the membrane (Singleton et al., 2000). The r's gene is another gene causing 
RhD negativity in African blacks, in which the 5' part of exon 3 and exons 
4, 5, 6, 7 and 8 have been replaced by the RHCE counterparts. 
A very weak form of the RhD antigen, called DEL, as described above, 
is found in the Japanese and Chinese population. DEL accounts for 10% 
and 30%, respectively, of the RhD-negative population in Japan and China 
(Mak et al., 1993), (Okubo et al., 1984). 
Some qualitative RhD variants (partial D) are mainly seen in certain 
ethnic populations, for example: DIIIa, DIIIb, DIVa and DOL are frequently 
found in blacks (Tippett et al., 1996), (Avent et al., 1999). DBT type II 
(Huang et al., 1999) and DHK (Hyodo et al., 2000) are more often seen in 
Japanese. 
1.4 Protein development 
1.4.1 Transcription and translation 
The production of all proteins, including transmembrane proteins such as 
the Rh polypeptides, starts in the nucleus. The envelope around the nucleus 
consists of an inner and an outer membrane, with passageways through nu-
clear pores. The outer nuclear membrane continues in the endoplasmatic 
reticulum (ER) membrane, and the space between it and the inner mem-
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Figure 1.8: Protein development (Pollard et al., 2002). 
(Left) The production of a protein starts in the nucleus where DNA is transcribed. In 
the ER translation, glycosylation and protein oligomerisation takes place. In the Golgi 
the proteins are processed and directed to their final destination. (Right) When proteins 
are misfolded, they will be eliminated. In the ER ubiquetin tags will mark the misfolded 
or unassembled proteins. Degradation takes place in the proteasome. Aggresomes are 
formed when the degradation capacity of the proteasome is exceeded. 
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brane continues in the ER lumen. mRNA molecules, which are transcribed 
from the DNA in the nucleus, and ribosomal subunits, which are assembled 
there, are exported from the nucleus to the cytosoL Many ribosomes in the 
cytosol can bind to single mRNA molecules, and the polyribosome that is 
formed will attach to a docking protein on the rough ER membrane through 
the signal recognition peptides (SRP) present on the growing polypeptide 
chains. This binding to the membrane initiates the translocation process 
that threads a loop of polypeptide across the ER membrane through a 
hydrophyllic pore in a protein translocator (the Sec6lp complex). Trans-
membrane proteins destined for the cell-plasma membrane are translocated 
across the ER membrane, but are not released into the lumen. Instead, they 
remain anchored in the lipid bilayer by one or more membrane-spanning 
a-helical regions in their polypeptide chain. These hydrophobic portions 
of the protein can act either as start-transfer or stop-transfer signals dur-
ing the translocation process. When a polypeptide such as the Rh protein 
contains multiple alternating start-transfer and stop-transfer signals, it will 
pass back and forth across the bilayer multiple times. ATP-driven heat-
shock proteins, such as BiP, serve as chaperones that bind nascent proteins 
and assist in their folding. 
1.4.2 Glycosylation and protein oligomerisation in the ER 
N-glycosylation (oligosaccharide attachment to asparagines) of RhAg starts 
in the ER by synthesis of high-mannose-oligosaccharide from dolichol-
phosphate carriers. 
During synthesis of the Rh polypeptides by the ribosomes, these pep-
tides are transferred to the ER as subunits of a hetero-oligomeric protein 
complex (the Rh complex). Assembly of proteins generally occurs prior 
to export and also involves chaperones that protect hydrophobic surfaces 
found in subunit interfaces. Because synthesis of protein subunits occur 
on distinct ribosomes and may be unbalanced, additional chaperones may 
promote subunit interactions and prevent premature export or degradation. 
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1.4.3 Routing and processing of proteins: Golgi complex 
and beyond 
The Golgi complex consists of at least three stacked compartments or cis-
ternae. Golgi stacks are highly polarised with respect to the composition 
of the individual cisternae. The complexed Rh proteins move from ER 
through endocytic compartments, carried by lipid-bound transport con-
tainers. These vesicles generally enter the cis side of the stack proximal 
to the nucleus, while processed material exits from cisternae found on the 
trans side. Each Golgi cisterna contains a different spectrum of process-
ing enzymes. All newly synthesized proteins that pass inspection proceed 
through the Golgi complex, even if they are not substrates for further pro-
cessing, such as RhD and RhCE. But most proteins, like RhAg, receive 
post-translational modifications, such as terminal glycosylation, before be-
ing shipped to their destination. Successful passage through the Golgi 
complex brings the near-final products to the trans-Golgi network (TGN), 
the major distribution centre, where they are packaged and sent to the cell 
membrane. 
1.4.4 Misfolded proteins 
A highly efficient quality control system in the ER guarantees that only 
properly folded proteins are delivered, whereas misfolded proteins or 
unassembled subunits of protein complexes are eliminated. This process 
is called: ER-associated degradation (ERAD) (Sommer et al., 1997). Un-
regulated proteolysis would be disastrous, therefore tightly regulated com-
partmentalized intracellular proteolytic activity must be used. Proteasomes 
are compartments for proteolysis of misfolded membrane proteins. These 
proteolytic machines, located in the cytoplasm, are assembled from multi-
ple protein subunits that form a small cylindrical compartment with the 
proteolytically active sites sequestered on the inside. The misfolded mem-
brane proteins located in the ER must be identified. The small polypeptide 
ubiquitin is central in this process by targeting molecules for degradation by 
proteasomes (Bonifacino et al., 1998). Ubiquitin binds post-translationally 
to Lysine residues on protein substrates and is recognised by the cellular 
machinery that targets them for proteolysis. The transfer of these mis-
folded membrane proteins, from the ER to the cytoplasmic proteosome, is 
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mediated by Sec61p, the same translocon that is used for translocation of 
nascent polypeptides through membranes (Plemper et al., 1999). Dyslo-
cated, ubiquitinated, misfolded proteins can either be rapidly degraded by 
cytosolic proteasomes or, when the degradation capacity of the proteasomes 
are exceeded, they aggregate. Misfolded, aggregated proteins are trans-
ported to the microtubule organising centre, where they are ensheathed by 
the intermediate filament vimentin. This structure is called the aggresome 
(Johnston et al., 1998). 
1. 5 Transfection model for Rh expression 
To study intracellular processes in RBCs a model had to be developed, 
because erythrocytes do not have a nucleus anymore. In-vitro expression 
of RH genes in eukaryotic cells has been tried by transfection with plas-
mid expression vectors but initially lacked success (Hermand et al., 1993), 
(Suyama et al., 1993). In 1996, Smythe et al. successfully used a retroviral 
gene transfer method to express RH-cDNA in K562 cells. K562 cells are 
erythroleukemic cells that already express RhAg, which is considered es-
sential for the expression of Rh antigens. Although the K562 cell line was 
derived from an RhD-positive patient, these cells express RhD to such a 
low extent that after transfection with RHD a clear rise in expression can 
be observed. 
1.6 Function of the Rh complex 
1.6.1 Similarities with the ammonium transport family 
The predicted topology of the Rh proteins in the cell membrane (poly-
topic, with cytoplasmic N- and C- termini) is characteristic for membrane 
transporters. RhAg bears an even closer resemblance to RBC membrane 
transporters, because it has an N-glycan on one of its extracellular loops. 
Ammonium transporters of the Mep I Amt family are polytopic mem-
brane proteins, highly conserved in eubacteria, archaebacteria, fungi, plants 
and invertebrates. 
In vertebrates no Mep I Amt (methylammonium permeases I (methyl-
) ammonium transporter) protein has yet been found. In the human 
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Figure 1.9: The ammonium transport family. 
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Phylogenetic tree of multiple sequences from human Rh blood group antigens, human 
Rh glycoproteins, non-human sequences with Rh homology, and ammonium transporters 
from yeast, bacteria, plants and worms. 
genome, the Rh family proteins are the most homologous to Mep / Amt 
transporters (Liu et al., 2001); a sequence identity of 20-27% exists be-
tween them (Marini et al., 2000). The Rh family consists of a primitive 
group (proteins located in uni-cellular slime molds, multi-cellular proto-
zoans and metazoans), an erythroid group (RhAg and RhD/RhCcEe), and 
a non-erythroid group (RhBG and RhCG) (Liu et al., 2001) (Figure 1.9). 
The tissue specificity of RhBG (expressed in kidney convoluted tubules 
and Henle's loop and in liver and skin) and RhCG (expressed in kidney 
collecting tubules and in testis seminiferous tubules), along with the se-
quence similarity to the ammonium transporters raised the possibility that 
these non-erythroid Rh homologues might be the long sought ammonium 
transporters in humans (Liu et al., 2001). 
1.6.2 RhAg and RhCG transport ammonium bi-direction-
ally in yeast cells 
To test whether human RhAg and RhCG are capable of ammonium trans-
port activity, Marini et al. performed functional complementation assays in 
a yeast mutant with deletions in the three endogenous ammonium trans-
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porter genes (yeast cells deleted of Mepl, Mep2 and Mep3, further referred 
to as triple-Mep6. yeast cells). In yeast, the Mep proteins import ammo-
nium as a nitrogen source necessary for growth. The triple-Mep6. yeast 
cells cannot grow on minimal media that contain less than 5mM ammo-
nium. Triple-Mep6. yeast cells expressing RhAg or RhCG did grow, even 
at lmM of ammonium, suggesting ammonium uptake activity. Also an en-
hanced resistance to toxic concentrations of methylammonium was found in 
triple-Mep6. yeast cells expressing RhAg, suggesting that RhAg mediates 
also the export of ammonium (Marini et al., 2000). 
1.6.3 RhAg mediates ammonium uptake in Xenopus 
oocytes 
Contrary to yeast cells, RhAg was fully glycosylated when expressed in 
Xenopus oocytes, suggesting that it was processed appropriately and traf-
ficked correctly to the oocyte plasma membrane. 
Oocytes expressing RhAg demonstrated an 8-10 fold increase in up-
take of ammonium, measured with the radioactive ammonium analogue 
14C-methylammonium. Because the uptake was increased by raising the 
external pH or lowering the intracellular pH, it was assumed that ammo-
nium uptake might be coupled to proton extrusion. Uptake mediated by 
methylammonium-H+ counter transport would therefore be an attractive 
mechanism to accumulate ammonium without compromising pH (Westhoff 
et al., 2002). 
1. 7 Scope of this thesis 
The first aim of this study was to define the molecular basis of weak-D 
phenotype, because that was not yet known at the start of my investiga-
tions. However, shortly after the start it was published that amino-acid 
alterations in RHD are present in individuals with the weak-D phenotype. 
We have investigated whether there is a direct correlation between these 
amino-acid substitutions and the lower expression of RhD, using an ery-
throleukemic K562 cell line model (Chapter 4). This eythroleukemic K562 
cell line model was furthermore used to investigate the processing of the 
weak-D antigen in the celL 
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Transfusion of RhD-positive blood to individuals with qualitatively al-
tered RhD may result in alloimmunization. Therefore, it is important to 
know whether the weak-D phenotypes are purely a quantitative variant or 
whether also qualitative changes are present in the weak-D polypeptide. 
Because no alloantibodies have been found in individuals with the most 
common weak-D phenotypes, the weak-D polypeptide was scrutinized by 
Scat chard plot analysis to detect possible qualitative alterations (Chapter 
3). We identified a weak-D phenotype with a high frequency in African 
blacks, investigated its molecular basis and studied whether it was only a 
quantitative or also a qualitative variant (Chapter 2). The reason for the 
heterogenicity of Rh and the differences in haplotypes between different 
ethnic populations have not been solved yet. Maybe some Rh phenotypes 
have functional advantages. Already for a long time, a transport function 
for the Rh protein had been assumed, because of its predicted topology in 
the cell membrane. After the discovery of the non-erythroid Rh-homologues 
(RhBG and RhCG), the missing link was identified in the nucleotide se-
quence similarity between Rh and the ammonium transporter family (Amt). 
By transfection studies, a transport function of ammonium in yeast cells 
has been shown for RhAg. The aim of our study was to investigate the 
involvement of the Rh complex in the transport of ammonium in human 
red blood cells (Chapter 5). 
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Chapter 2 
DAR, a new RhD variant 
involving ex on 4, 5 & 7, 
often in linkage with ceAR, a 
new Rhce variant; frequently 
found in African Blacks 
M. B. Hemker, P. C. 
D. J. van Rhenen, C. 
P. A. Maaskant-van Wijk. 
Abstract 
Ligthart, L. 
E. van der 
Berger, 
Schoot, 
The highly polymorphic Rh system is encoded by two homologous 
genes RHD and RHCE. Gene rearrangements, deletions, or point 
mutations may cause partial D and CE antigens. 
In this study, a new RHDvariant, DAR, and a new RHCEvari-
ant, ceAR, are described in four Dutch African Blacks. Serologi-
cally, DAR showed weaker reactions with a MoAb and a polyclonal 
antiserum against D. The DAR phenotype was characterized by 
complete loss of at least 9 of 37 RhD epitopes. RBCs expressing 
ceAR were all typed as vs-, v+. 
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DNA analysis showed a partial D allele with only three mu-
tations: C602G (exon 4), T667G (exon 5) and T1025C (exon 7). 
The ceAR allele carried G48C (exon 1), a hybrid exon 5 (A712G, 
C733G, A787G and T800A) and A916G (exon 6). 
To study the frequency of these new variants, a group of 
326 South-African Blacks was screened genomically. Of the 326 
donors, 16 (4.9%) carried the DAR allele, 20 (6.1%) the ceAR 
allele, and 14 (4.3%) both mutated alleles. Five of these donors 
(1.5%) had the DAR phenotype, indicating that they carried the 
DAR allele homozygously, or next to an RhD-negative allele. Im-
munogenicity of the RhD antigen for individuals with the DAR 
phenotype was proven, since one of the four Dutch individuals 
produced alloantibodies against RhD after multiple transfusions 
with RhD-positive blood. In a multi-ethnic society, the prevalence 
of this new RhD phenotype will increase and is therefore relevant 
in transfusion practice and in prevention of hemolytic disease of 
the newborn. 
2.1 Introduction 
The Rh blood group system is clinically important, because antibodies 
against Rh antigens are involved in haemolytic disease of the newborn, 
haemolytic transfusion reactions, and autoimmune haemolytic anaemia. 
The Rh system is complex; as many as 45 different antigens have been 
serologically defined (Issitt, 1994), (Daniels, 1995). These antigens are 
carried by non glycosylated, non phosphorylated polypeptides. The Rh 
polypeptides are predicted to have 12 transmembrane-spanning domains 
with intracellular N- and C- termini, resulting in 6 extracellular loops on 
which the Rh antigens are located (Cherif-Zahar et al., 1990), (Avent et 
al., 1992). Two highly homologous genes, RHCE and RHD, encode the Rh 
antigens. Both genes are localized on chromosome 1p34.3-p36.1 and are 
inherited together (Cherif-Zahar et al., 1991). RHCE gives rise to the C/c 
and E/e polymorphisms. RHD encodes the RhD antigen. Total or partial 
deletion of the RHD gene can result in the RhD-negative phenotype (Colin 
et al., 1991), (Hyland et al., 1994), (Umenishi et al., 1994), (Faas et al., 
1997-I), (Blunt et al., 1994). In non-Caucasians, it has been found that 
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RhD negativity can appear in individuals carrying the complete RHD gene 
(Daniels et al., 1997), (Okuda et al., 1997). 
The most immunogenic Rh antigen is the RhD antigen, comprising at 
least 30 epitopes (Scott et al., 1996), (Scott, 1996). 
Partial-D phenotypes, characterized by loss of epitopes, can arise from 
replacement of RHD exons by their RHCE counterparts as has been shown 
in DIIIb Dille D1Vb D Va D VI DFR and DBT and by point mutations 
' ' ' ' ' in the RHD gene that occur in Dn, DIVa, Dvn, DHMi, DNU and DHR. 
Frequencies of Dvn, DVI, DIV, Dv, Dn-like, and DFR are 1:900, 1:6800, 
1:10,000, 1:30,000, 1:30,000 and 1:60,000, respectively, as established with 
serological methods in a Caucasian population (Flegel et al., 1996). Allo-
antibodies may be produced against missing epitopes in individuals ex-
pressing RhD variants, when exposed to the complete antigen by blood 
transfusion or during pregnancy. 
Three types of RHCE variants have been described (Faas et al., 1997). 
Single point mutations are found in VS, V, cw, ex and Rh:26. RHCE exon 
replacements, in which exons of different alleles of RHCE are exchanged, 
were found in rGr and a variant in which exon 1 and intron 1 of the RHc 
allele are replaced by the corresponding part of the RHC allele. Finally, 
replacement of RHCE exons by their RHD equivalents may occur, as is 
found in D-- , De-, RoHar, RN and partial E. As in RHD variants, these 
exon replacements or mutations not only result in loss of epitopes, but may 
also account for the formation of new epitopes. 
In the present report, we describe a new partial-D antigen, called DAR, 
expressed in four unrelated Dutch women of African Black origin. In these 
four individuals, also a variant RHCE gene, called ceAR was found. That 
more African Blacks are carrier of the mutated RHD gene was suggested hy 
the fact that three of these four women were noticed in a routine pregnancy 
screening. Thereafter, blood was sent for confirmation of the Rh typing to 
the Central Laboratory for Blood Transfusion (CLB). We also screened 326 
African Black donors from the South African Blood Transfusion Service in 
Johannesburg (South Africa) for DAR and ceAR. 
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2.2 Materials and Methods 
Samples. EDTA anti-coagulated blood samples were obtained from four 
unrelated African Black women (identification numbers 3308, 3424, 3895 
and 4413). Three samples were noticed because of weak-D expression, dur-
ing routine pregnancy screening and sent to the CLB for confirmation. A 
blood sample of individual 4413 was referred to our lab because antibodies 
were detected. Red blood cells (RBCs) of these individuals were Rh pheno-
typed according to standard protocols with monoclonal antibody (MoAb) 
MS-201 (CLB, Amsterdam, The Netherlands), recognizing RhD epitope 
6/7 (9 epitope model) equal to RhD-epitope 12 (37 epitope model), a poly-
clonal reagent (anti-D with bromelain as enhancer, CLB) and MoAbs (all 
obtained from CLB, Amsterdam, Netherlands) recognizing RhC (MS 24), 
Rhc (MS 32), RhE (MS 260) or Rhe (MS 21, MS 63). Polyclonal reagents 
97-501639 (patient serum) and Q-sera were used to phenotype VS and V, 
respectively. The presence of the low incidence antigen D w, thus far only 
found in Dva, was tested with an anti-Rh23 by C. Green and G. Daniels 
(International Blood Group Reference Laboratory (IBGRL), Bristol, UK). 
Phenotyping for partial D was performed with a panel of selected MoAbs 
with known epitope specificity (Third International Workshop on Mono-
clonal Antibodies against Red Cell and Related Antigens, 1996, Nantes, 
France). RBCs of donor 3424 were sent to the IBGRL for confirmation. 
In the blood sample of individual 4413, RBC antibodies were present 
with the specificity of anti-D, -C, -E, -Fya, Jka, M and Sla. This individual 
suffered from sickle cell anemia and received multiple transfusions over the 
years. Adsorption-elution techniques were used to determine whether the 
anti-D antibodies were alloantibodies or autoantibodies. 
Blood samples of 326 South-African Black donors were randomly col-
lected by the South African Blood Transfusion Service in Johannesburg 
(courtesy of J. Hooydonk, Johannesburg, South Africa). Seven donors were 
serologically typed as RhD negative, all other donors were RhD positive. 
eDNA sequence analysis. White blood cell-reduced RBCs were en-
riched with reticulocytes as described before (Murphy et al., 1973), (Sim-
sek et al., 1994). RNA was isolated from the reticulocyte-enriched frac-
tion (Chomzynski et aL, 1987). eDNA was obtained by RT-PCR (reverse 
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transcriptase polymerase chain reaction) using Superscript II RNAse H-RT 
(Gibco BRL, Gaithersburg, MD), and full-length amplification was per-
formed with consensus primers as described in Table 2.1. PCR products 
were ligated into pGEM-T vector (system I, Promega, Madison, WI) and 
the vectors were introduced into competent Escherichia coli by electropo-
ration (Sambrook et al., 1989). Inserts were cycle-sequenced automatically 
(ABI-PRISM 377, DNA sequencer, Perkin Elmer, Norwalk, CT) on both 
strands. 
Genomic DNA analysis. Genomic DNA was isolated from peripheral 
blood leukocytes with a DNA isolation kit (Puregene, Minneapolis, MN). 
Sequence analysis. On genomic DNA, exon-specific PCRs were used. 
All primers are listed in Table 2.1. Exons 4 to 5 (including intron 
4) and 7 were amplified with RHD-specific primers (R496/Rex5AD2 
and R973/R1068, respectively) and cycle-sequenced automatically (ABI-
PRISM 377, DNA sequencer). Exon 5 and exon 6 were amplified with 
consensus primers (Rex5S2/Rex5A and Rex6S/Rex6A, respectively); PCR 
products were subcloned and sequenced. 
PCR assays. Five PCR allele specific primer amplifications (ASPAs) 
were designed specifically for detection of mutations. Primerset R31/R147 
and internal control primer R-15, all three primers located in exon 1, were 
used to recognize the RHC-specific nucleotide at position 48 (Faas et al., 
1996). An ASPA specific for RHCE nucleotides at position 602 and 667 
(primerset R581/R667) was developed to amplify intron 4. We applied an 
exon 5 ASPA, using an RHCE-specific sense primer (R678) and an RHD-
specific antisense primer (Rex5AD2) to detect a hybrid exon 5. An exon 
5 to 6 ASPA was used to amplify intron 5 with the RHCE-specific sense 
primer R678 in exon 5 and the RHD-specific antisense primer R933 in exon 
6. An exon 6 to 7 ASPA (primerset R973/R1044) with an RHD-specific 
sense primer in exon 6 and an RHCE-specific antisense primer in exon 7 
was developed to detect the RHCE-specific mutation in RHD-exon 7. 
RHD-specific multiplex PCR. RHD exons 3, 4, 5, 6, 7 and 9 were am-
plified with RHD-sequence-specific primers in a one-reaction mixture assay 
as described before (Maaskant-van Wijk et al., 1998). 
Restriction fragment length polymorphism of RH intron 5. To deter-
mine the origin of the intron 5 of the ceAR allele, intron 5 was amplified 
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Primer sequence Anneaung amplicon specificity 
time and 
temperature 
R-15 sense S'tatctagagacggacacaggA TGAGC3' 1' 60"C exon 1 consensus 
R31 sense 5'CGCTGCCTGCCCCTC!UC3' exon 1. C specific C specific: nt 48 
R147 antisense 5'TTGATAGGATGCCACGAGCCCC3' consensus 
R496 sense 5'CACATGAACATGATGCACA3' 1'55"C exon 4 to 5 D specific: nt 514 
Rex5AD2 antisense 5'cacCITGCTGATC'ITACC3' D specific: nt 787 
R581 sense 5'ACGGAGGATAAAGATCAGAG3' 1'55"C intron 4, CE specific CE specific: nt 602 
R667 antisense 5'CTCAGCAGAGCAGAGTTGAC3' CE specific: nt 667 
Rex5S2 sense 5' cctctctggccccaggCGCC3' 1'55"C exon5 consensus 
Rex5A antisense 5' cagcgccctgctcac3' consensus 
R678 sense 5'CTGCTGAGAAGTCCAATCC3' 1'55"C exon 5, CE-D hybrid CE specific: nt 707 
Rex5AD2 antisense 5'cacCTTGCTGATCTTACC3' D specific: nt 787 
R678 sense 5'CTGCTGAGAAGTCCAATCC3' 1'55"C exon 5 to 6, CE-D hybrid CE specific: nt 707 
R933 antisense 5'GTACTTGGCTCCCCCGAC3' D specific: nt 916 
R716 sense 5'TCAACACCTACTATGCTG3' 1'55"C intron 5 VS&D specific: nt 733 
R870 antisense 5'AGAAGGGATCAGGTGACACG3' consensus 
Rex6S sense 5' gctatttcttl£cag3' 30"48"C exon 6 consensus 
Rex6A antisense 5'tgtctagtttcttca3' u taq added consensus 
R973 sense 5'AGCTCCATCATGGGCTACAA3' 1'67"C exon 6 to 7, D-CE hybrid D specific: nt 992 
R!044 antisense 5'CACCAGCAGCACAATGTAGG3' CE specific: nt 1025 
R973 sense 5'AGCTCCATCATGGGCTACAA3' 1'55"C exon 7 D specific: nt 992 
R!068 antisense 5'ATTGCCGGCTCCGACGGTATC3' D specific: nt 1068 
R-15 sense 5'tatctagagacggacacaggATGAGC3' L5'55"C Full Length eDNA consensus 
R1339 antisense 5' gcgtttctcacgtacaaatgc3' consensus 
Table 2.1: Nucleotide sequences and positions of primers. 
The sequences of the oligonucleotides are given in capital letters when exon sequences 
are indicated and in small letters when intron sequences are indicated. 
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with sense primer R716 (specific for nt 733G, present in the RHCE allele of 
vs+ individuals and in the RHD allele) and antisense primer R870 ( consen-
sus primer). This product was RHD-specifically digested with restriction 
enzyme Apai (New England Biolabs Inc., Beverly, MA) and analyzed by 
electrophoresis in a 1% agarose gel. 
Southern blot analysis. 10 J-Lg DNA of all donors was digested with the 
endonuclease BamHI and after electrophoresis transferred to a nitrocellu-
lose membrane. Blots were hybridized with a 32P-labelled RH full-length 
eDNA (kindly provided by Dr. D. Anstee, IBGRL). The results were visu-
alized by autoradiography. 
PCR conditions. All PCR assays were performed in a Perkin-Elmer 
Cycler Model 480 (Norwalk, CT) on 200 ng of eDNA or gDNA in a total 
volume of 50 J-LL. Reaction mixtures contained 50 ng of each primer, 0.2 mM 
of each dNTP (Pharmacia) and 2 U of Taq DNA polymerase (Promega) in 
the appropriate buffer, supplemented with 1.5 mM MgCb. PCR conditions 
were 1 cycle of 5 minutes at 95°C, followed by 35 cycles of 1 minute at 
95°C, with an annealing time and temperature as described in Table 2.1 
and, depending on the size of the expected product, the extension time at 
72°C varied between 45 seconds and 2.5 minutes. Extension was completed 
during 5 minutes at 72°C. 
2.3 Results 
Serology. Individuals 3308, 3424, 3895, and 4413 were serologically typed 
as c-, c+, E- and e+, vs- and v+. RBCs of these four individuals 
showed weaker reactions with anti-D MoAb MS-201 and polyclonal anti-
D antiserum than did normal RhD-positive control cells. Therefore, with 
restricted screening protocols, these donors might be considered as express-
ing weak D. However, extensive serological studies of all four individuals 
showed a new partial-D pattern (see Table 2.2), in which 9 of the 37 epi-
topes were completely missing and 6 of the 37 epitopes showed different 
results with several MoAbs. These results were confirmed by Joyce Poole's 
laboratory of the IBGRL. RBCs of these four donors did not carry the low 
incidence antigen D w. 
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epitope- model Nantes DAR 
1-9 1-37 
I I LHM169/Sl ± 
I 2 LHM70/45, LHM174/102 
2 3 LOR12-E2, LORE ± 
2 4 LOR28-7E6 
3 5 LORll-209. LHM76/55, H41.11B7. H41 + 
4 6 LOR17-6C7 + 
5 7 CP:Z7-4C5 
IDR0-6 ± 
5 10 AUB-2F7/Fiss. MAR-lFS 
C205-29. CLASl-126. BS229. BS231 ± 
5 II 819 
617 12 175-2, LOR17-SD3. P3AF6, RUM-1. MS201. ± 
P3x61 
617 13 D-89/47. 17010C9, LOR28-21D3, H2D5D2F5 ± 
F5S + 
6/7 15 D-90n. D-90/17, NOI, SAL20-12D5. ± 
LHM50/2B, LHM!69/80, BIRMA-DG3. 
BIRMA-056, L87.1G7, 010 
6/7 17 HeM-92, NaTH53-2A7, P3Fl7, HIR0-1. HS114 
B9A4B2, NaTII28-3Cll, BS232 ± 
6/7 18 LHM59/20. T3D2F7, P3F20 
HG/92. LHMS0/3.5, LHM59/25, HM!O ± 
ID6-H8 + 
6/7 21 VOL-3F6 
D-90/12. BRADS ± 
HIR0-2 + 
8 22 LHM59/!9 
9 23 P3x21223B10 
BIRMA-D6. P3G6, MS26.HIR0-4,11IR0-7, ± 
HIRO-R 
31 NOU 
32 ZIG-189 
33 NaTHS7-4A5 
34 LORA 
35 SALSA-12 
36 NAU3-2E8, BTSN6, LHM76/59 ± 
NAU6-4D5 + 
37 822,HIR0-3 + 
Table 2.2: Epitope models (9 and 37) with the reaction pattern of the new 
partial D, tested with MoAbs described in the Nantes workshop (1996). 
The serology was performed as described before (Avent et al., 1997). This pattern was 
found in all nine individuals expressing DAR homozygously or next to a RhD-negative 
allele. These results were confirmed by Joyce Poole's laboratory of the IBGRL 
- (or +) = negative (or positive) MoAb reaction 
± = positive MoAb reaction, but weaker than that of normal RhD-positive contol cells 
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The antibodies present in the serum of patient 4413 were character-
ized with the adsorption-elution technique. It was shown that antibodies 
directed against RhD were present, among other antibodies. With agglu-
tination studies it was shown that these antibodies did not react with her 
own RBCs, nor with the RBCs of other donors with the DAR phenotype, 
but did react with RBCs from normal RhD-positive donors, indicating that 
these antibodies are alloanti-D. 
eDNA sequence analysis. Sequencing of eDNA from one individual 
(identification number 3424) showed the presence of three different tran-
scripts (Figure 2.1). At least three clones per different transcript were 
completely sequenced. 
1. A normal RHce transcript. 
2. An RHce-like transcript carrying G48C (Trp16Cys) in exon 1; A712G 
(Met238Val), C733G (Leu245Val), A787G (Arg263Gly) and T800A 
(Met267Lys) in exon 5 and A916G (Ile306Val) in exon 6. 
3. An RHD-like transcript carrying C602G (Thr201Arg) in exon 4, 
T667G (Phe223Val) in exon 5 and T1025C (Ile342Thr) in exon 7. 
Genomic DNA analysis. To confirm the mutations found in eDNA of 
individual 3424, as well as to show the presence of the mutations in the 
other three individuals 3308, 3895 and 4413, analysis on genomic DNA was 
performed. All of these results were in full concordance with the eDNA 
analysis. 
From individual 4413, not only the exons of interest, but all exons were 
amplified from genomic DNA and subsequently cycle sequenced. No other 
mutations were found. 
The mutations found in the RHce-like transcript were confirmed on 
genomic DNA by an ASPA which recognized the RHC-specific nucleotide 
at position 48, by sequence analysis of RHce-exon 5 which showed the 
mutations A712G, C733G, A787G and T800A; and by sequence analysis 
of RHce-exon 6 which showed A916G. The RHce origin of intron 5 was 
indicated by a remaining uncut part, after RHD-specific digestion with 
A pal of the 1791 bp product, obtained after RHD /VS-specific amplification 
of intron 5. 
48 
Transcript 1: normal ce-allele 
Transcript 2: partial-ce allele: ceAR 
48C 
Transcript 3: partial-D allele: DAR 
Exons 1 2 3 
712G 787G 
733G SOOA 9!6G 
602G 667G !025C 
4 5 6 7 8 
Figure 2.1: Transcripts as found by sequencing eDNA. 
DAR 
9 10 
Nucleotides derived from the RHCE-specific sequence are represented by a grey bar, 
whereas nucleotides derived from the RHD-specific sequence are represented by a black 
bar. RHD-specific exons or exon parts are represented by a black outer line, whereas 
those of RHCE are represented by a grey outer line. 
The mutations found in the RHD-like transcript were detected by se-
quence analysis of RHD-exon 4 to 5 and exon 7. Beside the mutations 
C602G and T667G, sequence analysis revealed a normal RHD-intron 4 
(Avent et al., 1997) and the T1025C mutation in RHD-exon 7. To show 
that only the mutated RHD transcript was present, in the absence of a 
normal RHD allele, the RHD-specific multiplex was performed. From all 
four DNA samples the 200bp internal control fragment from the ,6-actin 
gene was amplified. Amplification products from exons 3, 6, 7 and 9 were 
detected; whereas exons 4 and 5 were not amplified. 
Southern blot analysis. The BamHI digestion pattern of the genomic 
DNA from the four individuals (identification numbers 3308, 3424, 3895 
and 4413) showed no difference in the Rh patterns compared to a normal 
RhD-positive donor. 
Screening of the South-African Black donors. In 56 of the 326 
South-African Black donors (17.2%), the RHCE intron 4 PCR demon-
strated the two RHCE specific nucleotides in the exon 4 and 5 of the RHD 
gene, with an RHD intron 4 in between. All 56 of these donors were sero-
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logically RhD positive. In 16 of these 56 donors, the presence of T1025C 
was proven by the D-CE hybrid exon 6 to 7 PCR, indicating the presence 
of the DAR allele. 
Because a linkage between the DAR and the ceAR allele was assumed, 
we tested all 326 donors for the presence of the ceAR allele. In 20 of the 
326 donors (6.1%) the CE-D hybrid exon 5 PCR and the CE-D hybrid exon 
5 to 6 PCR gave positive results, indicating the presence of a ceAR allele. 
Of those 20 donors, 14 were also carrier of the DAR allele. Thus, 2 donors 
carried the DAR allele without the ceAR allele and 6 donors carried the 
ceAR allele without the DAR allele. 
Five of the 14 donors carrying the DAR and ceAR allele (1.5%) had the 
deviant RHD multiplex PCR pattern, missing exon 4 and 5. This indicates 
that these 5 donors were either homozygous for the DAR, or carried DAR 
on one allele and lacked RHD on the other. The results found on gDNA 
of these five donors were serologically confirmed and gave with all five the 
same 37 epitope pattern as shown in Table 2.2. 
In DNA of the 40 donors only carrying the C602G and T667G mutations 
in exon 4 and 5 of the RHD gene and not the T1025C mutation in exon 7, 
the CE-D hybrid exon 5 PCR and the CE-D hybrid exon 5 to 6 PCR gave 
negative results, indicating the absence of the ceAR allele. One of these 40 
donors showed the deviant RHD multiplex PCR pattern, missing exon 4 
and 5. 
2.4 Discussion 
In this study, a newly discovered RhD variant named DAR that occurs 
frequently in African Blacks, is described. This new RhD variant consists 
of an RHD allele with three point mutations on polymorphic sites, in which 
RHD-specific nucleotides are replaced by RHCE-specific ones. These mu-
tations are located in exon 4 (nt602), exon 5 (nt667) and exon 7 (nt1025). 
The four probands also had a variant RHce allele, called ceAR. This allele 
had an RHO-specific mutation on nt48 in exon 1, a hybrid exon 5 in which 
the polymorphic sites between nt712 and nt800 were replaced by RHD-
specific nucleotides, and an RHD-specific point mutation on polymorphic 
site nt916 in exon 6. 
This new RhD variant was previously described by us, as ARRO-I 
50 DAR 
(Hemker et al., 1998). At that time, sequence analysis was not completed. 
Further analysis revealed the mutation in exon 7 and the mutant RHce-
allele in these individuals. 
Serologically, this new RhD variant showed weaker reactions with a 
monoclonal anti-D and with polyclonal antiserum used for routine screen-
ing, indicating weak-D expression. The genomic features of the new vari-
ant have much resemblance with the recently described weak D type 4, in 
which also the mutations C602G and T667G are present, but the mutation 
T1025C is not (Wagner et al., 1999). However, with extensive serological 
testing, the RhD characteristics of the DAR phenotype gave a different, not 
previously described pattern of serological reactions with MoAbs. The loss 
of epitopes, as well as the finding of alloanti-D formation in an individual 
with the DAR phenotype, indicates that we are dealing with a new qual-
itative RhD variant with low expression. In one of the 40 South African 
Black donors in whom PCR-based analysis showed the mutation in exon 4 
and 5 but not in exon 7, the expression was not masked by the presence of 
a normal RHD gene. This donor is expected to present the weak D type 
4 phenotype. Preliminary serological results of this donor suggest a quan-
titative instead of a qualitative loss of epitopes, as can be expected from 
the results of Wagner et al. (1999). This is an intriguing observation in 
perspective of the effect of the mutation in exon 7 for the loss of epitopes. 
An explanation for this phenomenon can perhaps be found in the fact that 
the mutations in exon 4 and 5 do not change the polarity of the amino 
acids in the protein. In contrast, the transmembranal mutation in exon 
7 causes the incorporation of a hydrophilic amino acid (Thr) instead of a 
hydrophobic amino acid (Ile). This might result in a severe change in the 
conformation of the Rh protein, explaining the described loss of epitopes. 
In future, transfection studies will be performed to study this phenomenon 
in detail. 
The loss of so many RhD epitopes in DAR is the result of only three 
mutations in RHD, because from the variant Rhce-allele only addition of 
RhD epitopes can be expected. The mutations at the 3'end of exon 4 and 
the 5'end of exon 5 of the RHD allele are due to point mutations. This is 
suggested by the presence of a normal RHD intron 4, as shown by sequence 
analysis. However, aberrant nucleotides may occasionally be introduced 
if incorrect mismatch repair of the heteroduplex DNA takes place during 
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gene conversion (Huang et al., 1995). So, the DAR mutations on the 3'side 
of exon 4 and the 5'side of exon 5 also could be due to the occurrence 
of heteroduplex repair, rather than to spontaneous point mutations. The 
same phenomenon has been described for the glycophorins A and B, which 
are also encoded by highly homologous genes (Huang et al., 1995). 
The variant RHce-gene, ceAR, is characterized by a mutation in exon 
1, a hybrid exon 5, and a mutation in exon 6. The presence of G48C 
(Trp16Cys), the RHO-specific nucleotide in exon 1, without expression of 
this antigen, frequently occurs in African Blacks (Faas et al., 1999). The 
RHD-specific nucleotide found in exon 6 of the RHCE allele is probably 
caused by a point mutation or might be due to heteroduplex repair (see 
above), because restriction site analysis suggested a normal RHce-intron 5. 
Besides the ceAR allele also a complete RHce-allele was found, so it was 
not possible to test the loss of Rhce-epitope expression. All four individuals 
were expressing the rare vs-, v+ phenotype. Daniels has previously de-
scribed that the VSmutation (G733, in exon 5) surrounded by RHD-specific 
nucleotides in exon 5 and the V specific nucleotide 1006G (Gly336), pro-
vided the vs-, v+ serotype (Daniels et al., 1998). In this study, RHCE 
exon 6 was not sequenced. Therefore, four vs-, v+ samples of African 
Black donors, provided by Dr. G. L. Daniels (IBGRL) were sequenced, 
and indeed, these samples also showed the mutation in exon 6 as well as 
the RHC mutation (G48C). These results suggest that the most common 
genetic basis of the vs-, v+ phenotype is the ceAR variant. Furthermore, 
also these four donors carried the DAR allele. 
The four original probands in whom this new serological reaction pat-
tern was found, all proved to be of African Black origin. No Caucasians 
carrying this variant have so far been found during routine screening. This 
suggested that more African Blacks might be carriers of these genes. There-
fore, a group of 326 South-African Blacks was screened by genomic PCR. 
We found that 4.9% of this group are carriers of a DAR allele. Five donors 
(1.5%) had the gene homozygous or in combination with a RhD-negative 
allele, as was shown by the absence of the amplification products from exons 
4 and 5 in the multiplex PCR. These donors also had the same serological 
partial-D pattern as was shown in the 37 RhD-epitope model. The fact that 
so many South African Blacks are carriers of this gene suggests that these 
donors have an evolutionary advantage, as described for Duffy involving 
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malaria (Gelpi et al., 1976). So far, no correlations between Rh phenotypes 
and the occurrence of malaria have been found. However, these studies 
have been performed on immunologically recognized antigens, whereas this 
new variant is primarily recognized at the DNA leveL The frequency of the 
DAR phenotype (1.5%) in the African Black population is much higher than 
the frequency of D variants in the Caucasian population (0.1%- 0.001%), 
and therefore might have an impact on monoclonal reagent design. Testing 
the African Blacks for the presence of the ceAR revealed that 6.1% were 
carriers of this allele. 
The finding that the first four individuals tested expressed both variant 
alleles suggested that these two genes were inherited en bloc. By screening 
the 326 African Blacks, we expected to find only donors, carrying both 
mutated alleles or both normal alleles. The screening results did not confirm 
this idea, because besides donors with both variant alleles, also donors with 
only the DAR or ceAR allele were found. Nevertheless, the incidence of the 
combination is much higher than expected to occur by chance, indicating 
linkage of DAR and ceAR. 
Individuals with the DAR phenotype may form anti-D antibodies when 
exposed to a complete RhD antigen. Despite the loss of so many epitopes, a 
complete RhD antigen does not seem to be highly immunogenic for individ-
uals expressing DAR. Otherwise, the highly frequent DAR variant should 
have been recognized much earlier. A possible explanation for this low-
responsiveness may be that the footprints of most anti-D antibodies are 
related to one another, as was published recently (Chang et al., 1998). It 
is postulated that, in the alloimmune response against the RhD antigen 
in different individuals, a similar and restricted "pathway" is used. It is 
tempting to speculate, that in this variant, the apparent low immunogenic-
ity of the complete RhD antigen is due to the fact that the most common 
"pathway" could not be used, because these B cells have been clonally 
deleted or have become anergic to avoid self-reactivity. Probably a less 
common "pathway" has produced the anti-D made by the multi-transfused 
donor 4413. 
The clinical significance of these anti-D antibodies in this individual is 
not clear yet. Nevertheless, pregnant women and recipients of blood trans-
fusion expressing the DAR variant should be regarded as RhD negative. As 
donor, people expressing DAR should be carefully distinguished from RhD-
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negative donors by the use of selected reagents, because alloimmunization 
is likely to occur when administering RBCs expressing the DAR variant 
to RhD-negative recipients. Therefore, donors expressing DAR should be 
regarded as RhD positive. Hemolytic disease of the newborn could occur 
in fetuses expressing DAR when carried by an immunized RhD-negative 
mother, or in fetuses with the complete RhD antigen carried by mothers 
with the DAR phenotype. Therefore, in the future, anti-D monoclonals 
for immunoprophylaxis should be guaranteed to cover this new variant, 
especially because of the high incidence of this new variant in a multi-
ethnic society, in which RhD negativity is found more frequently than in 
the original African Black population. In addition, the chance of getting 
a population with an even higher frequency of people expressing DAR is 
increased, because the expression will not be masked by the presence of a 
normal RHD allele. 
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Chapter 3 
No altered RhD-protein 
structure and transcription 
level for the weak-D 
phenotype 
M.B. Hemker, M.T.B.P. ten Dam, P.C. Ligthart, 
G. Cheroutre, D.J. van Rhenen, P.A. Maaskant-van 
Wijk, C.E. van der Schoot. 
Abstract 
About 0.2% to 1% of the Caucasian population have RBCs with 
a reduced expression of the RhD antigen (weak D). Whether the 
weak-D phenotypes (caused by 22 different RHD alleles, with one 
or more point mutations) are purely quantitative variants or also 
have qualitative variations, is important for transfusion policy. 
The lower expression of RhD in the weak-D phenotype is not 
due to a change in the amount or stability of RHD mRNA, as was 
shown by RQ-PCR in this study. By fiowcytometry, no significant 
changes in expression of other proteins of the Rh complex were 
found, contributing to or caused by the weak-D antigen. 
A low Rhesus similarity index (RI), which is assumed to indi-
cate qualitative alterations, was measured in partial and weak-D 
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phenotypes by flowcytometry. Scatchard plot analysis and flow-
cytometry confirmed a significant lower epitope density on RBCs 
with the weak-D phenotype compared to the normal RhD-positive 
phenotype. But Scatchard plot analysis did not confirm possible 
qualitative alteration of the weak-D antigen. The affinity of each 
of the 7 MoAbs tested was not significantly different for the weak-
D antigen from that found for the normal RhD antigen. The low 
RI is not a good tool to observe qualitative alterations, because 
differences in epitope densities can be due to differences in affinity 
of antibodies, as was shown by Scatchard plot analysis. 
3.1 Introduction 
The Rh blood group system is clinically important, because antibodies 
against Rh antigens are involved in haemolytic disease of the newborn, 
haemolytic transfusion reactions and autoimmune haemolytic anaemia. 
Variations in RhD expression are either qualitative or quantitative, or 
a combination of these two. Red blood cells (RBCs) expressing qualitative 
variations (partial D) lack or gain epitopes, or some epitopes are changed 
in such a way that they seem to be present, but are less well recognised 
by the antibody. Individuals expressing a partial-D phenotype are able 
to form alloantibodies against the missing epitopes, when they encounter 
the complete RhD antigen. RBCs expressing quantitative variations can 
be divided in those with increased expression (e.g. D-- ) and those with 
decreased expression (weak D). 
About 0.2% to 1% of whites have RBCs with the weak-D phenotype. 
Because serologically it has been impossible to show qualitative differences 
between normal RhD and weak-D RBCs, it has become generally accepted 
that most weak Ds, if not all, possess a normal RhD antigen. Indeed, 
so far donors with the most common weak-D phenotypes do not form allo-
antibodies when the immune system gets in contact with the complete RhD 
antigen. 
A purely quantitative variation could be due to altered transcription 
activity of the RHD gene, or to reduced mRNA stability. The amount 
of RHD mRNA in reticulocytes of donors carrying the weak-D phenotype 
was measured before with a semi-quantitative PCR (Rouillac et al., 1996, 
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Beckers et al., 1997). Rouillac et al. reported reduced steady-state levels 
of RHD-mRNA transcripts in donors with a weak-D phenotype compared 
to levels of RHD-mRNA transcripts in donors with a normal expression of 
RhD. This is in contrast to Beckers et al., who found no differences in the 
amount of RHD-mRNA transcripts between normal and weak-D donors. 
To solve these discrepant results, we now determined the amount of RHD-
mRNA transcripts in reticulocytes of donors with weak-D phenotypes once 
again, but now more precisely with real-time quantitative PCR (RQ-PCR). 
Wagner et al. (1999) have shown that the weak-D phenotype is caused 
by many different RHD alleles encoding aberrant RhD proteins. In all 
22 different RHD alleles described for the weak-D phenotype, there are 
one or more point mutations located in the transmembrane or intracellular 
part of the RhD protein (http:/ jwww.uni-ulm.de/rvwfiegel/RH/, Wagner, 
Blood 1999). However, it is unclear whether these point mutations alter 
the exofacial structure of the RhD polypeptide, or only affect the formation 
of the Rh complex or the integration of the RhD polypeptide into the 
membrane without conformational changes in its extracellular loops. This 
distinction is important for transfusion policy. So far, no definite proof 
for qualitative variation has been obtained, since alloantibodies have never 
been found in individuals carrying the most common weak-D phenotypes. 
Alloantibodies have been found in two donors with weak-D phenotypes that 
are not frequently occurring (Wagner et al., 2000). One of these two donors 
carried the weak-D type 4.2, a genotype we like to refer to as the partial 
D DAR. The other donor carried the weak-D genotype 15, which might 
possibly also be a partial D. 
But, in a subsequent study, Wagner et al. (2000) suggested that these 
point mutations lead to qualitatively altered RhD antigens. This was based 
on the observation that in the different weak-D types the reduction of 
expression, as measured by fiowcytometry, is not observed to the same 
extent for all epitopes, as expressed with the Rh similarity index (RI). The 
RI is calculated as the ratio of the 10 percentile to the 90 percentile of the 
epitope densities detected with 59 anti-D MoAbs. As these studies were 
only done by fiowcytometry with a single antibody concentration, it cannot 
be formally excluded that differences in affinity and/ or concentrations of 
the antibodies are responsible for the differences in the RI. Therefore, in 
the present study we investigated by means of Scatchard plot analysis if 
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qualitative changes in the expression of the RhD protein of the two most 
common weak-D antigens (weak-D type 1 and weak-D type 2) occur. 
3.2 Materials and Methods 
Samples. Blood samples anticoagulated with EDTA were collected from 
Caucasian blood donors and characterised. RBCs of donors with the weak-
D phenotype (3-59, 3-62, 3-63, 3-66, 3-69, 3-77, 3-78, 3-82) were formerly 
used by Beckers et al. (1997). For Scatchard plot analysis also RBCs from 
other donors with the weak-D phenotype (40-1415, 40-1416, 40-1507, 40-
1511, 40-1514, 3-5166, 3-5328 (RBCs of this last donor were kindly pro-
vided by W.A. Flegel, Ulm, Germany) were used. RBCs were used of five 
donors with the D-- phenotype (3-5062, 3-2070, 3-2288, 3-2499, 3-2677), of 
one donor carrying the Rhnull phenotype (3-980), of two donors with the 
DVI type III (40-1510, 40-1517), of four donors with the DAR phenotype 
(3-5089, 3-5093, 3-5064, 3-5126) and of two donors with the DFR pheno-
type (3-5008, 3-5106). RhD-positive RBCs were used from blood donors 
with phenotypes R2R2 (n=1), R1R2 (n=6), R1R1 (n=9), R2r (n=2), Rlr 
(n=12), ROr (n=1), and RhD-negative RBCs of blood donors with pheno-
type rr (n=2) were used. 
Genomic DNA. Genomic DNA was isolated from peripheral blood 
leukocytes with a DNA isolation kit (Puregene, Minneapolis, MN, USA) 
Four allele-specific primer amplifications (ASP As) were designed specif-
ically to detect weak-D types 1 to 4. For weak-D type 1 (nt809 T_,.G), allele 
specific-sense primer WeakD1 (5'GCTATTTCTTTGCAGACTTATGG3') 
and D-specific antisense primer RexAD3 (5'TGTCTAGTTTCTTACCG-
GCAAGT3') were used. For weak-D type 2 (ntl154 G_,.C), allele specific 
sense primer WeakD2 (5'TATGCATTTAAACAGC3') and antisense primer 
Rex9a (5'GGTGAAAAATCTTAC3') were used. For weak-D type 3 (nt8 
C_,.G), allele specific sense primer WeakD3 (5'AGACGGACACAGGAT-
GAGCTG3') and antisense primer R127 (5'CCTTTTGATCCTCTAAG-
GAAGC3') were used. And for weak-D type 4 (nt602 c_,.G, nt667 T_,.G 
and nt819 G_,.A), CE-specific sense primer R581 (5'ACGGAGGATAAA-
GATCAGAG3') and CE-specific antisense primer R667 (5'CTCAGCA-
GAGCAGAGTTGAC3') were used, discriminating between RHD and 
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RHCE by their difference in length of intron 4. Primers specific for f3 
actin (sense primer f3ACTs: 5'CCTTCCTGGGCATGGAGTCCTG3' and 
antisense primer f3ACTas: 5'GGAGCAATGATCTTGATCTTC3') were 
added as internal control. All ASPAs were performed in 50-p,L mixtures 
and contained 200 ng of genomic DNA, 1.5 mM MgCl2, 200 p,M of each 
dNTP (Pharmacia, Uppsala, Sweden), 300 nM of each primer (Gibco BRL, 
Gaithersburg, MD) and 2 U of Taq polymerase (Promega, Madison, WI), 
pre-incubated with TaqStart antibody ( Clonetech Laboratories Inc, Palo 
Alto, CA, USA) The amplification was performed in a thermal cycler 
(Perkin-Elmer Applied Biosystems, model 9700, Shelton, CT) and con-
sisted of 5 minute 95°C, followed by 35 cycles of 1 minute at 95°C, 1 minute 
of 50°C to 64°C (64°C for weak-D type 1 and 3, 50°C for weak-D type 2 
and 59°C for weak-D type 4), 1 minute at 72°C and 5 minutes of 72°C. 
Sequence analysis. White blood cell-reduced RBCs were enriched for 
reticulocytes as described before (Murphy, 1973), (Simsek et al., 1994). 
mRNA was isolated from the reticulocyte-enriched fraction by standard 
procedures (Chomzynski et al., 1987). Each time mRNA was isolated from 
reticulocytes of weak-D donors, mRNA from reticulocytes of normal RhD-
positive donors was isolated at the same time. eDNA was obtained by 
reverse transcriptase. 1 J-Lg of RNA in a total reaction volume of 20 J-LL 
(containing 1x First strand buffer, 20 mM DTT, 1 mM dNTP's, 1 J-Lg 
random primers, 20 U RNAse OUT and 100 U MMLV-enzyme (Promega) 
was incubated for 60 minutes at 42°C. After inactivation for 3 minutes at 
99°C, 30 J-LL of H20 was added to make a total volume of 50 J-LL. 
Full-length amplification on eDNA was performed with consensus 
primers as described before (Hemker et al., 1999]. PCR products were 
ligated into pGEM-T vector (Promega) and the vectors were introduced 
into competent Escherichia coli by electroporation (Sambrook et al., 1989). 
Inserts were cycle sequenced automatically (ABI-PRISM 377, DNA se-
quencer; Perkin-Elmer, Norwalk, CT) on both strands. 
Quantification of eDNA by real time quantitative PCR (RQ-
PCR). All primers and probes used in the RQ-PCR were designed with 
the Primer Express version 1.0 software (PE Biosysytems, Foster City, 
CT, USA) and the Oligo 6.1 software (Dr W. Rychlik, Molecular Biol-
-------------------------
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ogy, Cascade, CO) according to the manufacturer's guidelines. eDNA 
specific primers and probes were developed for RHD, located in exon 6 
and 7 (sense primer Taq 915F: 5'CGTCGGGGGAGCCAAGTA3', anti-
sense primer Taq 1064R: 5'CCGGCTCCGACGGTATC3' and probe Taq 
986T: 5'CCCACAGCTCCATCATGGGCTACAA3') To correct for differ-
ences in the total amount of RNA input and for RT efficiency, the quantity 
of RHDtranscript in RBCs was "normalized" to the amount of KELL (sense 
primer Kell 1142F: 5'TGGAATATTTGAAAAACATGTCACAA3', anti-
sense primer Kell 1380R: 5'CTCGAAGAACGTGCCTGTCTC3', andre-
verse probe Tr-Kell1260: 5'CTTTCTGCGTGCCTCCTGGAATTGA3'), 
and in K562 cells to the amount of Cyclophilin (Control gene plate, Applied 
Biosystems). 
For RQ-PCR analysis the Taqman 1000 Reactions Gold with buffer 
A kit (PE Biosystems) was used. Reaction mixtures of 50 p,L contained 
the Taqman buffer A with the ROX dye as a passive reference, 5 mM 
MgCb, 200 p,M of each dNTP's, 300 nM primers, 100 nM probe, 1.25 U 
AmpliTaq Gold (PE Biosystems) and eDNA made from 10 ng of mRNA of 
reticulocytes ofweak-D donors and normal RhD-positive and RhD-negative 
donors or K562 cells. 
To quantify, a standard curve was made in each run from a ten-fold 
dilution of one of the samples, ranging from eDNA made of 100 ng to 
0.00001 ng of RNA. 
Serologic Analysis. Innitially, the weak-D samples were typed negative 
with polyclonal anti-RhD in direct testing, but all were positive in the 
indirect antiglobulin test (IAT). All weak-D samples gave a weak reaction 
with MoAb MS-201(CLB) 
The expression of different epitopes was tested in the indirect agglutina-
tion assay following standard procedures (as described before (Avent et al., 
1997)) with 70 selected monoclonal antibodies (MoAbs) with known epi-
tope specificity (Third International Workshop on Monoclonal Antibodies 
against Red Cell and Related Antigens, 1996, Nantes, France) 
Flowcytometry. Expression of RhD and parts of the Rh complex on 
RBCs was tested by FACS analysis. Murine monoclonal antibodies 
(MoAbs) BRIG 69 (anti-Rh29, kindly donated by Neil Avent, Bristol, UK), 
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5W2 (anti-Rh29, SBTS, Glasgow, Scotland), BS46 (19W3), BS56 (19W4) 
(anti-LWab, Biotest AG, Dreieich, Germany), LA18.18, 2D10 (anti-RhAg, 
CLB, Amsterdam), BRIC 126 (anti-CD47, F Spring, UK) FuJ30 (anti-Kell, 
Hisami Ikeda, Japan) and the human MoAb FLOS2/2 (anti-RhD, CLB, 
Amsterdam) were used. For each MoAb the optimal concentration was de-
termined by means of serial dilution. Antibody binding was demonstrated 
by Fluoresceine IsoThio Cyanate (FITC)-labelled goat-anti-human-Ig Fab 
fragments (Jackson ImmunoResearch), FITC-labelled goat-anti-mouse-Ig 
or PhycoErythrin (PE)-labelled goat-anti-mouse-Ig (DAKO A/S, Glostrup, 
Denmark). 
150,000 RBCs (concentration of 3*106 /mL) or 100,000 K562 cells were 
incubated with one of the MoAbs for 30 minutes, followed by incuba-
tion with either FITC-labelled goat-anti-human-Ig, FITC-labelled or PE-
labelled goat-anti-murine-IgG for another 30 minutes. All incubations 
were performed at room temperature. Cells were washed with phosphate-
buffered saline (PBS) containing 0.2% bovine serum albumin (BSA). Flow-
cytometric analysis of at least 10,000 cells was performed with a FACScan 
flow cytometer (Becton Dickinson Immunocytometry Systems, San Jose, 
CA). 
To compare epitope densities measured with different MoAbs in one 
experiment on different RBCs, flowcytometry was also performed with six 
of the MoAbs also used in the Scatchard plot experiments (HIRO 2 (III-1-
122), HIRO 55 (123), 187 1G7 (108), P3G6 (101), P3AF6 (102) and 170 
10C9 (136)) and a selection of MoAbs (6D10, RIMA 35, 415 1E4, OSK3-3, 
BRAD 8, 5C8, HIR095) used in the experiments of Wagner et al. (2000). 
All these MoAbs were obtained from the Third and Fourth International 
Workshops on Monoclonal Antibodies Against Red Blood cell and Related 
Antigens. The calculation of epitope densities was based on the median flu-
orescence detected with 'test RBC' relative to the 'standard RBC' (with the 
R1R2 phenotype, known epitope density 27,500 antigens/cell). These cal-
culations were performed with the spreadsheet version 1.1 <http:jwww.uni-
ulm.de / rvwflegel/RH/Paris2001 / >. Epitope densities, as calculated from 
flowcytometry experiments, performed by Flegel et al. were personally ob-
tained. 
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Scatchard plot analysis. Seven IgG anti-RhD MoAbs were used: 
HIR0-2 (epitope specificity (e.s.) 6.7 in the new epitope model, accord-
ing to the Fourth International Workshop, Paris(= e.s. 6.7-IV)), HIR0-55 
(=D6D02 e.s. 2.1-IV) (both kindly provided by Dr. Uchikawa, Japanese 
Red Cross Central Blood Centre, Tokyo, Japan) H41-11B7 (e.s. 3.1-IV), 
L87 1G7 (e.s. 6.3-IV) (both kindly provided by Dr. A. Rapaille, BTS, 
Liege, Belgique), P3G6 (e.s. 9.1-IV), P3AF6 (e.s. 6.1-IV) (both kindly 
provided by Dr. A. Martin, CRTS de Rennes, France) and 170 10C9 ( e.s. 
6.2-IV) (kindly provided by W. M. Eberlie, Dominion Biologicals Limited, 
Dartmouth, Nova Scotia, Canada). All MoAbs used for this assay were pu-
rified by passage through a protein A bead column, and labelled with the 
Ionogen method. Specific activity of the labelled antibody was determined 
by means of trichloric acid precipitation before and after dialysis. 
A two-fold serial dilution, starting at a concentration of 250 nM to 
0.5 nM, of the radioactive labelled antibody was made. An equal volume 
with 7x106 RBCs were added and incubated at 37°C till equilibrium had 
been reached (120 minutes for all MoAbs, as determined with an associa-
tion experiment for each MoAb). To prevent precipitation of RBCs during 
incubation, reaction tubes were mixed every 15 min. Unbound 125I-MoAb 
was removed by spinning the RBC suspension through a layer of 20% ( w jv) 
sucrose/ 0.1% (w/v) bovine serum albumin (BSA) in PBS. The amount 
of 125I-MoAb bound to the RBCs was measured for 1 minute in the RBC 
pellet on a multichannel gamma counter (Packard Instrument Company, 
Meriden, CT, USA). For each MoAb, the experiment was repeated three 
times. 
To calculate the number of epitopes on RBCs (Bmax) and the reciprocal 
of the affinity (Kd) the following assumptions were made: (i) for all MoAbs 
tested, non-specific binding was determined as the binding to RhD-negative 
cells, (ii) the molecular mass of all MoAbs is 160 kDa, (iii) only one MoAb 
can bind to a single epitope and (iv) binding of the MoAb to the RBCs 
follows the law of mass action and is reversible. To analyse the data, 
GraphPad Prism version 3.00 for Windows ( GraphPad Software, San Diego, 
California USA, www.graphpad.com), non-linear regression technique 'one-
site binding (hyperbola) was used. 
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Statistics. All results were expressed as the mean of at least three ex-
periments ± standard deviation (SD). Significance levels were determined 
with the two-sided Student's t-test. The data of Scatchard plot analysis 
did not have a normal distribution and were therefore compared with the 
Kruskall-Wallis test and Mann-Whitney test by the statistical computer 
program SPSS (SPSS Inc., Chicago, IL., www.spss.com). 
3.3 Results 
Molecular typing of weak-D samples. All 8 weak-D donors used by 
Beckers et al. (1997) carried one of the weak-D alleles described by Wagner 
et al. (1999) as shown by sequencing eDNA. Donors 3-62, 3-66, 3-69, 3-77, 
3-78, 3-82 all carried the weak-D type 1 allele ( nt809 T ---+G), donor 3-63 
carried the weak-D type 2 allele (nt1154 G---+C) and donor 3-59 carried 
the weak-D type 3 allele (nt8 C---+G). These mutations had been missed in 
our previous analysis (Beckers et al., 1997). Mutations were confirmed by 
ASPA-PCR on gDNA of these donors. 
The donors 40-1514 (weak-D type 1), 40-1415, 40-1416, 40-1507, 40-
1511 (weak-D type 2), 3-5328 (weak-D type 3) and 3-5166 (weak-D type 4, 
nt602 C---+G, nt667 T---+G and nt819 G---+A) were identified by ASPA-PCR 
on gDNA. 
Quantification of RHD mRNA by RQ-PCR. To compare the 
amount of RHD-mRNA transcripts of weak-D phenotypes with the RhD-
positive phenotype, RQ-PCR was performed. 
Reticulocytes of donors with weak-D phenotypes (n=9) had compara-
ble amounts of RHD mRNA independent of type, corrected for input, as 
reticulocytes of donors with a normal RhD-positive phenotype (Rlr n=3, 
R1R1 n=2). This RQ-PCR assay was not accurate enough to measure a 
twofold difference. The mean amount of RHD mRNA corrected for input 
(ratio RHD over Kell mRNA) of the weak-D phenotype was 1.4 ±0.6 and 
of the normal RhD phenotype 1.6 ±0.7 (p=0.68), as shown in Figure 3.1. 
No RHD mRNA was amplified from reticulocytes of donors carrying the 
RhD-negative or Rhnull phenotype, as expected. 
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Figure 3.1: The amount of RHD mRNA corrected for input. 
The amount of RHD mRNA corrected for input in reticulocytes from donors expressing 
normal RhD phenotypes (1.6 ±0.7) and different weak-D phenotypes (1.4 ±0.6). Values 
in ratios of RHD over Kell mRNA. 
Agglutination tests with a panel of RhD-specific MoAbs. RBCs 
from one donor of each weak-D phenotype (weak-D type 1, weak-D type 2, 
weak-D type 3 and weak-D type 4), three donors with a DAR phenotype 
and two donors with a normal RhD-positive phenotype (both Rlr) were 
tested with 70 MoAbs of the Third International Workshop on Monoclonal 
Antibodies against Red Cell and Related Antigens (1996, Nantes, France). 
Results are shown in Table 3.1. 
More positive reactions (with MoAb III-1-82 (LHM169/81), 48 (LOR28-
7E6), 46 (LOR17-8D3), 77 (LHM77/64), 53 (NAU3-2E8)) were detected 
in the weak-D phenotypes, compared to the partial-D phenotype DAR 
(Hemker et al., 1999), also described as weak-D type 4.2 by Wagner et al. 
(1999). Some epitopes seem to be absent in the weak-D phenotypes, but 
the MoA bs against those epitopes (III -1-79 (LHM70 /45), 48 (LO R28-7E6), 
54 (NAU6-1G6), 57 (NOU), 38 (NaTH87-4A5) also gave a weak reaction 
(2 instead of 4) for the RhD-positive phenotype. It might be that these 
epitopes cannot be detected by agglutination, because of low affinty of the 
antibody. The serologic results, data not shown, mainly indicate that it is 
hard to demonstrate qualitative variations by serologic analysis. 
Weak-D type 2 RBCs show a weaker reaction pattern than weak-D type 
1 RBCs. 
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pattern antibodies RhO positive partial RhO weak D type 
1-9 1-37 eoitooe model WS IV loG I oM R1r DAR 1 2 3 4 
3-5089 
18-862 3-5093 3-69 3-63 3-59 3-5166 
'3-5126 
1 1 1.} 
--
82 
-+ 3_ 
. 2 _2_ 3 2 
1 2 1,2 79 2 + 
83 2 + (+) 2 (+) 
2 3 2.1 44 3 2 + + 2 3 
51 3 - ND NO NO NO 
2 4 3.1 48 2 -
3 5 75 3 2 + 2 3 3 
106 3 2 2 + 2 3 
179 3 3 NO NO ND NO 
4 6 4.1 45 3 2 . + + 
5 7 5.1 116 3 + + 
42 4 - NO ND NO NO 
5 10 5.4 88,89 3 2 21+ + 2 3/+ 
41 3 1 ND ND ND ND 
__ 5 ____ ,_, 52 
- -; - ~ ' + . 6/7 12 5.5 69 -
6-1 102 3 3 2 + 2 3 
46 4 . 2 + 2 2 
113 4 2 . (+) + 
35 - ,,_4 
-· 
- -~-- . +f, . 
-"' 6/7 13 6.2 29,36,47,90,93,1 05 3 2 2 3 3 
6/7 15/16 6.3 71,81,97 3 21· 2 2 2/3 3 
32,58,1 08,1 14 3 
56 4 3 ND NO NO NO 
!11,95 3 
59 3 3 2 + 2 3 
80 3 __ 2 2 2 2 2 
6/7 17 6.4 134 3 - (+) 
115 3 - - (+) 
99 3 - (+) 
98 3 NO (+) 
28,34 4 (+)!- +I- +12 + 
37 3 (+) - + (+) 
39 4 - NO NO NO NO 
6/7 18 6.5 30 4 3 3 2 3 3 
119 3 . 
-
64,85 4 + + - +12 + 
86,87 4 - + (+)!-
100 
- -
. 
-
6/7 20/21 6.7 33 + 2 + 2 3 
94 4 - + 2 3 3 
122 4 4 2 2 3 3 
61 3 - NO NO NO NO 
8 22 8.1 7478 3 . NO NO NO NO 
9 23 9.1 112 3 2 2 + 3 3 
101 118 3 2 2 2 2/3 2/3 
120 121 3 3/- + + 2 3 
96 4 3 2 + 2 3 
77 3 - 3 3 3 3 
N/A 31 10.1 5457 2 . . . -
N/A 32 11.1 62 3 - NO NO NO NO 
NIA 33 12.1 38 2 - . NO NO 
N/A 34 13.1 so 2 - NO NO NO ND 
N/A 35 14.1 60 3 
-
NO NO NO NO 
N/A 36 15.1 72,76 3 2 2 2 3 3 
55 3 2 (+) + 2 2 
53 3 - +) (+) + + 
N/A 37 16.1 6873117124 3 213 2 21+ 3/2 3/2 
Table 3.1: Epitope models (9 and 37) with the reaction pattern of the 
weak Ds tested with MoAbs described in the Nantes Workshop 1996 
More positive reactions were detected with RBCs expressing weak RhD phenotypes than 
with RBCs expressing the weak partial-D phenotype DAR. Positive reactions were found 
in the range of "4" till "+" in declining agglutination strengths, negative agglutination 
reactions were described as "-" 
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Expression of proteins of the Rh complex on weak-D RBCs. To 
determine whether the expression of other parts of the Rh complex were al-
tered, contributing to or caused by the weak-D antigen, the numbers of total 
Rh (Rh29), RhD, RhAg, LW and CD47 sites on RBCs were determined on 
RhD-positive RBCs (Rlr, R2r, R1R2, R2R2 (n=2)), RhD-negative RBCs, 
weak-D phenotypes (type 1, 2 and 3), D-- and Rhnull RBCs. Results are 
depicted in Figure 3.2. No differences were observed between the different 
weak-D types; therefore, these results are pooled as weak D in this figure. 
BRIC 69 SW2 Flos2/2 
300.0E 
200,0 ~.·.·.·.·.•.·.· •••• ·••· •.·····.· 100,0 •: 
0,0 . . 
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2010 LA18.18 BRIC 126 
19W4 19W3 FuJ30 
, ... p... 100,0~.'.: .••.• •.· ,. •• ~~. , ... 
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Figure 3.2: The expression of different proteins of the Rh complex and 
control antigen (Kell). 
RBCs were tested for total Rh (BRIC69, 5W2), RhD (Flos2/2), RhAg (2D10, LA18.18), 
CD47 (BRIC126), LW (19W3, 19W4) and Kell ( FuJ30). The expression is related to 
RhD-positive RBCs (B), which is normalized at 100. A= D-- RBCs; B= RhD-positive 
RBCs; C= weak RhD RBCs; D= RhD negative RBCs; E= Rhnun RBCs. 
The expression of total Rh as measured both with MoAb BRIC69 and 
5W2 showed no significant difference between the weak-D phenotype (weak-
D type 1 (n=4) weak-D type 2 (n=l) and weak-D type 3 (n=l)), RhD-
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positive (n=4) and RhD-negative phenotype (rr, n=2). The D-- phenotype 
showed a lower expression of Rh29 with MoAb 5W2, whereas the expression 
measured with MoAb BRIC69 was normaL 
RBCs with the weak-D phenotype showed significant lower expression 
ofRhD, measured with FLOS 2/2 than RBCs with the normal RhD pheno-
type. (Mean epitope density of weak-D RBCs was 910 ±450, and the mean 
epitope density of the normal RhD-positive RBCs was 27,500 ±8,000). 
The expression of RhAg measured with MoAb 2D10 and LA18.18, was 
not different among RhD-positive, weak-D or RhD-negative RBCs. 
The number of LW antigens, measured with MoAbs 19W3 and 19W 4, 
were significantly lower on RBCs carrying the weak-D phenotype than on 
RBCs carrying the normal RhD phenotype (resp. p=0.005 and p=0.1), as 
described before by Beckers et al. (1997). 
The number of CD47 antigen, measured with ERIC 126, is equal on 
RBCs carrying the weak-D phenotype and RBCs with the normal RhD 
phenotype, but a significant lower (p< 0.001) number is expressed on RBCs 
carrying the D-- phenotype (n=5) 
The expression of Kell, as an internal control, measured with FuJ30, 
was similar for all RBCs tested. 
By fiowcytometry, the epitope densities of six weak-D type 1 and two 
normal RhD-positive (R1R2) phenotypes were determined with six of the 
MoAbs that were also used for Scatchard plot analysis and a selection of 
7 MoAbs used by Wagner et al. (2000). These 7 MoAbs were selected 
because of their relatively high (6D10, HIMA35, 415 1E4 and OSK3-3) or 
low (BRADS, 5C8, HIR095) expression levels on the weak-D type 1 in the 
fiowcytometry experiments (data kindly obtained from Dr. W. A. Flegel, 
Ulm, Germany). In Table 3.2, the expression of the weak-D phenotypes is 
related to the expression of the R1R2 phenotype. The expression of the 
weak-D type 1 phenotype in our experiment was comparable to theirs for 
the selection of 7 MoAbs of Wagner et al. (2000). The 6 MoAbs used in the 
Scatchard plot analysis, could be ranked among the other MoAbs for those 
that gave relatively high epitope densities on weak-D type 1 (1200 ±350; 
P3AF6; 4.9% of the number of epitopes on normal R1R2 cells), intermediate 
epitope densities (550 ±250; HIR02; 170 10C9; HIR055; 2.4%) and those 
with relatively low epitope densities (250 ±80; L87 1G7; 1.4%). 
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relatively high expression of weak RhO type 1 
6010 HlMA35 415 1E4 OSK3-3 
A 8 A 8 A 8 A 8 
wDl-A 3,7 5,1 3,1 7,6 2,7 3,2 3,3 7,7 
wDl-B 4,3 5,3 3,8 8,0 3,3 3,7 4,0 7,9 
wDl-C 5,1 4,5 7,1 6,5 
wOl-D 3,5 2,8 4,4 4,7 
wDl-E 2,3 1,9 3,4 3,5 
wOl-F 2.4 2 6 3 9 4,5 
mean wDl 4,0 4,0 3,4 4,6 3,0 4,3 3,6 5,8 
relatively low expression of weak RhO type 1 
BRADS 5C8 HlR095 
A 8 A 8 A 8 
wDl-A 0,9 2,6 0,5 1,3 1,1 1,0 
wDl-B 1,3 1,1 0,6 1,1 1,2 0,9 
wDl-C 1,3 2,1 1,3 
wOl-D 0,6 1,0 1,7 
wDl-E 0,1 0,2 1,0 
wOl-F 0 5 0,5 1,4 
mean wDl 1,1 1,0 0,6 1,0 1,2 1,2 
Scatchard Plot MoAbs 
P3AFG P3G6 HlR055 HlRO 2 170 10C9 
8 8 8 8 8 
wDl-A 5,2 4,7 5,6 2,0 3,7 
wDl-B 6,0 1,4 3,1 1,6 2,8 
wDl-C 6,4 3,0 2,7 4,0 4,1 
wDl-D 4,3 1,8 1,7 2,0 2,9 
wDl-E 3,2 1,1 0,5 1,1 2,1 
wOl-F 4,0 1,4 0.7 1 4 2 2 
mean wD1 4,9 2,2 2,4 2,0 3,0 
relatively high 
Table 3.2: RhD expression of weak-D type 1 RBCs as a percentage of RhD 
expression of R1R2 RBCs, measured by flowcytometry. 
Anti-D MoAbs are classified in relatively high expression (6D10, HIMA35, 415 1E4, 
OSK3-3) and relatively low expression (BRADS, 5C8, HIR095) on weak-D type 1 RBCs. 
MoAb P3AF6 could be ranked among the MoAbs with relatively high expression, MoAb 
L87 1G7 could be ranked among MoAbs with relatively low expression on weak-D type 
1, compared to RBCs with the R1R2 phenotype. (A) Data obtained from Dr. W. A. 
Flegel (Ulm, Germany); (B) current study. 
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Scatchard plot analysis. To determine the affinity of a MoAb for the 
different RhD phenotypes and to compare the affinities between the differ-
ent MoAbs, Scatchard plot analysis was performed. RBCs of the following 
phenotypes were used: weak-D type 1 (n=2), weak-D type 2 (n=4), DVI 
type III (n=2), DAR (n=2), DFR (n=2) and as normal control RhD posi-
tive (n=5) and RhD negative (n=2). 
The data in Table 3.3 and 3.4 are presented as the mean of three ex-
periments, with the 95% confidence interval. The data of the number of 
epitopes (Bmax) are presented in Table 3.3, the data of the Kd (reciprocal 
of the affinity) are presented in Table 3.4. 
With the different RhD MoAbs about the same amounts of RhD anti-
gens were measured per RBC. Homozygous RhD-positive (DD) RBCs ex-
pressed 31,915 ±2,275, and heterozygous RhD-positive (Dd) RBCs R2r: 
27,140 ±2,526 and Rlr: 12,970 ±4,782. However, from Table 3.3 it is clear 
that only minor differences were observed in the quantification of RhD epi-
topes with the same MoAb on the phenotypically same RBCs of different 
donors, but that slightly larger differences were observed in the quantifi-
cation of different RhD epitopes (measured with different MoAbs) of one 
donor. These differences are probably due to differences in specific activity 
of the labelled antibodies. This latter effect does not hamper the compari-
son of Kd values of one antibody for the different RBC types. 
With each MoAb a significantly lower amount (p<O.OOOl) of epitopes 
was found on the weak-D RBCs (930 ±450) compared to RhD-positive 
RBCs (21,000 ±9,700). The expression of RhD antigens was significantly 
lower (p<0.001) on weak-D type 2 RBCs (630 ±200) than on weak-D type 
1 RBCs (1,450 ±400), for all MoAbs tested. The RhD epitopes tested with 
the different MoAbs on partial-D RBCs varied between no expression at 
all (Dvr type III phenotype with MoAb HIR055 (epitope 2.1-IV) and L87 
1G7 (epitope 6.3-IV) and DFR phenotype with MoAb 170 10C9 (epitope 
6.2-IV) and HIR02 (epitope 6.7-IV)) and weak expression compared to 
the normal RhD phenotypes, as expected (Fourth International Workshop 
on Monoclonal Antibodies against Red Blood Cell and Related Antigens, 
2001, Paris, France) These results support the validity of our method. 
Most importantly, no significant differences in the Kd (reciprocal of the 
affinity) of the different MoAbs between weak-D RBCs and the normal 
RhD-positive RBCs were found, as shown in Table 3.4. If there would have 
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been qualitative differences between the normal RhD antigen and the weak-
D antigen an increase in Kd had been observed. Only for MoAb HIR055 
a lower Kd (higher affinity) was observed in weak-D type 2 RBCs. Indeed, 
in partial-D phenotypes reduced affinities were observed for some of the 
MoAbs. Significant reduction in affinity was found in 170 10C9 for DAR, 
P3AF6 for DFR and H4111B7 for DVI_ No affinity was found in 170 10C9 
and HIR02 for DFR and HIR055 and L787 1G7 for Dvr_ All expected, 
according to the Fourth International Workshop on Monoclonal Antibodies 
against Red Blood Cell and Related Antigens. 
To investigate whether the difference in epitope density, as measured 
by fiowcytometry, between the different MoAbs could be due to differences 
in affinity of the MoAbs, we closely examined the Kds of these MoAbs 
and their epitope densities measured by fiowcytometry. In Figure 3.3, all 
seven MoAbs tested by fiowcytometry and Scatchard plot are compared 
with each other ( 42 comparisons), the coordinates of a dot is the ratio of 
the% epitopes measured with MoAb A to MoAb Bon a weak-D phenotype 
(x-axis) and the ratio of the Kd of MoAb A to MoAb B (y-axis). 
We noticed, that if two MoAbs have comparable affinities (Kd MoAb 
A: Kd MoAb B = 1), also the epitope density detected by fiowcytometry is 
comparable (% expression measured with FAGS with MoAb A: % expres-
sion measured with FAGS with MoAb B = 1), depicted in Figure 3.3 as 
black diamonds. And when the affinity of one MoAb is significantly higher 
than the other (Kd MoAb A: Kd MoAb B < 1 or >1), this MoAb detects 
a higher epitope density than the other (% expression measured with FAGS 
with MoAbA:% expression measured with FAGS with MoAbB > 1 or <1), 
depicted as grey squares. This indicates that the epitope density measured 
by fiowcytometry is greatly influenced by the affinity of the antibody. The 
combinations of MoAbs that had significant (p< 0.05) differences in Kd 
were : HIR055 & P3AF6, H41 11B7 & P3AF6, H41 11B7 & 170 10C9, 
H41 11B7 & L87 1G7, H41 11B7 & P3G6, P3AF6 & 170 10C9, P3AF6 & 
L87 1G7, P3AF6 & HIR02, P3AF6 & P3G6, 170 10C9 & HIR02, L87 1G7 
& HIR02 and HIR02 & P3G6. 
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antibody HIROSS H4111B7 P3AF6 170 10C9 L871G7 HIR02 P3G6 
epitope (9-37) 2-? 3-5 6/7-12 6/7-13 617-15/16 6/7-20/21 9-23 
Controls 
RlRl 34790 34030 ND ND 31270 ND ND 
(33330-36250) (32220-35840) ND ND (28850-33680) ND ND 
R1R2 32410 30110 ND ND 28880 ND ND 
(30690-34120) {28200-32020) ND ND (30890-34490) ND ND 
R2c 30050 25850 ND ND 25520 ND ND 
(27600-32490) (24340-27350) ND ND (24260-26770) ND ND 
Ric ND ND 10900 8169 ND 20770 7570 
ND ND (10440-11350) (7816-8521) ND (19860-21670) (7260-7879) 
Ric 19100 14080 9659 9654 15960 17950 8863 
(17770-20430) (12800-15370) (9322-9996) (9333-9975) (15490-16420) { 17200-1871 0) (8400-9327) 
WcakD 
Type 1 ND ND 1793 1511 ND 2052 1266 
ND ND {1616-1971) (1476-1545) ND (1937-2168) (1205-1327) 
Type 1 1002 1510 1801 866 1649 1661 89i 
{824-1180) (1342-1678) (1685-1917) (834-899) (1578-1720) (1499·1822) (833·949) 
Type 2 371 555 726.7 392 697 1052 398 
(271-471) (451·658) (679·774) (359·424) (601.792) (967-1138) (344·352) 
Type 2 746 731 523 572 948 912 587 
(650·841) (657-806) (464-582) (541·603) (905.992) (837·987) (524-650) 
Type 2 380 6il ND ND 624 ND ND 
(291-489) (551·672) ND ND (591·657) ND ND 
Type 2 384 878 ND ND 609 ND ND 
(334·433) (683·1073) ND ND (572·648) ND ND 
Partial D 
DAR ND ND 867 33i ND 1580 632 
ND ND (728·1006) (265·396) ND (1458·1703) (562-703) 
DAR ND ND 1636 775 ND 2882 1327 
ND ND (1528-1744) (692-858) ND (2694-3070) (1265-1388) 
DFR ND ND 1241 ND 5762 
ND ND (804-1680) ND (5090-6434) 
DFR ND ND 950 ND 1436 
ND ND (364-1537) ND (1343-1529) 
DVJ 4874 ND ND ND ND 
(4279-5470) ND ND ND ND 
DVI 9088 ND ND ND ND 
{8519·9658) ND ND ND ND 
Table 3.3: RhD Epitope densities (Bmax) as determined by Scatchard plot 
analysis using 7 different MoAbs. 
Between brackets is the 95% confidence interval of three independent experiments. The 
epitope density of normal RhD-positive RBCs (controls) is significantly higher than the 
epitope density of weak-D RBCs (weak D). The epitope density on RBCs expressing 
weak-D type 1 is significantly higher than the epitope density on weak-D type 2 RBCs. 
As expected, epitope loss was demonstrated on RBCs expressing partial D in concordance 
with the variant analysed. ND= not done. 
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antibody HIROSS H4111B7 P3AF6 170 10C9 L871G7 HIR02 P3G6 
epitope (9-37) 2-? 3-5 6/7-12 6/7-13 6/7-15/16 6/7-20/21 9-23 
Controls 
R!Rl 11.2 10.9 ND ND 5.6 ND ND 
(9.7-12.7) (9.0-12.9) ND ND (3.9-7.3) ND ND 
R2r 11.8 9.2 ND ND 4.1 ND ND 
(8.7-15.0) (7.4-11.0) ND ND (3.2-4.9) ND ND 
R!R2 10.3 9.2 ND ND 3.8 ND ND 
(8.6-12.0) (7.1-11.4) ND ND (1.9-5.8) ND ND 
Rlr ND ND 1.9 2.6 ND 9.5 2.1 
ND ND (1.5-2.3) (2.2-3.1) ND (7.9-11.1) (1.7-2.6) 
R!r 8.3 5.8 1.7 3.0 3.0 7.4 2.7 
(6.3-10.3) (3.8-7.7) (1.4-2.0) (2.6-3.4) (2.6-3.4) (6.2-8.7) (2.1-3.3) 
WeakD 
Type 1 ND ND 2.3 4.6 ND 11.7 2.9 
RO, ND ND (1.3-3.4) (4.3-5.0) ND (9.3-14.1) (2.3-3.5) 
Type 1 5.2 12.4 2.1 4.2 7.2 8.3 5.6 
Rl' (1.6-8.7) (8.5-!6.3) (1.5-2.8) (3.6-4.8) (6.0-8.4) (5.3-11.3) (4.2-7.0) 
Type 2 1.8 4.9 1.4 2.4 4.2 7.4 4.0 
R2' (0.4-4.0) (1.4-8.4) (0.9-1.8) (1.6-3.2) (1.9-6.6) (5.0-9.8) (1.7-6.3) 
Type 2 3.8 3.8 1.8 3.2 2.9 7.7 2.3 
R2' (2.0-5.6) (2.2-5.4) (0.8-2.8) (2.5-3.8) (2.3-3.5) (5.2-10.2) (1.2-3.5) 
Type 2 2.2 8.1 ND ND 3.4 ND ND 
Ru (0-4.4) (5.6-10.7) ND ND (2.6-4.2) ND ND 
Type 2 3.5 13 ND ND 3.1 ND ND 
Ru (1.8-5.1) (4.9-21.1) ND ND (2.2-3.9) ND ND 
Partial D 
DAR ND ND 2.8 16.2 ND 11.1 2.9 
RO, ND ND (0.7-4.8) (7.5-24.9) ND (7.9-14.2) (1.6-4.2) 
DAR ND ND 2.3 IS ND 14.9 4.4 
RO, ND ND (1.6-3.1) (12.6-23.3) ND (11.6-18.3) (3.5-5.3) 
DFR ND ND 202 ND 4.6 
ND ND (96.0-308) ND (2.4-6.9) 
DFR ND ND 233 ND 1.8 
Rl' ND ND (28.7-437) ND (1.2-2.4) 
DVI 23.8 ND ND ND ND 
R!, (15.4-32.2) ND ND ND ND 
DVI 16.9 ND ND ND ND 
RJ' (13.6-20.2) ND ND ND ND 
Table 3.4: The Kd (M-1 ) as the reciprocal of the affinity of 7 anti-D MoAbs 
by Scatchard plot analysis. 
Between brackets is the 95% confidence interval of three independent experiments. The 
Kd of each MoAb did not show significant difference between the weak-D phenotype and 
normal D-positive phenotype. Between several MoAbs, the Kd of both normal D-positive 
and weak-D RBCs, did show significant differences. The Kd for the partial-D phenotype 
ranged from normal to extremely increased. 
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Figure 3.3: Kds measured with Scat chard plot analysis (y-axis) vs expres-
sion measured with fiowcytometry (x-axis). 
Comparison of two MoAbs with Kds in the same range are depicted as black diamonds. 
Comparison of two MoAbs with significantly different Kds are depicted as grey squares. 
When the Kds of two MoAbs are comparable, they also detect the same amount of 
epitopes by fiowcytometry. If the Kd of a MoAb is significantly higher (affinity is lower), 
less epitopes are detected and if the Kd of a MoAb is significantly lower, more epitopes 
are detected by that MoAb with fiowcytometry. 
3.4 Discussion 
Serologically, the weak-D phenotype is characterized by weak or negative 
agglutination reactions with polyclonal anti-RhD in an immediate-spin test. 
This agglutination can be enhanced in the indirect antiglobulin test (Race 
et al., 1948), (Stratton et al., 1948). RHD transcripts from people whose 
RBCs express a weak form of the RhD antigen were found to have missense 
mutation(s) within the predicted transmembrane or cytoplasmic domains 
of the RhD (Wagner et al., 1999). 
In the present study, we definitely prove that the lower expression of 
RhD in the most frequently occurring weak-D phenotypes is not due to 
a reduced amount or stability of RHD mRNA. By RQ-PCR, we showed 
in this study that equal amounts of RHD mRN A were isolated from the 
reticulocytes of donors carrying the weak-D phenotype types 1 & 2 and 
of donors carrying a normal D antigen. Preceding studies of Rouillac et 
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al. (1996) and Beckers et al. (1997) have studied the amount of mRNA 
before, with opposite results. Both studies used semi-quantitative PCR 
and therefore can be considered less accurate than RQ-PCR. 
By fiowcytometry, we examined whether the expression of other compo-
nents of the Rh complex (RhAg, CD47 and LW) was altered, contributing 
to, or caused by, the weak-D antigen. The lower expression of LW, also de-
scribed by Beckers et al. (1997), was confirmed. Most probably the lower 
expression of LW is caused by the weak expression of RhD, since the mu-
tations found in the weak-D phenotype have already been shown to be 
responsible for the lower expression of RhD (Chapter 4). No significant 
changes in expression of CD47 were observed. We also made two notewor-
thy side observations by means of fiowcytometry. The first observation was 
that the MoAb 5W2 (anti-Rh29) is probably directed against CE and not 
against total Rh, because 5W2 did not show expression in D-- and Rhnull 
RBCs. The second observation was a significant decrease in expression 
of CD47 (with MoAb BRIC126), not only on Rhnull RBCs, but also on 
D-- RBCs of all five donors, as described before (Gardner et al., 1991). 
This reduced expression of CD47 in the absence of RhCcEe suggests a cor-
relation between RhCcEe and CD47. Recent studies have revealed more 
about the attachment of the Rh complex to the cytosketon (see Figure 
1.5). The spectrin cytoskeleton is attached to band 3 via ankyrin. Band 
3 is linked to CD47 through interaction with protein 4.2 (Rybicki et al., 
1996), (Mouro-Chanteloup et al., 2003), (Bruce et al., 2003). And CD47 is 
associated with the Rh complex (Dahl et al., 2003) probably as concluded 
from this study via RhCcEe. 
The observation that the weak-D phenotype has normal levels of mu-
tated RHD mRNA leads to two possible hypotheses. The mutation found in 
the weak-D phenotype leads to a qualitatively altered weak-D antigen, like 
for example the partial-D variant DAR. Or the mutation found in the weak-
D phenotype leads to misfolding of a part of the RhD proteins, as has been 
observed for the Cystic Fybrosis Transmembrane Conductance Regulator 
protein ( CFTR) (Cheng et al., 1990). Thirteen of the 24 amino acid substi-
tutions in the 22 different weak-D types are located in the preserved regions 
of the Rh homologues (regions with identical or similar amino acids in RhD, 
RHCcEe, RhBG and RhCG). These well-preserved areas might be essential 
for the processing/ routing of the protein to the membrane. If RhD proteins 
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are misfolded, they will be unable to form a complex with the accessory 
proteins, therefore cannot be properly transported to the RBC membrane 
and will be degraded intracellularly (by proteasomes or lysosomes). If so, 
the small amount of properly folded RhD protein expressed on the RBC 
membrane is like the normal D antigen, and therefore the weak-D pheno-
type would purely be a quantitative variant. The difference between the 
two hypotheses is very important for the transfusion policy. The first hy-
pothesis implicates that alloantibodies can be formed, when an individual 
with the weak-D phenotype is transfused with RhD-positive RBCs. In con-
sequence, individuals with the weak-D phenotype should always be trans-
fused with RhD-negative RBCs or RBCs with the same weak-D phenotype. 
The second hypothesis implicates that alloantibodies will never be formed 
and individuals can be considered as RhD positive. Till now, alloantibod-
ies have never been found in persons carrying the weak-D phenotype, even 
though weak-D recipients receive RhD-positive RBCs, but this does not 
exclude that the weak-D antigen is not a qualitative variant. The normal 
RhD phenotype is not very immunogenic for some qualitative variants, like 
the DAR variant, which was frequently found in a South African popula-
tion (phenotype frequency 1.5%). Only two persons expressing the DAR 
phenotype, described in the literature, have been identified with alloanti-D 
(Hemker et al., 1999). The location of the mutations found in the different 
weak-D types (transmembrane or intracellular) is not a sufficient argument 
for this lack of alloantibody response. Although most partial-D antigens, 
and other immunogenic polymorphic bloodgroup antigens, have amino acid 
substitutions on the extracellular side of the protein, some partial-D anti-
gens (Drna, Drnc, Drv type III, DAR and the VS epitope) have amino acid 
subsitutions only on the transmembrane or intracellular side of the protein 
(Avent et al., 2000). Also individuals with these variants are known to pro-
duce alloantibodies. This indicates that not only extracellular mutations 
lead to conformational changes (qualitative alterations) in the exofacial 
loops. 
One way to demonstrate possible qualitative changes of the weak-D 
antigen is to look at the expression level of the different epitopes. If there is 
a change among the expression levels of the different epitopes, a qualitative 
variation is likely. A tool to observe qualitative changes in expression of the 
different epitopes is the Rh similarity index (RI). The RI is calculated as 
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the ratio of the lOth percentile to the goth percentile of the epitope densities 
detected with 59 anti-D MoAbs by flowcytometry. The RI may range from 
1 in normal RhD to 0 in partial D which are lacking many epitopes. Wagner 
et al. (2000) suggested that most weak-D types carry altered RhD antigens, 
because of their low RL 
A disadvantage of the RI is that the affinities of the MoAbs are not 
taken into consideration. By flowcytometry, antibodies with high affinity 
will still demonstrate high numbers of epitopes on weak-D antigens, while 
MoAbs with low affinity will fail to demonstrate all epitopes on weak-D 
antigens because of early dissociation of the antibody with the antigen 
(Van Bockstaele et al., 1986). Indeed, in the present study we demon-
strated, by Scatchard plot analysis, that the differences in epitope densities 
measured by the different MoAbs could be due to the affinity of the MoAbs. 
Moabs with equal affinities for the RhD antigens demonstrate equal epi-
tope densities on weak-D samples in flowcytometry, whereas MoAbs with 
large differences in affinity demonstrated similarly large differences in epi-
tope densities. Therefore, it cannot be concluded that the wider variance in 
epitope densities as reflected in the RI, is due to qualitative changes of the 
RhD antigen, as the lower RI might also be caused by differences in affinity 
of the antibodies. Moreover, with each MoAb, no significant difference in 
affinity was found between weak-D and normal-D antigens, again suggest-
ing that the conformation of these antigens was comparable. As expected, 
the affinity for some epitopes on partial D antigens was significantly lower 
(p< 0.0001). Besides neglecting the MoAb properties, in another way the 
RI does not only represent the qualitative differences of RhD. Small differ-
ences in fluorescence (for example of technical origin, therefore independent 
of cell type) in RBCs with high expression will be negligible (i.e., epitope 
density 10th percentile=27,350, goth percentile=27,650, Rl=0.99), while 
the same small difference in fluorescence in RBCs with low expression has 
an enormous impact on the RI (i.e. epitope density 10th percentile=500, 
goth percentile=800, Rl=0.6). These two remarks do not withstand that 
flowcytometry is very robust and reproducible, as has been tested in 12 
laboratories (Flegel et al., 2002). 
Scatchard plot analysis could be used to obtain the affinity ( =1/Kd) of 
MoAbs to the antigenic site (as described above), but also to obtain the epi-
tope densities (=Bmax). The epitope densities on the weak-D RBCs were 
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significantly lower than on normal RhD-positive RBCs, as expected, and 
were comparable to the fiowcytometry values of Wagner et al. (2000). Also 
a significantly lower number of RhD epitopes was observed on cells with 
the weak-D type 2 phenotype compared to the weak-D type 1 phenotype, 
conform the fiowcytometry values and agglutination strength difference be-
tween these phenotypes. 
As encountered before, the number of epitopes measured was dependent 
on the MoAb used in the Scatchard plot. This problem was encountered 
before (Moreau et al., 1987), and three hypotheses were formed. The Rh 
polypeptides could be present at varying depths within the lipid bilayer 
(Garrick et al., 1988); this was suggested by the finding that the addition of 
cholesterol into the RBC membrane increases the number of available RhD-
antigen sites (Shinitky et al., 1979). Also the estimation of the number of 
epitopes is ultimately dependent on determination of specific activity of 
the 125!-labelled MoAbs. This measurement is extremely sensitive to the 
presence of non-protein contaminants in the MoAb preparations. Thus 
the determination of the specific activity may have been incorrect, leading 
to an incorrect estimate of epitope number (Garrick et al., 1993). The 
last hypothesis suggested that some MoAbs measure a reduced number of 
epitopes because they are unable to bind to the epitope due to partial steric 
hindrance of neighbouring molecules (Garrick et al., 1993). 
Concluding, with Scatchard plot analysis and fiowcytometry a signifi-
cant lower epitope density was found in RBCs with the weak-D phenotype 
than with the normal D-positive phenotype. This is not due to a differ-
ence in amount or stability of RhD transcripts, because similar amounts 
of RHD mRNA were found in normal RhD and weak-D RBCs. Scatchard 
plot analysis did not confirm possible qualitative alteration of the weak-D 
antigen, because the affinity for the weak-D antigen and the normal RhD 
antigen for each MoAb did not differ significantly. We also proved that 
the differences in epitope density on the weak-D RBCs measured with the 
different MoAbs (rendered by a low RI), are caused by properties of the 
MoAbs and do not have to be due to a qualitative change of the weak-D 
antigen. Besides, also technical aspects can cause a low RI when measur-
ing low epitope densities. Therefore, there are still no solid arguments to 
consider weak D as not only a quantitive, but also a qualitative variant. 
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Chapter 4 
A K562 erythroleukemic cell 
line transfection model for 
the weak D type 1 and 3 
M. B. Hemker, G. Cheroutre, D. J. van Rhenen, 
P. A. Maaskant-van Wijk, C. E. van der Schoot 
Abstract 
About 0.2% to 1% of Caucasian population has red blood cells 
(RBCs) with a reduced expression of the RhD antigen (weak D). 
Different mutations in the RHD gene have been found in donors 
with the weak-D phenotype. The lower expression of RhD in the 
weak-D phenotype is not due to a change in the amount or stabil-
ity of mutated RHD mRNA, as was shown by RQ-PCR in RBCs. 
The expression of other components of the Rh complex was mea-
sured, by flowcytometry. Only the expression of LW showed sig-
nificant lower expression, probably caused by the weak-D antigen. 
To formally prove that the mutations are responsible for the re-
duced expression of RhD, a K562 transfection model was used 
expressing the weak-D type 1 (transmembrane nt809 T--+G) or 
3 (intracellular nt8 C--+G). In these K562 cells, a decreased ex-
pression of RhD without affecting the transcription level in the 
K562 model was shown. We postulated that the translocation 
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of the protein to the cell membrane might be interrupted by the 
weak-D mutations. To investigate this possibility, RhD was fused 
to green fluorescent protein (GFP) to localise the weak-D protein 
in the K562 cell. Degradation of intracellular misfolded proteins 
was prevented by proteasome inhibition. However, the genesis of 
the weak-D phenotype remains unsolved, because the inhibition of 
proteasomes did not lead to an accumulation of mutant proteins 
in our K562 model. This might be due to the experimental set-up, 
because K562 cells lack some essential components to yield com-
plete Rh complexes, and GFP might possibly lead to a change in 
conformation or processing of the fusion protein. 
4.1 Introduction 
About 0.2- 1% of Caucasians has red blood cells (RBCs) with reduced ex-
pression of the RhD antigen (weak D). Serologically, the weak-D phenotype 
is characterized by weak or negative agglutination reactions with polyclonal 
anti-RhD in an immediate-spin test. This agglutination is enhanced in the 
indirect antiglobulin test (Race et al., 1948), (Stratton et al., 1948). 
The lower expression of RhD in weak D is not due to a change in 
the amount or stability of RHD mRNA, as was shown before by RQ-PCR 
(Chapter 3). By flowcytometry, no significant changes were found in the 
expression of other components of the Rh complex (such as RhAg and LW) 
that might contribute to or be caused by the weak-D antigen (Chapter 3). 
In RHDtranscripts from weak-D individuals, missense mutation(s) have 
been found within the predicted transmembrane or cytoplasmic domains of 
RhD (Wagner et al., 1999). Subsequently, the Rhesus similarity index (RI) 
was introduced, a way to express the variation between the expression den-
sities of 59 epitopes measured by flowcytometry, and qualitative alteration 
of the weak-D protein was assumed. In a subsequent study, we showed by 
Scatchard plot analysis that the RI not merely reflects qualitative changes 
of the RhD antigen, because the RI is strongly influenced by the affinity of 
the antibodies used to detect RhD. 
Rh antigens are defined by a complex association of membrane polypep-
tides, assembled by non-covalent bonds. Rh and RhAg form the core of the 
Rh complex and are accompanied by CD47, LW and Glycophorin B (GPB). 
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Protein 4.2 provides a link between band 3 and the Rh complex via CD4 7 
(Figure 1.5). A current model suggests that if one subunit of the major 
components (Rh, RhAg) is missing, the Rh complex is not assembled or 
transported to the cell surface. As seen in the Rhnull phenotype, mutations 
in RHA G not only affect the transcription of the RHA G gene but can also 
affect the processing of the RhAg protein in several ways, which in turn 
may alter the formation of the Rh complex. Since it was shown that muta-
tions causing weak D do not affect transcription of RHD, the processing of 
the RhD protein to the cell membrane might be affected, resulting in weak 
expression of RhD. Also mutations in Rh-associated proteins may result 
in decreased expression of Rh antigens. For example, a lower expression 
of RhD was found on Southeast Asian Ovalocytosis red cells, which are 
heterozygous for a mutant band 3 containing a nine-amino-acid deletion 
(Tanner, 1997), (Tanner, 2002), and on band-3 Coimbra red cells, which 
are homozygous for a V488M mutation in band 3 (Ribeiro et al., 2000). 
The RH gene expression has been investigated in K562 cells, which 
appeared to be a good in vitro model to mimick red blood cells (Smythe et 
al., 1996). Retroviral gene transfer was used to transduce K562 cells with 
cDNAs, because transfection with plasmid expression vectors had met with 
very little success (Hermand et al., 1993), (Suyama et al., 1993). K562 cells 
are originally chronic myeloid erythroleukaemia cells that already express 
RhAg, which is considered to be essential for the expressi_o~ of R~ antigens. 
Although the K562 cell line was derived from an RhD-pos1tlve pat1ent, these 
cells express RhD to such a low extent that after transfection with RHD a 
clear rise in RhD expression can be observed. 
The present study was performed to examine whether and in ~hich way 
the point mutations found in weak-D alleles lead to weak express~on of the 
RhD protein. For this purpose, K562 cells were transfected w1th RHD, 
weak-D type 1 (wD1) or weak-D type 3 (wD3), or with RHD-GFP, weak-D 
type 1-GFP (wD1-GFP) or weak-D type 3-GFP (wD3-GFP) (GFP=green 
fluorescent protein). 
4.2 Materials and Methods 
Retroviral transduction. The construction of K562 cells expressing 
normal RhD (RHD-K562), the weak-D type-1 phenotype (wD1-K562) 
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labelled, PE-labelled or Cy5-labelled goat-anti-human-IgG for another 30 
minutes. All incubations were performed at room temperature. The cells 
were washed with phosphate-buffered saline (PBS) containing 0.2% (v/v) 
bovine serum albumin (BSA). Flowcytometric analysis of at least 10,000 
cells was performed with a FACScan fiowcytometer (Becton Dickinson Im-
munocytometry Systems, San Jose, CA). 
Confocal microscope imaging. Cells were prepared as for flowcytro-
metric analysis. The following additional antibodies and fluorochromes 
were used: C-20 (polyclonal IgG goat-anti-Vimentin, Santa Cruz Biotech-
nology, Santa Cruz, CA), Hoechst 33258 (to visualise the nucleus, Molec-
ular Probes, Eugene, OR) TRITC-labelled goat-anti-human-IgG (Jackson 
ImmunoResearch) and Alexa568-labelled rabbit-anti-goat-IgG (Molecular 
Probes). K562 cells were analysed as cytospins or on poly-L-lysine coated 
slides. Vectashield (Vector laboratories, Burlingane, CA) was added be-
tween the cells and coverslip, to enhance fluorescence. Images were recorded 
with a ZEISS LSM510 confocal microscope with appropriate filter settings. 
Cross-talk between the green and red channel was avoided by use of se-
quential scanning. 
Immunoblotting. For immunodetection, 106 cells were boiled in 50 J-LL 
of sodium dodecyl sulfate sample buffer (125 mM Tris, pH 6.8; 20% [wt/vol] 
sodium dodecyl sulfate; and 12.5% [voljvol] ;3-mercaptoethanol) and were 
loaded on a 12.5% polyacrylamide gel, according to Laemmli, in a gel ap-
paratus (Mini-Protean II, BioRad, Hercules, CA). Western blotting was 
performed (Mini Trans-Blot cell, BioRad) according to the manufacturer's 
recommendations. Detection of proteins was performed as described pre-
viously, with JL-8 (anti-GFP, BD Biosciences Clonetech). In the dot blot 
assay, an antibody directed against GPDH was used as an internal controL 
Proteasome inhibition. Proteasomes were inhibited with the protea-
some inhibitor Lactacystin (Calbiochem, La Jolla, CA). Cells were cultured 
overnight in IMDM complete containing 10 J-LM Lactacystin and compared 
to cells that were cultured in IMDM complete without additives. Pro-
teasome inhibition was checked by reduction of cell growth. Colouring 
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Vimentin (with MoAb C-20) to observe typical ring-like structures in the 
cells was used to check for the formation of aggresomes. 
4.3 Results 
Mutant RHD transfected K562 cells. To examine the influence of 
the mutations found in weak-D genotypes, a model was constructed for 
the weak-D type-1 phenotype and the weak-D type-3 phenotype in the 
erythroleukemic cell line K562. 
After transduction, K562 single cell colonies were selected with higher 
expression of total Rh (measured with MoAb ERIC 69) than the wild-
type K562 cells (WT-K562 cells). By making single cell colonies, it is 
possible to compare the variation in Rh expression among different colonies 
and to correct for differences in transfection efficiency. Twelve colonies of 
the wD1-K562 cells, wD3-K562 cells and RHD-K562 cells were used for 
further fl.owcytometric analysis. WT-K562 cells, pB-K562 cells (K562 cells 
transfected with an empty pBabe-puro vector) and RHcE-K562 (K562 cells 
transfected with RHcE) (Faas et al., 2001) were used as control samples. 
As shown in Figure 4.1, the expression of total Rh (Rh29) measured with 
MoAb BRIC69, was significantly lower (p=0.002) in wD3-K562 cells than 
in RHD-K562 cells or wD1-K562 cells. WT-K562 cells and pB-K562 cells 
showed a very low expression of Rh29. The expression of RhD, measured 
with MoAb FLOS2/2, was significantly lower in wD1-K562 cells and in 
wD3-K562 cells than in RHD-K562 cells (p < 0.04 and p=0.001, respec-
tively). The expression of RhAg, measured with MoAb 2D10, was com-
parable for wD1-K562 cells, wD3-K562 cells, RHD-K562 cells, RHcE-K562 
cells, WT-K562 cells and pB-K562 cells. The expression of LW antigens, 
measured with MoAbs 19W3 and 19W4, was significantly lower (p < 0.001) 
in wD3-K562 cells than in RHD-K562 cells or wD1-K562 cells. The expres-
sion of the CD47 antigen, measured with ERIC 126 did not differ among 
wD1-K562 cells, wD3-K562 cells and RHD-K562 cells, but was significantly 
higher (p=0.02) on RHcE-K562 cells. 
To exclude that the lower expression of RhD caused by the weak D 
point mutations in the K562 model is due to a lower transcription level or 
lower stability ofmRNA, the amount of RHD-mRNA was quantified by RQ-
PCR. All12 colonies of each cell type were tested. The results are shown in 
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Figure 4.1: The expression of different proteins of the Rh complex on K562 
cells, as measured by :flowcytometry. 
The expression of total Rh (BRIC69), RhD (Flos2/2), RhAg (2D10), CD47 (BRIC126) 
and LW (19W3, 19W4) was measured on K562 cells expressing normal RhD (nD), weak 
D type 1 (wD1), weak D type 3 (wD3), wild type (WT), empty pBabe puro vector (pB) 
and RhcE (cE). Expression is related to K562 cells expressing normal RhD. 
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Figure 4.2: Amount of RHD mRNA corrected for input. 
The amount of RHD-mRNA corrected for input in K562 cells expressing (A) normal 
RhD (RhD) (n=12), weak D type 1 (wD1) (n=12), and weak D type 3 (wD3) (n=12) 
and (B) RhD (n=1), wD1 (n=1), wD3 (n=1), green fluorescent protein (GFP) (n=1), 
RHD-GFP fusion protein (RHD-GFP) (=1), wD1-GFP fusion protein (wD1-GFP) (=1), 
wD3-GFP fusion protein (wD3-GFP) (=1). No differences could be found in the amount 
of RHD-mRNA among the different K562 cell types. 
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Figure 4.2A. The amount of RHD-mRNA corrected for input of wD1-K562 
cells (ratio RHD-mRNA to cyclophillin-mRNA ± SD = 0.68 ±0.45) and 
wD3-K562 cells (0.81 ±0.62) was comparable to the amount of RHD-mRNA 
in RHD-K562 cells (0.65 ±0.26) (n=12). A small amount of RHD-mRNA 
(0.014 ±0.007) was found in WT-K562 cells (As was previously described 
by Suyama et al., 1994), pB-K562 cells and RHcE-K562 cells. Also in 
the K562 cells transfected with GFP-fusion proteins, the same amounts 
of RHD-mRNA were found with RQ-PCR for RHD-GFP, wD1-GFP and 
wD3-GFP (mean ratio in all GFP-fusion K562 cells± SD=0.7 ±0.4; Figure 
4.2B). 
Based on these results, it can be concluded that the amino-acid al-
terations found in individuals with weak-D phenotypes lead to decreased 
expression of RhD without affecting the transcription level in the K562 
model. 
RhD and GFP expression in GFP-fusion K562 cells. The GFP-
fusion proteins were developed to visualize the localisation of the RhD 
protein or weak-D protein in or at the surface of K562 cells and to be able 
to use an antibody against GFP for immunodetection. 
Figure 4.3: Green fluorescent protein (GFP) expression. 
GFP expression measured on K562 cells expressing GFP fusion proteins. The GFP 
expression in the GFP-fusion K562 cells was highest for RHD-GFP K562 cells (black 
line), followed by wD3-GFP (dark-grey line) and lowest for wDl-GFP K562 cells (dashed 
dark-grey line. GFP expression of all GFP-transfected K562 cells was higher than the 
autofluorescence of WT-K562 cells (light-grey line). 
The GFP expression in the GFP-fusion K562 cells was highest for RHD-
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GFP K562 cells, followed by wD3-GFP and lowest for wDl-GFP K562 cells 
(Figure 4.3). 
Localisation of the GFP-fusion protein. Confocal Laser Scanning 
Microscopy (CLSM) was performed to study the localisation of the GFP-
fusion proteins in K562 cells. 
A distinct GFP expression on the membrane of the cell was observed 
in RHD-GFP, wDl-GFP and wD3-GFP K562 cells. GFP expression in the 
GFP-K562 cells was diffusely distributed through the whole cell, including 
the nucleus. No difference in expression of GFP was observed between 
RHD-GFP, wDl-GFP and wD3-GFP K562 cells. There was no relevant 
autofluorescence in the GFP-channel in WT-K562 cells. 
RhD expression, measured with MoAb Flos2/2, was co-localised with 
GFP on the cell membrane in the RHD-GFP-fusion K562 cells. No intracel-
lular staining was seen in these cells. No difference in RhD expression was 
observed among RHD, wDl, wD3, RHD-GFP, wDl-GFP and wD3-GFP 
K562 cells (Figure 4.4). 
Immunodetection of the GFP-fusion protein. As a control for the 
amount of free GFP, immunoblotting was performed with an antibody 
against GFP (JL-8). 
In the GFP-K562 cells a product of 27kD, representing free GFP, was 
detected in a major amount. Also in the GFP-fusion K562 cells a product 
of 27kD was detected, but only in a minor amount. In the RHD-GFP K562 
cells, wDl-GFP K562 cells and wD3-GFP K562 cells no RHD-GFP fusion 
product (of 57kD) was detected, which might be due to the multi-spanning 
organisation of RhD and therefore to complexes that are too large to run 
into the gel (Figure 4.5). 
Proteasome inhibition. To investigate whether proteasome inhibition 
results in accumulation of mutant RhD proteins, and therefore enhances the 
intracellular expression of RhD and/or GFP, K562 cells were overnight in-
cubated with proteasome inhibitor Lactacystin. Proteasome inhibition was 
confirmed by the observation of growth reduction. No other control could 
be used since MHC class I, downregulated after inhibition of proteasomes, 
is not present in K562 cells. 
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Figure 4.4: Confocal image of K562 cells. 
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Confocal image of K562 cells expressing green fluorescent protein (GFP), RhD and RHD-
GFP fusion proteins (RHD-GFP). The upper images only show GFP (green), the middle 
images only show RhD (red), the lowest images merge GFP and RhD detection (co-
localisation=yellow). The profile shows the expression of GFP (green) and RhD (red) of 
a cross-section of the K562 cell. 
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Figure 4.5: Western blot of GFP-fusion proteins. 
In the GFP-K562 cells a product of 27kD, representing free GFP, was detected in a major 
amount. Also in the GFP-fusion K562 cells a product of 27kD was detected, but only 
in a minor amount. In the RHD-GFP K562 cells, wDl-GFP K562 cells and wD3-GFP 
K562 cells no RHD-GFP fusion product (of 57kD) was detected. 
By fl.owcytometry, no increase in expression of RhD, measured with the 
conformation-independent MoAb LOR15C9, was observed in any of the 
permeabilised non-GFP K562 cell lines (RhD, wD1, wD3) after incubation 
with Lactacystin (Figure 4.6). Also no increase in expression of GFP was 
observed in any of the GFP-fusion K562 cell lines after incubation with the 
proteasome inhibitor Lactacystin (Figure 4. 7). 
By CLSM no increase in intracellular expression of GFP was seen in 
the GFP-fusion K562 cells after incubation with lactacystin (Figure 4.8). 
Aggresomes, typical ring-like Vimentin structures (Johnston et al., 
1998), were not observed by CLSM in permeabilised cells after proteasome 
inhibition. 
Immunoblotting was performed to quantify the amount of GFP in the 
GFP-fusion K562 cells before and after proteasome inhibition. Dot-blot 
analysis was performed, because immunodetection of the GFP-fusion pro-
teins by Western blot with SDS-PAGE was not possible. A large amount of 
GFP was present in RHD-GFP K562 cells, wD3-GFP K562 cells and wD1-
GFP, representing free GFP and GFP fused to RhD. A small amount of 
GFP was detected in the GFP K562 cells, representing only free GFP. For 
all GFP-fusion K562 cells no increase in amount of GFP was observed after 
incubation with Lactacystin. Equal amounts of all cells were used, because 
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Figure 4.6: Expression of RhD 
Expression of RhD before (continuous line) and after (dashed line) proteasome inhibi-
tion of wild type K562 cells (WT), K562 cells expressing RhD (RhD), weak D type 1 
(wD1) and weak D type 3 (wD3), by fiowcytometry with anti-D MoAb LOR15C9. Cells 
were permeabilised (P+) or not permeabilised (P-). No increase in RhD expression was 
observed in any of the K562 cell lines, with or without permeabilisation. 
GFP RhD-GFP wD1-GFP wD3-GFP 
Figure 4.7: Expression of GFP. 
Expression of green fi uorescent protein before (continuous line) and after (dashed line) 
proteasome inhibition of K562 cells expressing GFP (GFP), K562 cells expressing RHD-
GFP fusion proteins (RHD-GFP), weak D type 1-GFP fusion proteins (wD1-GFP) and 
weak D type 3-GFP fusion proteins (wD3-GFP). No increase in GFP expression was 
observed in any of the GFP fusion K562 cell lines. 
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Figure 4.8: Confocal image of K562 cells. 
Confocal image of K562 cells expressing green fluorescent protein (GFP) fusion proteins 
(RHD-GFP. wDl-GFP, wD3-GFP) before (upper) and after (lower) proteasome inhibi-
tion. No increase in intracellular expression of GFP was seen in the GFP-fusion K562 
cell types after incubation with lactacystin 
no difference in the amount of the control protein GPDH was detected 
(Figure 4.9). 
4.4 Discussion 
In RHD transcripts from weak-D individuals missense mutation(s) have 
been found within the predicted transmembrane or cytoplasmic domains of 
RhD (Wagner et al., 1999). In RBCs, these point mutations do not affect 
the amount or stability of the RHD-mRNA and neither do they lead to 
qualitative alterations of the weak-D antigen, as was determined by RQ-
PCR and Scatchard plot analysis (Chapter 3). 
To formally prove that the single nucleotide mutations found in donors 
with weak-D phenotypes really cause decreased expression of RhD, K562 
cells were transfected with a construct containing normal RHD ( RHD-
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Figure 4.9: Dot blot. 
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Dot blot detecting GFP (with JL8) and a control for input (co Ab GPDH), before (-L) 
and after ( +L) proteasome inhibition of K562 cells expressing GFP (GFP), K562 cells 
expressing RHD-GFP fusion proteins (RHD-GFP), weak-D type 1-GFP fusion proteins 
(wDl-GFP) and weak-D type 3-GFP fusion proteins (wD3-GFP). A large amount of GFP 
was present in RHD-GFP K562 cells, wD3-GFP K562 cells and wDl-GFP K562 cells, 
representing free GFP and GFP fused to RhD. A small amount of GFP was detected 
in the GFP K562 cells, representing only free GFP. In none of the GFP fusion K562 
cell types an increase in amount of GFP was observed after proteasome inhibition. The 
amount of the control protein GPDH was equal in all cell types, indicating that equal 
amounts of all cell types were used. 
K562) or with constructs containing the weak-D type 1 mutation (wD1-
K562) (T-tG at nt809, transmembrane, exon 6) or the weak-D type 3 
mutation (wD3-K562) (C-tG at nt8, intracellular, exon 1) both obtained 
by site-directed mutagenesis. As shown by fiowcytometry, both wD1-K562 
cells and wD3-K562 cells expressed RhD at reduced levels compared to 
RHD-K562 cells. Equal RHD mRNA levels were detected in wD1-K562 
cells, wD3-K562 cells and RHD-K562 cells by RQ-PCR. This confirms that, 
as seen in RBCs, the weak-RHD point mutations introduced in the RHD-
K562 cells did not have an effect on the transcription level of RHD. 
Although the reduction of RhD expression in wD1-K562 cells and wD3-
K562 cells compared to RHD-K562 is significant (40% of RHD-K562), it is 
not as low as in the weak-D RBCs (3% of normal RhD-positive RBC). The 
fact that the point mutations found in RBCs with the weak-D phenotypes 
did not cause the same strong reduction of RhD expression in K562 cells 
(even more pronounced for the wD1-K562 cells than for the wD3-K562 
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cells), might be due to the artificial expression system used in transfected 
K562 cells. The expression system with the SV 40 promoter could lead to 
an excess of RHD transcripts, resulting in a relatively high expression of 
mutant RhD protein on the membrane. The relatively low expression of 
RhD in RHD-K562 cells might be due to limiting amounts of other proteins 
of the Rh complex, such as RhAg (Mouro-Chanteloup et al., 2002). The 
mutation of the weak-D type 3 phenotype is located intracellularly near the 
N-terminus of the protein. It has been suggested that the tetrameric core of 
the Rh complex is formed by binding of theN-termini of two Rh30-proteins 
(RhD or RhCE) and two RhAg proteins (Eyers et al., 1994). A mutation 
in the N-terminus might interfere with the Rh complex formation with the 
RhAg proteins. Mutations in RhAg in Rhnull cells of the regulator type 
have taught us that complex formation is necessary for transport to the 
membrane (Cartron, 2000). Furthermore, K562 cells lack the expression of 
band 3. Beckmann et al. have co-transfected band 3 with RHD in K562 cells 
and observed an enhanced expression of RhD. They concluded that band 
3 might play a role in the translocation (and so enhances the movement 
of Rh components to the cell membrane) of the Rh complex or affects its 
conformation in the plasma membrane (Beckmann et al., 2001). Bruce et 
al. have shown that band 3 is involved in the association of the Rh complex 
to the membrane skeleton and proposed a band-3 macrocomplex in which 
the Rh complex and band 3 are linked via protein 4.2 and CD47 (Bruce et 
al., 2003). The stronger expression of RhcE in RH cE-K562 transfected cells 
compared to RhD expression in RHD-K562 transfected cells after band-3 
co-transfection may be explained by an interaction that is stronger between 
band 3 and the Rh complex containing the CcEe polypeptide than between 
band 3 and the Rh complex containing the RhD polypeptide. This notion 
and the proposed band-3 macrocomplex is in line with our observation that 
CD4 7 might have a stronger interaction with the RhCcEe polypeptide, as 
was shown by an decreased expression of CD47 in D-- RBCs (Chapter 3) 
and an increased expression of CD47 in RhcE-transfected K562 cells. 
The observation that the weak-D phenotype has normal levels of mu-
tated RHD mRNA leads to two hypotheses. The mutations found in the 
weak-D phenotypes lead to misfolding of all RhD proteins, of which most 
will not form a complex and are degraded, but some are expressed on the 
membrane and therefore are qualitatively altered and weakly expressed, 
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like for example the partial-D variant DAR. Alternatively, the mutation 
found in the weak-D phenotype leads to misfolding of most of the RhD-
proteins, but some are folded correctly, similar to the situation observed for 
the Cystic Fibrosis Transmembrane conductance regulator protein (CFTR) 
(Cheng et al., 1990). Thirteen of the 24 amino-acid substitutions in the 
24 weak-D phenotypes are located in the preserved regions of the Rh ho-
mologues (regions with identical or similar amino acids in RhD, RhCcEe, 
RhBG and RhCG), and most weak-D amino-acid substitutions are not lo-
cated on RhD /RhCcEe polymorphic sites. It might be that these well 
preserved areas or non-polymorphic sites are essential for the translocation 
of the protein to the cell membrane. If RhD proteins are misfolded, they 
will be unable to form a complex with the accessory proteins; therefore, 
they cannot be properly transported to the RBC membrane and will be 
degraded intracellularly (by proteasomes and lysosomes). Then the small 
amount of properly folded RhD protein expressed on the RBC membrane 
has the normal RhD-antigen conformation, and therefore the weak-D phe-
notype would purely be a quantitative variant. The difference between the 
two hypotheses is very important for transfusion policy. The first hypoth-
esis implicates that alloantibodies may be formed when an individual with 
the weak-D phenotype is transfused with normal RhD-positive RBCs. In 
that case, individuals with the weak-D phenotype should always be trans-
fused with RhD-negative RBCs or RBCs with the same weak-D type. The 
second hypothesis implicates that alloantibodies will never be formed, and 
weak-D individuals can be considered as RhD positive. 
The GFP-fusion proteins were developed to determine the localisation 
of the RhD protein in K562 cells and to quantify the amount of protein 
independently of the conformation. The GFP-fusion proteins wDl-GFP 
and wD3-GFP had a reduced expression of GFP compared to RHD-GFP, 
without a reduction in the amount of RHD mRNA. Confocal microscopy 
was used to localise the GFP-fusion protein, which was recognised by co-
localisation of GFP and RhD. RHD-GFP, wDl-GFP and wD3-GFP were 
almost exclusively present on the extracellular membrane. As expected, 
GFP-K562 cells only expressed GFP, diffusely distributed throughout the 
whole cell, and RHD-K562 cells only expressed RhD, almost exclusively 
localised on the extracellular membrane. Not much free GFP was present in 
the GFP-fusion K562 cells, as was shown by immunodetection on Western 
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blot. 
As the non-GFP and the GFP-fusion K562 cells both seem to be a good 
model for the weak-D phenotype, they were used to test the hypothesis 
about the genesis of the weak-D phenotype. To remove intracellular, mis-
folded or uncornplexed proteins, the intracellular ubiquitination pathway 
will be enhanced and proteasomes, which are more prone to remove trans-
membrane proteins than lysosomes, will be upregulated. By inhibition of 
these proteasomes with Lactacystin, an intracellular accumulation of mis-
folded or uncomplexed proteins might be expected. Aggregated misfolded 
or uncomplexed proteins may also segregate as aggresomes, ensheathed by 
the intermediate filament Vimentin (Johnston et al., 1998). In our K562 
model, proteasome inhibition should result in an increase in intracellular 
RhD in non-GFP K562 cells, an increase in intracellular GFP in GFP-fusion 
proteins and the presence of aggresomes. However, after proteasome inhi-
bition, no increase in expression of RhD was observed in non-GFP K562 
cells by flowcytometry, and no increase in GFP expression was observed 
in GFP-fusion proteins by flowcytometry, CLSM or immunoblotting. And 
aggresomes, typical ring-like Vimentin structures, were not detected by 
CLSM. 
The proteasome inhibition experiments presented in this study did not 
confirm the hypothesis on disturbance in the translocation of the weak-
D proteins. This might be due to the fact that another mechanism is 
underlying the genesis of the weak-D phenotype, but arguments can also 
be found to criticise the approach we used to confirm the hypothesis. To 
follow the processing of the weak-D protein, this model might have some 
disadvantages, as indicated below. The fact that the non-GFP proteins do 
not show an increased expression of intracellular RhD after inhibition of the 
proteasomes might be due to the MoAb LOR15C9. Although LOR15C9 is 
the only antibody recognizing a linear RhD epitope, it might be that the 
affinity or specificity is too low to recognise the misfolded or uncomplexed 
RhD protein. This may be the reason that equal expression levels of RhD 
were measured before and after incubation with Lactacystin. GFP-fusion 
proteins were developed to detect the RhD antigen without the use of an 
antibody. But the GFP-fusion proteins do have several other disadvantages. 
The first disadvantage concerns the effect of GFP on RhD expression. Since 
GFP has almost the same size and weight as RhD (27kD vs 30kD), this 
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might possibly lead to a change in conformation or processing of the fusion 
protein. Indeed, we observed a much lower expression of RhD as measured 
by fiowcytometry in the GFP-fusion transfectants than in the non-GFP 
transfectants. The second disadvantage concerns the stability of the GFP-
fusion protein. It is unknown whether the misfolded GFP-fusion proteins 
are completely degraded by the proteasomes or whether only the misfolded 
RhD part is degraded, leaving a free GFP protein intact. And it might 
also be that just after translation, part of the GFP-fusion proteins are 
spliced into separate GFP and RhD proteins. The presence of free GFP was 
demonstrated by immunodetection in Western blot analysis. In both cases, 
proteasome inhibition increased the expression of the GFP-fusion protein, 
but not of free GFP. If there is more free GFP in the cells than GFP-
fusion protein, the increase after proteasome inhibition cannot be noticed 
by fiowcytornetry or CLSM. However, these options are not very likely, 
because free GFP is present in the cells, but only in limited amounts. The 
third disadvantage concerns the use of an artificial promotor in the K562 
transfection model. The use of the artificial promotor can lead to an excess 
of (weak) RhD(-GFP) proteins, as described before. The production of the 
other Rh-complex proteins, such as RhAg, are regulated by the natural 
promotor of the K562 cell, and may therefore not be produced in sufficient 
amounts to form complete Rh complexes with all the (weak) D(-GFP) 
proteins. From Rhnull cells of the regulator type, we know that complex 
formation with RhAg is necessary for transport of the RhD(-GFP) to the 
membrane (Mouro-Chanteloup et al., 2002). When the proteasome activity 
is insufficient to degrade the excess of RhD (-GFP) proteins, no difference 
will be observed before and after proteasome inhibition. 
In conclusion, the mutations found in the weak-D phenotype directly 
lead to a decreased expression of RhD without affecting the transcription 
level in the K562 model. The genesis of the weak-D phenotype remains 
unsolved, since the inhibition of proteasomes did not lead to an accumu-
lation of mutant proteins in our K562 model. This might be due to the 
approach we used. Fusion of RhD with another, smaller and better im-
munodetectable tag (such as HA) might bypass some of the disadvantages 
encountered with the GFP fusion. Also co-expression of other parts of 
the Rh complex, which are not sufficiently produced to yield complete Rh 
complexes (e.g. RhAg) or to properly translocate or present the Rh com-
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plex on the cell membrane (e.g. band 3), might be an approach to further 
investigate the genesis of the weak-D phenotype. 
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Chapter 5 
The Rh complex exports 
from human red • ammonium 
blood cells 
M. B. Hemker, G. Cheroutre, R. van Zwieten, 
P. A. Maaskant-van Wijk, D. Roos, J. A. Loos, 
C. E. van der Schoot, A. E. G. Kr. von dem Borne 
Abstract 
The Rh blood group system represents a major immunodominant 
protein complex on red blood cells (RBCs). Recently, the Rh 
homologues RhAG and RhCG were shown to promote ammonium 
ion transport in yeast. In this study, we show that also on RBCs 
the human Rh complex functions as an exporter of ammonium 
lOllS. 
We measured the ammonium import during the incubation 
of the RBCs in a solution containing a radiolabelled analogue of 
NH4 Cl (14C-methyl-NH3 Cl). Rhnull cells of the regulator type (ex-
pressing no Rh-complex proteins) accumulated at room tempera-
ture radiolabelled methyl-ammonium ions to significantly higher 
levels (p=0.05) than normal RBCs. Rhnull cells of the amorph 
type (expressing limited amounts of Rh-complex proteins) accu-
mulated an intermediate amount of methyl-ammonium ions. To 
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show that a decreased export contributes to its accumulation, the 
release of intracellular methyl-ammonium from the cells was mea-
sured over time. In 30 seconds, normal RBCs released 87% of the 
intracellular methyl-ammonium ions, whereas Rhnull cells of the 
regulator type released only 46%. 
We conclude that the Rh complex is involved in the export of 
ammonium from RBCs. 
5.1 Introduction 
The Rh blood group system, expressed on red blood cells (RBCs), is of 
clinical importance, because antibodies against Rh antigens are involved in 
haemolytic disease of the newborn, haemolytic transfusion reactions and au-
toimmune haemolytic anaemia. Rh antigens are expressed on polypeptides 
encoded by the two highly homologous genes RHD and RHCE (reviewed 
in Avent et al., 2000). Several RBC membrane glycoproteins are associ-
ated with these Rh polypeptides, such as RhAG (GP50), LW, CD47 and 
glycophorin B. (Cartron et al., 1998) The Rh complex has an estimated 
molecular mass of 170 kD (Hartel-Schenk et al., 1992), and consists of a 
tetramer with two RhAG molecules and two RhCcEe or RhD polypeptides 
(Eyers et al., 1994). The Rhnull phenotype, in which no Rh antigens can be 
detected on RBC, is a rare autosomal recessive disorder characterized by 
a varying degree of haemolytic anaemia and spherostomatocytosis (Huang 
et al., 1999). 
DNA sequencing revealed that the erythroid Rh homologues 
RhD /RhCE and especially RhAG are related to the family of ammonium 
transporters, although nucleotide homology was not high (Marini et al., 
1997). Recently, the non-erythroid Rh homologues RhBG and RhCG have 
been described, which seem to be the missing link in the ammonium trans-
porter phylogenetic tree (Liu et al., 2000 & 2001). For these closely related 
non-erythroid Rh homologues, located in liver, skin, proximal tubules of 
the kidney (RhBG) and the testis, and in the collecting tubules of the kid-
ney (RhCG), an ammonium transport function has been proposed. Marini 
et al. (2000) have shown that RhAG and RhCG ( =RhGK) transfected into 
yeast promote ammonium ion (NH!) transport. However, it is not known 
whether RhAG and/ or RhD / CE also function as an ammonium transporter 
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in RBCs. 
It has been known for a long time that RBCs can be selectively lysed by 
a buffer containing NH4Cl and KHCOs (Figure 5.1) (Roos et al., 1970). We 
postulated that a possible role for the Rh complex in NH! transport might 
be revealed in an ammonium lysis assay. The enzyme carbonic anhydrase, 
present in RBCs, plays a central role in this selective lysis, because lysis is 
restricted to RBC and is strongly inhibited by inhibitors of this enzyme. 
Ammonia (NHs), formed by dissociation from NH! in the lysis buffer, 
diffuses into the RBC. Intracellularly, this NHs is bound to H+ derived 
from H2COs, formed by carbonic anhydrase from H20 and C02. The 
remaining HC03 inside the cell is exchanged for Cl- from the outside of the 
RBC by the anion exchanger band 3 (Tanner et al., 1988). Accumulation 
of NH! and Cl- in the RBC results in osmotic swelling and successive 
lysis of the RBCs. In initial experiments we found that Rhnull cells, which 
express no (regulator type) or limited amounts (amorph type) of the Rh 
proteins, were more sensitive to NH4Cl-induced lysis than normal RBCs 
(p<0.0001). Moreover, Rhnull cells of the regulator type were most sensitive 
to lysis. Although these results indicate that the Rh complex is involved in 
the export of NH! from the RBC, we cannot exclude that this decreased 
resistance is due to the known decreased osmotic resistance of Rhnull cells. 
Therefore, we studied the role of the Rh complex in NH! transport 
directly by analysis of the transport of radiolabelled methyl-ammonium in 
normal and Rhnull RBCs. 
5.2 Materials and Methods 
Samples. Cryopreserved (in 38% glycerol) RBC samples (anti-coagulated 
in citrate) were obtained from 21 normal donors with common Rh pheno-
types (R1r: 18-880, 18-882, 18-908; R2R2: 18-919, 18-911, 18-923; R2r: 
18-756, 18-877, 18-930; R1R1: 13-7818, 13-7920, 13-7922; ROr: 13-7772, 
13-8701, 13-8498; rr: 18-919, 18-911, 18-923, 18-903, 18-830, 18-921) and 
from 6 donors with the Rhnull phenotype (3-510, 3-980, 3-2301, 3-371, 3-617, 
3-5134). The Rhnull cells were completely deficient in RhD and RhCE as 
determined by both FACS analysis with ERIC 69 (a monoclonal antibody 
(MoAb) against RhD/CE) (Avent et al., 1988) and agglutination with a 
panel of human antisera. Four of the six Rhnull donors were of the regulator 
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Figure 5.1: Scheme of RBCs incubated in a solution containing NH4Cl and 
KHC03 . 
NH3 diffuses into the RBC. The enzyme carbonic anhydrase in the RBC converts C02 
and H20 into H+ and HC03. HC03 inside the cell is exchanged for Cl- from the 
outside. NH3 is protonated to NH:i. Accumulation of NH:i and Cl- in the RBC results 
in osmotic swelling and successive lysis. The Rh complex promotes the export of the 
intracellularly formed NH:i, thereby preventing the attraction of HzO and lysis. 
type, which is due to a molecular defect in the RHAG gene (Cherif-Zahar 
et al., 1996), resulting in the lack of expression of the complete Rh com-
plex. The absence of these proteins was determined by FACS analysis with 
the MoAbs 2D10 (anti-RhAG) and LA18.18 (anti-RhAG) (Von dem Borne 
et al., 1990; Mallinson et al., 1990). The other two Rhnull donors were of 
the amorph type because their RBCs lacked expression of RhD and RhCE, 
but RhAG was still expressed. Rhnull of the amorph type is the result of a 
molecular change in RHCE in tandem with a deleted RHD (Avent et al., 
1998; Cherif-Zahar et al., 1998 ;Huang et al, 1998). All RBCs were incu-
bated in sorbitol for 5 minutes directly after thawing from liquid nitrogen 
storage, suspended in erythrocyte preservation medium (CLB, Amsterdam, 
The Netherlands) and used within 4 days after thawing. Before use, the 
RBCs were washed three times with phosphate-buffered saline (PBS). 
The presence of ATP in all cryopreserved RBCs used, was demonstrated 
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by means of bioluminescent determination with luciferasejluciferin (Sigma 
Chemical Company, St.Louis, MO, USA); comparable amounts of ATP 
were found in all RBC suspensions. 
Scatchard plot analysis. The expression of RhAG was determined by 
Scatchard plot analysis with the 1251-labelled anti-RhAG MoAb 2D10 (125I-
2D10). The MoAb was labelled with the iodogen method. Two-fold serial 
dilutions from 250 nM to 0.5 nM of 125I-2D10 were made in a volume 
of 35 f.JL. RBCs were added (7 x106 RBCs in 35 ttL) and incubated at 
37°C until equilibrium was reached (120 minutes), as determined with a 
2D10 association experiment. To separate free 125I-2D10 from 125I-2D10 
bound to the RBCs, 50 ttL of the reaction volume was spun through a 
layer of 20% (w/v) sucrose/ 0.1% (w/v) bovine serum albumin (BSA) in 
PBS. Radioactive counts were measured in the RBC pellet for 1 minute 
on a Wallac multi-channel gamma-counter (Packard Instrument Company, 
Meriden, CT, USA). Non-specific binding was determined as the binding 
of 125I-2D10 to Rhnull cells of the regulator type. To analyse the data, 
GraphPad Prism version 3.00 for Windows was used (GraphPad Software, 
San Diego, CA, USA, http:/ jwww.graphpad.com/welcome.htm) with the 
non-linear regression technique 'one-site' binding (hyperbola). 
14C-methyl-ammonium loading. Because the radioactive isotope of 
nitrogen, 13N, has a short half life (only 10 minutes), the radiolabelled am-
monium analogue 14C-methyl-ammonium was used in our studies of ammo-
nium transport (Hackette et al., 1970). The ability of the Mep/AMT/Rh 
family (including RhAG) to transport 14C-methyl ammonium has been 
demonstrated before (Marini et al., 2000; Hackette et al., 1970). Indeed, 
in RBCs, similar kinetics of lysis were seen with methyl-NHsCl as with 
NH4Cl (data not shown). At RT and at 0°C, the intracellular concentra-
tion of 14C-methyl-ammonium was measured at different times after adding 
this ammonium chloride analogue to the cells. In this experiment, we used 
RBCs of four normal phenotyped donors, two donors with Rhnull of the 
regulator type and two donors with Rhnull of the amorph type. The exper-
iment was repeated three times. RBCs (1.6 x108 suspended in 160 ttL of 
PBS) were incubated with an equal volume of an isomolar PBS solution, 
containing 31 mM methyl-NH3Cl, of which 2%0 was 14C-methyl-NH3Cl 
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(143.4 Bq/p,L), 10 mM KHCOs and 0.1 mM EDTA. RBCs were separated 
from the solution by centrifugation through a Ficoll layer (1.077 gjcm3 , 
Amersham Pharmacia AB, Uppsala, Sweden). The minimal time needed 
for the procedure of sample taking, centrifugation and removing the Ficoll 
gradient was 2 minutes. The pellet was then resuspended in 116 p,L of 
PBS, and the proteins were precipitated by the addition of 6 p,L of perchlo-
ric acid (PCA). After 15 minutes of incubation on ice, the samples were 
centrifuged. One hundred p,L of clear supernatant was mixed with 10mL 
of the scintillation fluid Ultima Gold (Packard Instrument Company), and 
the radioactivity was measured in a 1900TR liquid scintillation analyser 
(Packard Instrument Company). The Transformed Spectral Index of the 
External Standard Spectrum (tSIE) was used to monitor and compensate 
for the quench level of each sample. The quench index was calculated from 
the Compton spectrum, induced by an external standard source (133Ba), 
and the measurements are, therefore, described as dpm instead of cpm. Ra-
dioactive counts are given as the average of 5 independent measurements. 
By measuring the optical density of the supernatant at 405 nm it was shown 
that in 31 mM methyl-NHsCl no lysis of RBC occurred. 
14C-methyl-ammonium release. Release of 14C-methyl-
ammonium/ ammonia in the supernatant and the amount of 14C-
methyl-ammonium/ ammonia left in the pellet was measured after different 
release periods at RT in normal RBCs (n=4), Rhnull cells of the amorph 
type (n=1) and Rhnull cells of the regulator type (n=2). The experiment 
was repeated three times. 
RBCs (2 x108 ) suspended in 200 p,L of PBS were incubated on ice for 
30 minutes with an equal volume of an isomolar PBS solution, contain-
ing 31 mM methyl-NH3 Cl, of which 2%0 was 14C-methyl-NHsCl, 10 mM 
KHCOs and 0.1 mM EDTA. The RBC suspension was divided into two 
parts, and the RBCs in both were separated from the solution by centrifu-
gation through a Ficolllayer. The RBC pellet of one part was resuspended 
in 116 p,L of PBS. The counts measured by means of scintillation in the 
clear supernatant obtained after the PCA precipitation procedure of these 
RBCs represent the total uptake of the 14C-methyl-NHt. The RBC pellet 
of the second part was resuspended in 300 p,L of ice-cold PBS or in 300 p,L 
of 31 mM unlabelled isomolar methyl-NHsCl solution. Samples of 100 p,L 
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were taken at RT, and the RBCs were spun down after 30 seconds, 90 sec-
onds and 180 seconds. The minimal time needed for separating the RBCs 
from the supernatant with the released counts is 30 seconds. The counts 
measured by means of scintillation in the supernatant of these samples rep-
resent the release of both 14C-methyl-NH!and 14C-methyl-NH2. The RBC 
pellets of these samples were resuspended in 116 p,L of PBS. Counts mea-
sured by means of scintillation in the clear supernatant obtained after PCA 
precipitation of these RBCs represent the remaining 14C-methyl-NH!in the 
RBC pellet after release. 
14C-benzylamine and 14C-urea loading and release. Loading and 
release experiments with 14C-benzylamine and 14C-urea were similarly per-
formed as with 14C-methyl-ammonium. We used RBCs of four donors with 
the normal phenotype and of three donors with the Rhnull phenotype (reg-
ulator (n=2) or amorph type (n=1)). The RBCs were incubated in an 
isomolar solution of PBS solution containing 31 mM benzylamine, of which 
2%o was 14C- benzylamine (138.8 Bq/ p,L), 10 mM of KHC03 and 0.1 mM 
EDTA or 200 p,M urea, of which 10% (37 Bq/ p,L) was 14C-urea. In the urea 
loading and release experiments also RBCs were tested from two donors (13-
9172, 13-7995) with the Kiddnun, Jk(a-b-), phenotype, missing the urea 
transporter (Sands et al., 1997). 
Correction for residual water. To measure the adherence of resid-
ual water to the different RBC types, we used (3000 MW) FITC-dextran 
(Molecular probes, Eugene, Oregon, USA). FITC-dextran is a fluorescent 
molecule that does not enter the RBC, but can be spun through the Ficoll 
layer in the watermantle of the RBC. We incubated the RBCs in an isomolar 
solution containing FITC-dextran (diluted 1:50). RBCs were precipitated 
with PCA as described above. The pH of the supernatant was restored 
with K2C03, precipitated salts were removed by spinning the samples for 
15 minutes at 4°C. The fluorescence of the supernatant was measured in 
a fiat-bottomed white polystyrene plate on the HT Soft multi-well reader 
(Perkin-Elmer, Norwalk, CT, USA) 
Statistics. The data of the different donors with the same phenotype 
were comparable and were, therefore, considered as one group. All results 
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were expressed as the mean of at least three experiments ± standard devia-
tion (SD). Significance levels were determined with the two-sided Student's 
t-test. 
5.3 Results 
RhAG expression on RBCs. The amount of RhAG expressed on the 
two Rhnull cells of the amorph type in comparison with normal RBCs of 
eight different donors, representing four different phenotypes, was deter-
mined by Scatchard plot analysis. The number of binding sites for MoAb 
2D10 on the RBCs of the two Rhnull RhAG-positive donors was 33% ±4% 
and 38% ±7%, respectively, of the binding sites on normal cells (n=8) 
as determined in three independent experiments. No expression of RhAG 
was seen on Rhnull cells of the regulator type. No clear differences in the 
amount of RhAG expressed on RBCs of the various Rh phenotypes were 
found, in particular no clear gene dosage effect was seen for RhD-positive 
and RhD-negative RBCs (data not shown). 
14C-methyl-ammonium loading. The RBCs were incubated at room 
temperature (RT) or at 0°C with a solution containing 14C-methyl-
ammonium chloride in the presence of an excess of unlabelled methyl-
ammonium chloride (31 mM) (see Material & Methods). Under these condi-
tions, methyl-NH2 diffuses freely into the RBCs and is quickly protonated 
to methyl-NHT- After different time points, the amount of intracellular 
14C-methyl-NHt jNH2 in the RBCs was measured. 
At RT in normal RBCs, the plateau of a low concentration of in-
tracellular methyl-NHt jNH2 was immediately reached, possibly because 
all methyl-NH2 converted to methyl-NHtwas pumped out of the RBC. 
In Rhnull cells, the intracellular methyl-NHt jNH2 concentration increased 
during the incubation period (Figure 5.2A). After 32 minutes, Rhnull cells 
of the regulator type and the amorph type contained about 2 times more 
14C-methyl-ammonium than the normal RBCs did (p<0.008). At 0°C in 
normal RBCs, an increase in methyl-ammonium content was observed with 
time; with similar kinetics, the same plateau was reached as was observed 
for the two types of Rhnull cells (Figure 5.2B). 
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14C-methyl-ammonium release. Loading of RBCs with 14C-methyl-
NHi /NH2 was performed for 30 minutes at 0°C, because all RBCs ac-
cumulated the same amount of 14C-methyl-NHi jNH2 under these condi-
tions. After loading, the cells were incubated at RT. The release of 14C-
methyl- NHt jNH2 was expressed as a percentage of the total intracellular 
amount after loading with 14C-methyl-NHi jNH2 (Figure 5.3). Normal 
RBCs had released almost all intracellularly loaded 14C-methyl-NHi jNH2 
within the first 30 seconds. The Rhnull cells of the regulator type (with-
out RhAG) did not release all loaded methyl-ammonium within 3 minutes 
(p<0.006). In Rhnull cells of the amorph type (with RhAG) the release of 
methyl-ammonium was slower than in normal RBCs. It took significantly 
more time (90 seconds at RT, p=0.013) to release the radiolabelled methyl-
ammonium than in normal RBCs. No clear differences were seen between 
the release of 14C-methyl-NHi /NH2 when the loaded RBCs were resus-
pended in PBS or when the cells were resuspended in an isomolar solution 
containing 31 mM methyl-NH3Cl concentrations (data not shown). In all 
samples, the sum of the radioactivity in the supernatant and in the pellet 
constituted the radioactivity of the input. 
14C-benzylamine and 14C-urea loading and release. To determine 
whether the observed differences between normal RBCs and Rhnull cells 
were specific for ammonium transport, the transport of radiolabelled ben-
zylamine and urea was measured as welL Loading the RBCs at RT with 
14C-benzylamine, a plateau of low concentration of intracellular benzy-
lamine was immediately reached in Rhnull and normal RBCs. The per-
centages of released 14C-benzylamine after 30 seconds, 90 seconds and 180 
seconds, measured in three separate experiments after loading the RBCs 
with equal amounts of 14C-benzylamine, were similar in Rhnull cells and in 
normal RBCs. In 30 seconds, normal RBCs released 82.9% ±6.5%, Rhnull 
amorph type 83% ±10.2% and Rhnull regulator type 84% ±8.5%. After 
180 seconds, normal RBCs released 85.9% ±5%, Rhnull amorph type 88.2% 
±3.5% and Rhnull regulator type 88.4% ±4.2% (n=3). 
Also by loading with 14C-urea, a plateau of low concentration of in-
tracellular urea was immediately reached in normal and Rhnull RBCs, but 
in Kiddnull cells the intracellular urea concentration increased during the 
incubation period (Figure 5.4). After 15 minutes Kiddnull RBCs contained 
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about 7 times more 14C-urea than did normal and Rhnull RBCs (p:S0.006). 
To measure the release of intracellular urea, all RBCs were loaded with 
equal amounts of 14C-urea and then incubated in an isomolar phosphate-
buffered solution (Figure 5.5). Both normal and Rhnull (regulator and 
amorph type) RBCs released 87% of the intracellular accumulated urea 
within 30 seconds, while the Kiddnull RBCs released only 42% (p<<O.OOOl). 
In 180 seconds, Kiddnull RBCs released 82% of the intracellular urea, which 
was still significantly less than the normal and Rhnull RBCs (p<0.02). 
Correction for residual water. To exclude a difference in the amount 
of residual water, we measured the amount of FITC-dextran adhered to 
the different cell types. No differences were measured in fluorescence be-
tween the different RBC types (n=3). The proportion of contamination 
of external medium in the RBC pellet in Rhnull cells was 0.21% ±0.02% 
and in normal RBCs 0.22% ±0.11%. This indicates that the proportion of 
contamination of external medium in the RBC pellet between the different 
RBC types is comparable. 
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Figure 5.2: 14C-rnethyl-arnrnoniurn loading at RT (A) and 0°C(B). 
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Radioactivity of 14C-methyl-ammonium measured in pellets of normal RBCs (n=4) 
(black diamond) and Rhnull cells of the amorph type (n=2) (grey triangle) and the 
regulator type (n=2) (grey square) after different incubation times in a 31 mM methyl-
NH3Cl (2%0 14C-methyl-NH3Cl) solution. Before counting the radioactivity, the proteins 
were precipitated as described in "Materials and Methods". The data are depicted as 
the mean ± SD of three experiments. Data of the different donors are pooled. The 
radioactive counts are given as the average of five independent measurements, corrected 
with an external control (dpm). Significantly more 14C-methyl-ammonium/ammonia 
was loaded in Rhnull cells than in normal RBCs at RT (A). In normal RBCs significantly 
more radioactivity was loaded at 0°C than at RT (B). 
30" 90" 180" 30" 90" 180" 
normal amorph type regular type 
Figure 5.3: 14C-rnethyl-arnrnoniurn release. 
RBCs were loaded with 14C-methyl-ammoniumjammonia by incubation on ice for 
30 minutes in an isomolar buffer containing 15.5 mM methyl-NH3Cl of which 2%0 
was 14C-methyl-NH3Cl. Loaded RBCs were incubated in PBS at RT. Release of 
14C-methyl-ammoniumjammonia in the supernatant and the amount of 14C-methyl-
ammonium/ ammonia in the pellet was measured after different release periods at RT 
in normal RBCs (n=4), Rhnull cells ofthe amorph type (n=1) and Rhnull cells of the reg-
ulator type (n=2). The results are expressed as percentage of total intracellular amount 
after loading with 14C-methyl-ammonium. The sum of radioactivity in the pellet and in 
the supernatant was always 100%. The data are depicted as the percentage of radioac-
tivity released by the cells after 30, 90 and 180 sec, mean ± SD of three independent 
experiments. Data of the different donors are pooled. 
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Figure 5.4: 14C-urea loading at RT. 
Radioactive counts of 14 C-urea measured in pellets of normal RBCs (n=4) (black dia-
monds) and Rhnu!l cells ofthe regulator type and amorph type (n=3) (grey squares) and 
the Kiddnu!l RBCs (n=1) (open triangles) after different incubation times in a 100 J-LM 
urea (10% 14C-urea) solution. Before counting the radioactivity, the proteins were pre-
cipitated as described in "Materials and Methods". The data are depicted as the mean 
± SD of three experiments. Data of the different donors were pooled; no differences were 
seen between the two Rhnull types. The radioactive counts are given as the average of 
five independent measurements, corrected with an external control ( dpm). Significantly 
more 14C-urea was loaded in Kiddnull cells than in normal RBCs and Rhnull cells. 
normal Rhnull Kiddnull 
Figure 5.5: 14C-urea release. 
RBCs were loaded with 14C-urea by incubation on ice for 30 minutes in an isomolar buffer 
containing 100 J-LM urea of which 10% was 14C-urea. Loaded RBCs were incubated in 
PBS at RT. Release of 14C-urea in the supernatant and the amount of 14C-urea in the 
pellet was measured after different release periods at RT in normal RBCs (n=4), Rhnull 
cells (n=3) and Kiddnull cells (n=2) and expressed as percentage of total intracellular 
amount after loading with 14C-methyl-ammonium. The sum of radioactivity in the pellet 
and in the supernatant was always 100%. The data are depicted as the percentage 
of radioactivity released by the cells after 30, 90 and 180 sec, mean ± SD of three 
independent experiments. Data of the different donors were pooled. 
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5.4 Discussion 
Previously, it has been shown that RhAG transfected into yeast promotes 
NHt transport, both import and export (Marini et al., 2000). In the present 
study, we show that also in RBCs the Rh complex functions as an am-
monium/ ammonia exporter. Based on experiments with Rhnull cells, we 
postulate that upon incubation with an aqueous solution of NHt, in which 
ammonium ions are in equilibrium with ammonia, NH3 can diffuse over the 
RBC membrane, independent of the presence of the Rh complex. Within 
the red cell, NH3 binds H+ derived from H2C03, formed by carbonic an-
hydrase from H20 and C02 (Figure 5.1). The Rh complex promotes the 
export of this intracellularly formed NHt. Initially, we noticed that upon 
incubation in a lysis solution, containing 77.5 mM NH4Cl and KHC03, 
Rhnull cells lyse significantly faster than normal RB Cs (data not shown). 
Because it is known that Rhnull cells are osmotically more fragile, this obser-
vation might be independent of any transport function of the Rh complex. 
But it already argues against a major role for the Rh complex in the im-
port of ammonium. It has previously been shown that the RBC membrane 
is permeable for NH3, whereas no NHt influx was seen (Labotka et al., 
1995). Whether the import of ammonium takes place by free diffusion of 
the gaseous ammonia through the lipid bilayer or whether another carrier 
protein in the RBC membrane is needed, as suggested by Ludewig et al. 
(2001), has to be investigated. 
To investigate whether increased accumulation of ammonium ions takes 
place upon incubation in a solution containing NH4Cl and KHC03, the 
concentration of radioactive intracellular methyl-ammonium was measured 
over time after incubation in a non-lysing isomolar solution with 15.5 mM 
methyl-NH3Cl/2%o14C-methyl-NH3Cl. Indeed, the amount of 14C-methyl-
NHt jNH2 in Rhnull cells increased over time and was two times higher in 
Rhnull cells than in normal RBCs after 30 minutes, which again demon-
strates that the presence of the Rh complex is not a prerequisite for ammo-
nium influx. Since this increased accumulation might be due to a missing 
exporter for 14C-methyl-ammonium in Rhnull cells, the release of radioac-
tivity from 14C-methyl- NHt jNH2-loaded RBCs was measured. Rhnull cells 
of the regulator type showed a low release of 14C-methyl-NHt jNH2 in 30 
seconds compared to an almost complete release in normal RBCs. The 
low release measured in Rhnull cells of the regulator type is probably the 
118 FUNCTION OF THE RH COMPLEX 
gaseous 14CHs-NH2 that can freely diffuse out of the RBCs. An alternative 
explanation might be the presence of an additional ammonia transporter in 
RBCs, which is present in normal RBC as well as in Rhnull cells (Ludewig 
et al., 2001). The release of 14C-methyl-NHt jNH2 by Rhnull cells of the 
amorph type was intermediate after 30 seconds, but increased in 3 minutes 
to an almost complete release. This is most probably due to a decreased 
export capacity by the limited amount of RhAG proteins and/ or due to the 
lack of RhD / CE proteins in the complex. 
The differences in counts measured in the loading and release experi-
ments are not due to differences in residual water between the cell types, 
because the proportion of contamination of external medium in the RBC 
pellet between the different RBC types is comparably low. 
To show that the Rhnull cells, except for (methyl-) ammonium trans-
port, behave normally in transport processes, the export of other radioac-
tive molecules was also measured. Neither 14C-benzylamine nor 14C-urea 
showed increased uptake in Rhnull cells compared with normal RBCs. Also 
the release of these radioactive substances from preloaded cells was com-
parable. These results indicate that Rhnull cells do not differ in cell volume 
and surface area from normal RBCs. The Kiddnull RBCs (missing the urea 
transporter Jk (Sidoux-Walter et al., 1999)), used as a control for urea 
transport, did show an increased accumulation of 14C-urea and a decreased 
release, compared with normal RBCs and also Rhnull cells. This implies 
that our methods are capable of measuring impaired transport. 
It has been described that the Kidd protein, after transfection into the 
Xenopus oocyte is involved in import of urea (Sands et al., 1997; Sidoux-
Walter et al., 1999). Also, RhAG transfected into the Xenopus oocyte 
or yeast cell functions as an importer of ammonium (Marini et al., 2000; 
Westhoff et al., 2002). Our experiments with null cells demonstrate that 
both the Kidd protein and the Rh complex in RBCs are involved in the 
export and are not essential for the import of urea and ammonium, respec-
tively. However, possible differences in kinetics of import between normal 
and null cells might have been missed by our technical approach, because 
this process is too fast. 
In RBCs lacking the Rh proteins, completely as in Rhnull cells of the 
regulator type or partially as in Rhnull cells of the amorph type, the trans-
port of NH! is diminished. The Rhnull cells of the amorph type express 
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33-38% of RhAG antigens compared to RhD-positive and RhD-negative 
phenotypes. Because the accumulation in the Rhnull cells of the amorph 
type shows intermediate results in all tests, there may be a dose-dependent 
effect proportional to the amount of RhAG proteins. Whether the poly-
morphic RhD and RhCE polypeptides are similarly involved in NH! export 
cannot be concluded from our experiments. The Rhnull cells of the amorph 
type show that the polymorphic Rh polypeptides are not a prerequisite 
for ammonium transport, but since so far RhD or RhCE polypeptides have 
never been expressed in a complex with a non-functional mutant of the Rh-
family (RhAG, RhBG or RhCG), this question remains unanswered. We 
did not find functional differences between RhD-positive and RhD-negative 
RBCs (data not shown). 
The ammonium transport function of the Rh proteins could serve as a 
protection for the RBC in an environment with high ammonium levels, as 
may be found in the kidney during the excretion of acids. If Rh proteins 
are absent, haemolysis might then occur, as noticed in Rhnull donors. 
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Chapter 6 
General discussion 
The expression of Rh can vary. This thesis mainly involves the RhD pro-
teins with weak expression. A central question in this thesis is whether 
these RhD proteins also have qualitative variations, because then alloanti-
bodies can be formed by weak-D individuals against the normal D antigen 
or against the weak-D antigen by normal D individuals. This would have 
implications for transfusion policy. To investigate qualitative variations, 
knowledge about the tertiary structure of RhD is indispensible. Also in-
sights in the processing of the Rh proteins might give us a clue about the 
genesis and nature of the weak D proteins. The variations of Rh phenotypes 
between ethnic populations is already known, but only speculations can be 
made for the reason of this variation; it might be related to the function 
of Rh. Involvement of the Rh complex in ammonium transport has been 
shown, but the complete process has not been fully elucidated. 
6.1 Variation in expression of Rh antigens 
The RhD-antigen expression varies considerably between individuals, from 
the greatly enhanced expression of the D-- phenotype, via the normal phe-
notypes (in decreasing order: R2R2, R1R2, RlRl, R2r, Rlr) to the weak-D 
phenotypes. Besides quantitative variations also qualitative variations oc-
cur. In qualitative variants (partial Ds), one or more epitopes of RhD 
are missing and the remainder is expressed normally or weakly, whereas in 
purely quantitative variants, all epitopes are considered to be expressed. 
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However, the division between qualitatively and purely quantitatively al-
tered antigens is often not distinct and they are difficult to differentiate, 
especially in qualitatively altered antigens that are weakly expressed. The 
ability to generate alloantibodies against RhD in partial-D phenotypes, but 
not in weak-D phenotypes, is probably the most suitable distinction. 
An example of a variant with weak expression of a qualitatively altered 
D antigen is the DAR phenotype (Chapter 2). This partial D is genotyp-
ically characterised by RHCE-specific nucleotides in exons 4, 5 and 7 and 
is frequently found in African Blacks. Because of its weak expression, this 
RhD variant is also known as weak-D type 4.2.0 (Wagner et al., 2000), 
but the presence of alloantibodies in individuals with the DAR phenotype, 
after transfusion with RhD-positive blood, is the definite proof that DAR 
is also a qualitatively altered antigen. Other proven. qualitatively altered 
RhD antigens with a very weak expression (less than 4000 sites/cell) are 
Dn, Drvt, Drv type III, DVI type 1 and 2, Dvn, DMHI, DHO, DHR and 
DIM (Table 1.1, General Introduction). The distribution of the amino acid 
(aa) alterations over the RhD protein (intracellular or transmembrane vs 
extracellular regions, RhD-specific aa's replaced by RhCE-specific aa's vs 
novel aa's, specifically located in the preserved region of the Rh super fam-
ily or not) is not different from partial-D antigens with normal expression. 
The complete RhD antigen can be very immunogenic for these partial-D 
phenotypes with weak expression (e.g. DVI type 1 and 2) (Lacey et al., 
1983)(Jones et al., 1995). 
Most partial-D antigens are characterised by amino-acid alterations in 
the extracellular domain of the RhD protein. However, in some partial 
D's (DIIIa, Dille, DIII type VI and DAR) amino-acid substitutions are only 
present in the transmembrane or intracellular part of the protein. Because 
individuals carrying these variants are known to produce alloantibodies, it 
can be concluded that epitope loss can be caused by amino-acid substitu-
tions in every part of the protein. The mutations found in the different 
weak-D types are all located in regions of the RHD gene encoding trans-
membrane or intracellular parts of the protein. These mutations might 
cause conformational changes or regions of local unfolding by affecting 
charged residues in transmembrane domains, which break the hydropho-
bicity of the helices (Bonifacino et al., 1991) 
To elucidate whether weak-D phenotypes are purely quantitative vari-
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ants, or whether, besides weak D type 4.2.0 (DAR), also other weak D 
types are due to qualitative variations, was one of the aims of this thesis. 
Besides alloantibody formation, other indications for qualitative variations 
have not been helpful. The Rhesus similarity index (RI), a way to express 
variation among the expression of 59 epitopes measured by flowcytometry, 
was thought to give an indication on qualitative variation. Because in most 
weak D's not all epitopes are expressed in equal amounts, represented by 
a low RI, qualitative alteration of the weak-D protein have been assumed. 
(Wagner et al., 2000). However, our Scatchard plot analysis did not con-
firm qualitative alteration of the weak-D antigen, because the affinities of 
several antibodies tested (directed against different epitopes) for the weak-
D antigen were not significantly different from those for the normal RhD 
antigen (Chapter 3). The same study revealed that the wider variance in 
epitope expression, reflected by a lower RI, is due to differences in affinity 
of the antibodies. This was concluded from the observation that MoAbs 
with equal affinities for the RhD antigen demonstrated equal epitope ex-
pression, whereas MoAbs with large differences in affinity demonstrated 
similarly large differences in epitope expression. Therefore, the RI does not 
merely reflect qualitative changes of the RhD antigen. 
By expressing weak-D mRNA in K562 cells, we clearly found that the 
mutations in individuals with the weak-D phenotypes are indeed responsi-
ble for the weak expression of RhD (Chapter 4). The query then was how 
these mutations lead to a reduced expression of RhD. Weak-D mutations do 
not involve the amount or stability of the RHD mRNA, as we have shown 
by RQ-PCR in both RBCs and K562 cells. Weak-D mutations also do not 
lead to obvious qualitative alterations of the weak-D antigen, as we have 
shown by Scatchard plot analysis on RBCs (Chapter 3). Subsequently, we 
investigated whether the weak-D point mutations might affect the forma-
tion of the Rh complex or the integration of the RhD polypeptide into the 
membrane without conformational changes in its extracellular loops. 
Weak-D proteins that are not properly processed for integration into 
the membrane will be degraded by proteasomes. Inhibition of these pro-
teasomes with Lactacystin would then lead to intracellular accumulation 
of RhD proteins. However, in our K562 model no increase in intracellular 
RhD, weak-D type-1 or weak-D type-3 protein was observed by flowcytom-
etry after incubation with the proteasome inhibitor Lactacystin (Chapter 
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4). To circumvent the possibility that the MoAb LOR15C9 is unable to 
recognise unprocessed weak D, a K562 model was created expressing GFP-
fusion proteins. The RHD-GFP, the weak-D type-1-GFP and the weak-D 
type-3-GFP fusion proteins were recognized by membrane localization of 
GFP and by co-localization of RhD with GFP. But again, no increase in 
intracellular expression of GFP was observed by flowcytometry and con-
focal microscopy after inhibition of the proteasome activity. Nevertheless, 
the misfolded or uncomplexed protein hypothesis should not immediately 
be rejected, because the approach to prove the hypothesis might not be 
right. The GFP-tag has the same size as the Rh protein, possibly leading 
to a change in conformation or processing of the fusion protein. Also the 
use of an artificial promotor and K562 cells that do not resemble RBCs in 
all characteristics could be a point of concern in this approach. 
The existence of phenotypes with qualitatively altered RhD antigens 
with low expression raises some questions concerning their genesis. When 
the partial D antigen is due to more than one amino-acid change (e.g. DIVb, 
D1v type III, DVI type 1 and 2, DAR), then one amino-acid change may 
cause the conformational change, while another one may affect the pro-
cessing of the protein to the membrane. But in case only one amino-acid 
change causes the partial D (Dvn, DHMI, DHO, DHR, DIM), maybe the 
amino-acid changes in these partial-D antigens do not only influence the 
conformation of the proteins, but also influence the stability of the mRNA 
transcripts or the processing of the proteins that lead to their stable in-
tegration in the membrane. The latter is more plausible because reduced 
stability of RHD mRNA has never been observed. It is remarkable that the 
mutations in the partial-D antigens with weak expression due to one point 
mutation are never located on polymorphic sites, and are thus not replaced 
by RHCE-specific nucleotides, and that they are always located extracel-
lularly (except for DHMI). In contrast, partial-D antigens with normal 
expression always have their mutations on polymorphic sites, and weak-D 
antigens always have intracellular or transmembrane mutations. 
Alloantibody formation in individuals with a variant-RhD pheno-
type. Until now, no alloantibodies have been found in individuals with 
the most common weak-D phenotypes. This implicates that it is not likely 
that these antigens are qualitatively altered. When individuals with partial 
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D phenotypes are transfused with normal RhD-positive blood, they may 
produce alloantibodies. For carriers of partial-D variants, complete RhD 
antigen might be relatively immunogenic (as with D vr) or less immunogenic 
(as with DAR). New insight in the epitope model provides an explana-
tion for the low immunogenicity of complete RhD in individuals with some 
variant-RhD antigens. The conventional idea was that epitopes overlap 
but are spatially different. Chang et al. (1998) proposed a completely new 
model in which epitopes do not spatially differ, but differ only in number 
and arrangements of contact residues present (Figure 6.1). In other words, 
the footprints of most, if not all, anti-D antibodies are essentially identi-
caL They came to this model by analysing anti-RhD antibodies that were 
obtained by a Fab/phage display-based method, using a library made from 
peripheral blood. Detailed analysis of randomly selected clones revealed 
that, whereas the clones had a specificity for at least half of the major 
RhD epitopes, in all clones only four closely related heavy-chain germline 
genes were used (VH3-33 superspecies) and nearly all V k light chains were 
derived from one germline gene (DPK9). This new model suggests that in 
the alloimmune response against RhD, similar and restricted pathways are 
used in different individuals. It is tempting to speculate that, for example, 
in the partial-D variant DAR, the apparently low immunogenicity for the 
complete antigen is due to the fact that the most common pathway could 
not be used, because these B cells have been clonally deleted or have be-
come anergic to avoid self-reactivity. Probably, in those individuals with 
the DAR phenotype who did make alloantibodies, a less common pathway 
has been used to produce the anti-D (Chapter 2). 
The mechanism for low immunogenicity, as described above for the DAR 
phenotype, might also account for the weak-D phenotype, and for that 
reason we cannot exclude that weak D might be a qualitatively altered 
antigen. 
To elucidate whether specific parts of the RhD allele are provoking an 
alloimmune respons, Stott et al. (2000) investigated the helper response 
that drives the production of alloanti-D. They studied the proliferation 
of peripheral blood mononuclear cells (PBMCs) from RhD-negative in-
dividuals who developed alloanti-D upon stimulation with a panel of 68 
overlapping synthetic 15-mer peptides, spanning the complete sequence of 
the RhD protein. The number of peptides that induced a proliferative re-
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Figure 6.1: : Models for RhD antigen/ antibody binding. 
Conventional model (A) and model proposed by Chang et al. (1998) (B).The conventional 
model shows spatially different epitopes, while the proposed model only differs in number 
and arrangement of contact residues presented. In the proposed model of Chang et al. a 
genetic relationship between the antibodies can be expected. 
sponse was unrelated to either the frequency of, or the time since, exposure 
to RhD-positive RBCs, but seemed to be strongly correlated to the level of 
alloanti-D antibodies. The identification of alloreactive T-cell epitopes on 
the Rh protein showed that not only extracellularly located RhD sequences 
stimulate T-cells from alloimmune donors. Most peptides contained RhD-
specific polymorphisms, but also responses to peptides that are identical in 
RhD and RhCE were observed. This could be explained by a difference in 
processing between RhD and RhCcEe proteins by the antigen-presenting 
cells (APCs). If so, highly stimulatory peptides, although not containing 
RhD-specific polymorphisms, are only generated from the RhD protein. 
From this study, it can be concluded that also the T-cell epitopes (15-
mer peptides) in which the amino-acid substitutions of the weak-D antigens 
are located, can be very alloreactive to PBMCs. Thus, this cannot be the 
reason that no alloantibodies have been found in individuals with the weak-
D phenotype. 
6.1. VARIATION IN EXPRESSION OF RH ANTIGENS 129 
Tertiary structure of the RhD protein. To investigate the tertiary 
structure of the RhD protein, the patterns of RhD-epitope expression have 
been related to the regions of RhD amino-acid alterations in the partial-
D phenotypes (Scott et al., 1996), (Cartron et al., 1996). Approximately 
five to eight amino acids are usually critically involved in determining a 
protein epitope, although a further ten amino acids may interact with the 
antigen-binding site of an antibody (Crumpton, 1974), (Amit et al., 1986), 
(Van Regenmortel et al., 1988). Epitopes are formed on a sequential run 
of amino-acid residues along a protein chain, or composed of amino acids 
drawn from different parts of the polypeptide chain that are brought to-
gether by the conformational folds in the tertiary structure of the protein 
(Atassi et al., 1978). The use ofpartial-D antigens to assess information on 
the tertiary structure of RhD can never be absolute, because the majority 
of partial-D phenotypes are knock-outs, in which loss of RhD epitopes is 
observed. Additional information will be obtained with a knock-in model, 
because most partial-D phenotypes are a combination of mutations in dif-
ferent loops. Also, only a limited panel of partial-D phenotypes is provided 
by nature. It cannot be assumed that the molecular changes associated 
with the epitope deficiency are directly responsible for their expression. 
Changes in one region of the RhD protein may affect other domains, and 
the substitution of amino acids for others with different size or charge may 
significantly alter RhD presentation. 
To study the role of various amino acids in RhD-epitope presentation, a 
method in which RhD-specific amino acids were introduced by site-directed 
mutagenesis into an RhcE protein (knock-in phenotypes) has been de-
scribed by Avent et al. (2000) The 3rd, 4th and 6th extracellular loops were 
introduced, because only these loops comprise RhD-specific sites. With the 
results, a model was proposed for the arrangement of the RhD protein in 
the RBC membrane (Figure 6.2). This model takes into account that the 
possible physical size of an anti-RhD paratope is not more than 20 A in 
diameter. It was assumed that loops 3 and 4, as well as 4 and 6, must 
be in close proximity, whereas loop 3 and 6 are non-adjacent, because no 
RhD epitopes are dependent on this structure. The model proposed the 
localisation of six different RhD epitope clusters. Epitope 3 and 9 require 
RhD-specific sequences on exofacialloop 6 (cluster A), and possibly epitope 
4 also requires loop 6 (cluster E). The expression of epitopes 5 and 6/7 is 
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dependent on a combination of loop 3 and 4 (cluster F). The expression 
of epitope 5 is dependent on loop 4 and 6 (cluster B). The expression of 
epitope 2 (partly), 5 and 6/7 is dependent on loop 3, 4 and 6 (cluster C). 
Expression of epitope 1, part of 2 and the complete epitope 8 is lacking in 
this modeL This was due to the c-critical residue Pro-103, because K562 
cell lines expressing an RhD-CE(loop 2,3,4,6)-D hybrid containing Ser 103 
did express epitope 8. This model is entirely consistent with the known 
partial-D variants and will be useful until high-resolution three-dimensional 
structures of RhD-protein crystals are available. 
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Figure 6.2: Diagrammic model of the RhD protein viewed from outside the 
membrane. 
Circles (numbered 1-12) represent membrane-spanning domains, black lines indicate the 
extracellular loops and grey lines represent the cytoplasmatic loops. The proposed local-
isation of the six different epitope clusters are represented by dashed circles. 
The above-presented study shows that the expression of one RhD epi-
tope is dependent on a combination of multiple RhD-specific sequences in 
different parts of the RhD polypeptide. This phenomenon is also observed 
for the epitopes VS (RH20) and V (RH10). The VS and V epitopes, vari-
ants of Rhce, are almost exclusively found in the black African population. 
Anti-VS and anti-V have been found frequently, often in sera containing 
other antibodies, but they have never been reported to be clinically im-
portant. The vs+v+ phenotype is caused by a point mutation in exon 5, 
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nt733 C---tG (aa245 Leu ---tVal), of the RHce allele. An additional muta-
tion in exon 7, nt1006 G ---tT (aa336 Gly---tCys) leads to the loss of the 
V epitope (vs+v-) (Figure 6.3) (Daniels et al., 1998). But the ceAR al-
lele leads to the vs-v+w phenotype. This allele is characterised by an 
RHCE-D-CE gene, with nt733 C---tG and additional mutations in exon 5 
and 6 (nt712 A---tG, nt787 A---tG, nt800 T---tA and nt916 A---tG) (Chapter 
2). Probably, the amino-acid change aa245 Leu---t Val, in the surrounding 
of RHD polymorphic sites, does not give rise to the VS epitope, although 
it still contributes to the expression of the V epitope. 
VS-V-
VS+V+ 
VS+V-
5' 
1 
RHCE 
ex on 
3 
10 
Figure 6.3: Representation of the 10 RHCE exons of several VS/V pheno-
types. 
Codon 245Val ( exon 5) gives rise to the vs+v+ phenotype. Codons 245Val and 336Cys 
( exon 7) give rise to the vs+v- phenotype. Codon 245Val surrounded by co dons 238Val, 
263Gly and 267Lys (exons 5 and 6) gives rise to the vs-y+w phenotype. 
Different roles for RhAg and RhD /RhCcEe in the processing of 
the Rh complex- RhD /RhCcEe and RhAg appear to be both necessary 
for the surface expression of the Rh complex, but they differ notably in 
the factors that determine their cell-surface expression. Whereas RhD and 
RhCcEe have never been found in the absence of RhAg, RhD /RhCcEe 
might be partially dispensable for the routing of RhAg to the membrane. 
This can be concluded from four observations: i) a significant level of RhAg 
is still expressed on the RBC surface in Rhnull RBCs of the amorph type 
(Cherif-Zahar et al., 1996), ii) a significant level ofRhAg is still expressed on 
K562 cells that display no or very low amounts of RhD/RhCcEe (Anstee 
et al.,1992), (Suyama et al., 1994), (Cherif-Zahar et al.,1998), iii) RhAg 
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is expressed before RhD and RhCcEe during differentiation of erythroid 
progenitors in vitro (Bony et al., 1999), (Southcott et al., 1999) and iv) 
evolutionary, RHD and RHCE are probably derived from RHAG (Carrit et 
al., 1997). 
RhD and RhCcEe might be involved in the stability of RhAg once ex-
pressed at the cell membrane, rather than in the dynamic translocation pro-
cess of RhAg towards the membrane. This can be concluded from the fact 
that the membrane instability of RhAg in the absence of RhD /RhCcEe is 
not observed in nucleated cells, presumably because of the constant neosyn-
thesis of the RhAg polypeptide in these cells (Mouro-Chanteloup et al., 
2002). However, the underglycosylation of RhAg in Rhnull cells suggests 
that the transit time of RhAg in the Golgi might also be regulated by 
RhD /RhCcEe (Ridgwell et al., 1994). 
In contrast to RhD and RhCcEe, RhAg is not known to be polymorphic. 
That is, no alloantibodies have been found against polymorphic RhAg epi-
topes. The only mutations of the RHA G gene that have been found result 
in defective membrane expression of RhAg in Rhnull individuals (Cartron, 
1999), (Huang et al., 2000), (Huang, 1998), (Cartron, 2000), (Huang et 
al., 1997). This is due to one of the following mechanisms: i) the muta-
tions in RhAg result in the absence or instability of the mRNA transcript, 
due to aberrant splicing, and the RhAg protein cannot be formed. ii) the 
mutations cause a premature stopcodon, most often leading to diminished 
mRNA levels, but if translated, the predicted RhAg mutant is a truncated 
polypeptide, rapidly degraded in the ER. Or iii) the mutations alter the 
conformation required for the assembly and/ or intracellular transport of 
the protein to the membrane. This last possibility has been deduced from 
6 patients with missense mutations (Mli; S79N; V270I & G280R; G279E; 
G380V and D399Y) in RhAg, in whom both RhAg and RhD /RhCE are 
expected to be produced. Examples of this third hypothesis have been 
observed for other cell surface molecules, such as Cystic Fibrosis trans-
membrane regulator protein (CFTR) and Aquaporin-2 (AQP-2) (Cheng et 
al., 1990), (Deen et al., 1995). 
Clinical implications for blood-transfusion policy. If the weak-D 
phenotype is solely characterized by quantitative variations, individuals 
carrying this phenotype can be considered as RhD positive. Our results do 
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not indisputably prove that there are not qualitative alterations of the weak-
D antigen, but show that there are no hard indications for their existence. 
With Scatchard plot analysis we demonstrated that the Rhesus similarity 
Index (RI) is not the right tool for determining qualitative differences, 
especially not for phenotypes with a low number of antigenic sites. 
Therefore, a transfusion policy should be recommended in which not 
only donors but also recipients with the weak-D phenotype should be con-
sidered as RhD-positive. Also, antenatal immune prophylaxis should not 
be recommended for women with the weak-D phenotype. In this regard, 
it is important to mention that, with sensitive techniques and monoclonal 
antibodies, weak-D phenotypes are nowadays often typed as normal RhD 
positive. We observed, by serological screening for weak-D donors among 
the donors of the Sanquin Bloodbank Region Southwest that the distribu-
tion of the different weak-D types was not as expected from the genomic 
population study of Wagner et al. (1999) in Germany. This led us to con-
clude that only the weaker weak-D types are still recognized by serological 
screening. In our group, the weak-D type 2 (rv500 sites/cell) is more fre-
quently observed than weak-D type 1 (rv1300 sites/cell) (61% vs 30%), 
although weak-D type 1 was far more common in the German study (18% 
weak-D type 2 vs 70% weak-D type 1). Thus, although the most com-
mon weak-D type 1 is mostly typed as RhD positive, this has not led to 
alloimmunisation in individuals with this phenotype. This indicates that 
the immunogenicity of normal RhD antigen in these donors is extremely 
low, otherwise immunisations would have been observed. By typing the 
partial-D phenotype R0 Har as normal RhD-positive, alloimmunisations did 
occur. 
Partial-D types with weak expression (such as DAR = weak-D type 
4.2.0) need to be distinguished from the normal RhD-positive phenotypes, 
and transfusion policy or antenatal prophylaxis should be adjusted accord-
ingly, because alloimmunisation may occur. 
Variations between various ethnic populations. Many RhD variants 
are more frequently found in certain ethnic populations. The DAR pheno-
type (Chapter 2) is frequently occurring in African Blacks (1.6%), but this 
phenotype has not yet been identified in other populations. About 0.2-1% 
of the Caucasians express the weak-D phenotype. The allele frequency of 
134 DISCUSSION 
the weak-D phenotypes is about 0.0025-0.0125. Probably, weak-D alleles 
do not occur with this frequency or even at all in African Blacks or Asians. 
However, it cannot be excluded that weak-D phenotypes are disguised by 
the presence of an RhD-positive allele, abundantly found in these popula-
tions. 
It has been suggested that distinct differences between the various pop-
ulations and the great diversity of RhD variants in the African population 
are due to major population events. Diversity is influenced by several fac-
tors, such as natural selection, population admixture, recombinant and gene 
conversion, population size and demographic structure. Starting from the 
idea that the world population originated in Africa some 200,000 to 100,000 
years ago, small fractions of this African population dispersed to other parts 
of the world about 50,000 years ago. (Wright et al., 1999). These small 
fractions of founders are the starting points of new populations. Because 
these populations were very small, they determine most of the haplotypes 
that exist today. A second important population event for Northern Eu-
rope is the time period of the last ice age (30,000 till 15,000 years ago), 
with subsequent recolonysation by small numbers of founders. Again a 
bottleneck, explaining the high incidence of certain RhD phenotypes (such 
as RhD negativity) in this population (Reich et al., 2001). 
But, of course, it might also be that a certain RhD phenotype has re-
sulted in an evolutionary benefit. An example of selective advantage of 
a blood group is found in individuals with the Duffy phenotype Fy(a-b-), 
often Blacks who are resistent to tertian malaria, because the Plasmodium 
vivax parasite is unable to invade the RBC with this phenotype. (Miller 
et al., 1976) Another example of balanced genetic polymorphism is sickle 
cell haemoglobin (HbS), characterised by an amino-acid substitution in 
the beta-globin molecule (/36 Glu---+ Val). Many epidemiologic studies have 
shown that HbS is common in areas of Africa with a high incidence of 
Plasmodium falciparum. Malaria is seldom found in carriers of the sickle 
cell trait, which suggests that this genetic determinant imparts a selective 
advantage to people living in areas where the parasite is common. Further-
more, in vitro studies have shown that at oxygen tensions similar to those 
in tissue, the parasite grows poorly in RBCs with HbS. 
Now that the ammonium-transport function of Rh has been demon-
strated, we can postulate that trivial changes in the Rh complex caused by 
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mutations in the RH genes might result in an altered ammonium concen-
tration within the cells, which might affect the suitability of the cells as a 
host for certain pathogens. In this way, an evolutionary balance between 
the pathogen and its host could be responsible for the high level of Rh 
polymorphism. 
6.2 Function of the Rh complex 
For a long time, the function of Rh has remained a mistery. The predicted 
topology of the Rh proteins in the cell membrane (polytopic, with cyto-
plasmic N- and C-termini and N-glycan on one of its extracellular loops 
[for RhAg]) is characteristic for membrane transporters. Rapid progression 
in understanding the fuction of Rh was made when the non-erythroid Rh 
homologues RhBG and RhCG were identified and ammonium transport by 
RhAg and RhCG was observed in yeast cells. 
We have shown that the Rh complex is involved in the export of am-
monium from human RBCs (Chapter 5). This was concluded from differ-
ences between RBCs with various phenotypes in the uptake and release of 
a radiolabelled analogue of ammonium. Rhnull cells of the regulator type 
(expressing no Rh-complex proteins) accumulated significantly higher lev-
els of radiolabelled methyl-ammonium ions than did normal RBC. This 
accumulation was due to a decreased export, as was shown by a signifi-
cantly reduced release of intracellular radiolabelled methyl-ammonium ions 
by Rhnull cells of the regulator type. However, the more problems have 
been solved, the more questions can be raised about the function of Rh, 
for instance i) What is the impact of mutations in the preserved regions of 
the Rh homologues on their function? ii) How is the energy provided for 
the transport function? iii) Is RhAg or RhD /RhCcEe responsible for the 
ammonium-transport function? And iv) might other ions than ammonium 
ions be the target molecules for Rh? 
i) Similarities of Rh with the ammonium-transport family. As de-
scribed in the general introduction, DNA sequencing has revealed that the 
erythroid Rh homologues and non-erythroid homologues are related to the 
family of ammonium transporters (Marini et al., 1997). The expansion of 
the Rh family during mammalian evolution implies two possible outcomes 
136 DISCUSSION 
with regard to their specification. Either they serve to transport the same 
or similar ligands, but differ in kinetics and regulatory modes, or they may 
each perform a completely different function (Liu et al., 2001). The latter 
is less likely, considering the remarkable evolutionary conservation of the 
entire Rh family (Figure 6.4). 
A relatively high extent of homology is found between the Rh homo-
logues, with 184 (38%) of the 480 amino acids well preserved. These pre-
served amino acids are mainly located in the transmembrane areas (109 
amino acids of the 184). And although RhCcEe has more resemblence to 
RhAg than RhD, RhD has less amino-acid alterations in the preserved re-
gions of RhAg, RhBG and RhCG than has RhCcEe. Of the 35 amino-acid 
differences between RhCcEe and RhD, 11 amino acids of RhCcEe have a 
change of property in the preserved regions (11 of the 35 = 31%). Change of 
property means a change in the amino-acid properties: hydrophilic, acidic, 
amido, aromatic, basic, hydroxyl containing, proline and sulphur contain-
ing. In contrast, only 2 of the amino acids of RhD have a change of property 
in the preserved regions (2 of the 35 = 6%). The 24 amino-acid differ-
ences that have been found in the 22 different weak-D gena/phenotypes 
are mainly located in the preserved regions of the Rh homologues (13 of 
the 24 = 54%). Mutations in the preserved areas might have more effect 
on the processing, conformation or function of the protein. Thus, RhD 
might have a higher resemblance to an ammonium transporter than does 
RhCcEe. 
ii) Energy supply of the transport process. The Rh complex is able 
to export ammonium ions from human RBCs against a concentration gra-
dient, because no clear difference was observed between the release of 14C-
methyl-NHs+ from loaded cells, whether NH4Cl was present extracellularly 
or not (Chapter 5). This thermodynamically uphill transport requires en-
ergy. We do not know whether the Rh complex uses energy directly derived 
from ATP hydrolysis. The Rh proteins do not belong to the family of ATP-
binding-cassette transporters and, so far, there are no indications that it 
can function as an ATPase. 
Many active transport processes are not directly driven by the hydrol-
ysis of ATP. Instead, the uphill transport of an ion or molecule is often 
coupled to the downhill flow of another ion. So, in RBCs, energy to ex-
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port ammonium might be derived from coupled ion transport such as Na+-
antiport. 
iii) Difference in function for RhAg and RhD? RhAg bears a 
greater resemblance to both primitive and non-erythroid Rh homologues 
and therefore bears a greater resemblance with the Mep/ Amt (methy-
lammonium permeases / (methyl-) ammonium transport) family than do 
RhD /RhCcEe. RhD and RhCcEe most likely originated from an RhAg-
like ancestor. Comparison of the orthologues in various species shows less 
sequence conservation in genes encoding RhD /RhCcEe than in genes encod-
ing RhAg, indicating that the latter may provide a more basal physiological 
function (Matassi et al., 1999). 
RhAg on its own is able to export ammonium ions, as we showed with 
RBCs of the Rhnull amorph phenotype. Whether RhD and RhCcEe also 
function as an ammonium transporter in RBCs cannot be concluded from 
our study, because RBCs with expression of RhD and/ or RhCcEe without 
RhAg do not exist. Because no difference was observed in the transport 
of ammonium between RBCs with or without expression of RhD (RhD 
positive vs RhD negative), or with or without the expression of RhCcEe 
(RhD positive and RhD negative vs D-- , unpublished observations), it can 
be excluded that RhD and/ or RhCcEe play a major role in the transport of 
ammonium ions. Maybe RhD and/or RhCcEe are involved in transport of 
other N-containing substances. Transport experiments we performed with 
other N-containing substances, such as benzylamine (C7HgN-HCl), aniline 
(C5H7N-HCl) and dapsone (4,4-diaminodifenylsulfon, a drug used for M. 
leprae, P. carinii, chloroquine-resistant malaria, Dermatitis herpetiformis 
and Polycytemia vera) did not demonstrate involvement of the Rh complex 
(unpublished observations). 
As suggested before, the polymorphic character of RhD and RhCcEe 
and the great phenotypic differences between ethnic populations, suggest 
a transport function of ammonium or another molecule that needs adapt-
ability. 
Figure 6.4: Alignment of the Rh homologues. 
The amino-acid sequences of erythroid Rh homologues: RhD (with the different weak-D types), 
RhCcEe, and RhAg and of the non-erythroid Rh homologues RhBG and RhCG are aligned. The 
localisation of the amino acids is indicated above the RhD sequence by a line (intracellular), a 
double line (transmembrane) or no line (extracellular). Preserved regions of the Rh homologues 
are marked in dark grey (identical amino acids) or in light grey (amino acids with the same property) 
A change in (property of) amino acids in the preserved regions of the Rh homologues is marked in 
black. 
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iv) Transport of C02 by Rh. It has been hypothesised that the 
molecule to be transported by Rh proteins is C02 rather than NH3, given 
the distribution of Rh proteins among organisms and the organ and tissue 
distribution among animals (Soupene et al., 2002). This speculation was 
tested by Soupene et al. with the green alga Chlamydomonas reinhardtii, 
a photosynthetic microbe containing endogenous RH genes. The RH genes 
Rh1 and Rh2 of C. reinhardtii have a sequence identity with RhAG of 32.3 
and 31.8% respectively. The expression of the RH1 gene seemed to be 
upregulated in air supplemented with 3% C02 and downregulated in air 
supplemented with 0.035% C02. The amount of carbonic anhydrase varied 
in the opposite direction. From this observation, the authors concluded 
that Rh proteins might be biological gas channels for C02. However, by 
measuring the expression levels of certain proteins in response to a stimu-
lus, an indirect effect may be observed. In the ammonium transport model 
(Chapter 5), the extracellular C02 concentration may also have implica-
tions for the expression of Rh, but via NH!; Extracellular C02 may, via 
passive diffusion, increase the concentration of intracellular C02, which be-
comes HC03 with OH- derived from H20. The H+ from H20 will form 
NH! with intracellular NH3 and shall be exported by the Rh complex. The 
increased export may lead to increased expression of Rh proteins. This in-
direct correlation was confirmed by the observation that upregulation of 
Rh only occurred when NH4Cl was used as a nitrogen source (Soupene 
et al.,2002). The downregulation of carbonic anhydrase I expression un-
der hight levels of C02 seems contradictory, but no information was given 
about the expression of the iso-enzyme carbonic anhydrase II, widely dis-
tributed and responsible for the highest turnover of C02 hydration (Sanyal 
et al., 1981). Soupene's study also included ammonium transport experi-
ments, in which the authors did not observe intracellular accumulation of 
14C-methylammonium when the algae were grown under conditions with 
N~Cl and high C02. This can easily be explained by the increased Rh ex-
pression under these conditions: the increased export capacity is sufficient 
to avoid accumulation of 14C-methylammonium. This study of Soupene et 
al. does not convince us that the target molecule for transport by the Rh 
complex is C02 rather that NH! jNH3. 
Bruce et al. (2003) also comply to the supposition that Rh is involved in 
C02 transport. They state that the presence of all components within the 
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band-3 macrocomplex render it likely that the individual components have 
linked functional or regulatory roles. They state that, since bicarbonate is 
transported through band 3 to leave the cell in exchange for chloride, this 
e:ffiux acidifies the cell and causes release of 02, and thus link is provided 
between coordinated C02 uptake and 02 release. But this argument that 
the structural macrocomplex is formed because of its functional roles can 
also be used for ammonium transport. Band 3 also plays a role in the export 
of ammonium, since band 3 exports bicarbonate and therefore indirectly 
stimulates that NHs is protonated to NHt. 
In conclusion, as long as the function of RhD in the RBC is unknown, 
it will be difficult to answer the question whether there has been an evo-
lutionary benefit of the RhD-negative phenotype, let alone of the weak-D 
phenotype. The increased prevalence of RhD negativity in Caucasians, 
compared to Blacks and Asians might suggest a functional role. Although 
a founder effect in Caucasians cannot be excluded, the (supposed) increased 
prevalence of weak D in Caucasians might argue against this. 
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Appendix 
Amino acid 1-letter 3-letter codons property 
code code 
Alanine A Ala GCU GCC GCA GCG hydrophobic 
Arginine R Arg CGU CGC CGA CGG AGA AGG basic 
Asparagine N Asn AAU AAC amido 
Aspartaat D Asp GAU GAC acidic 
Cysteine c Cys UGU UGC sulphur containing 
Glutamaat E Glu GAA GAG acidic 
Glutamine Q Gin CAA CAG amido 
Glycine G Gly GGU GGC GGA GGG hydrophobic 
Histidine H His CAU CAC basic 
Isoleucine I lie AUU AUC AUA hydrophobic 
Leucine L Leu UUA UUG CUU CUC CUA CUG hydrophobic 
Lysine K Lys AAA AAG basic 
Methionine M Met AUG sulphur containing 
Phenylalanine F Phe uuu uuc aromatic 
Proline p Pro CCU CCC CCA CCG proline 
Serine s Ser UCU UCC UCA UCG AGU AGC hydroxyl containing 
Treonine T Thr ACU ACC ACA ACG hydroxyl containing 
Tryptophan w Trp UGG aromatic 
Tyrosine y Tyr UAU UAC aromatic 
Valine v Val GUU GUC GUA GUG hydrophobic 
stop UAA UAG UGA 
start AUG 
Table 1: Amino acids 
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nt RHD: 
RHC: 
aa RhO: 
RhCEc: 
RhcEc: 
nt . RJID: 
RHc; 
aa RhD: 
RhCEc: 
RhcEc: 
nt RHD: 
RHc; 
aa RbD: 
RhCEc: 
RhcEc: 
nt RHO: 
RHc: 
aa RhD: 
RhCcEc: 
nt RHD: 
RHc: 
aa RhD: 
'RhCcE: 
RhCce: 
nt RHD: 
'RHc: 
aa RhD: 
RhCcEc: 
nt RHO: 
RI-le: 
RhCcEe: 
nt RHD: 
,RHc: 
aa RhD: 
RhCcEc: 
exon\ 
ATG ACG TCf AAG TAC CCG CGG TCT GTC CGG 
lottacellulur 
Tmnsmcmbmne domain 2 
v v 
1oop2 
APPENDIX 
CGC TGC CfG CCC ere TGG: GCC CTA AC\' CTG GAA GO\ GCT CfC ATI 
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Tmnsmcmbrune domain I 
c:-;on3 
T A l 
':.T ATI CGG CTG GCC' ACC ATG AGT,' GCT TTG TCG GTG CTG ATC 
M 
M 
Trun~mcmbmne domain 4 
GGC MC CTG AGG ATG GTC ATC AGT AAT ATC, TIC AAC 
ACC 
"" 
0 N M v ! N N Y V F 
T 
Extruce!lulur 1oop3 Trunsmcmbn 
cxon5 
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""" 
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W N 
Extrn.cellulur loop 6 
APPENDIX 
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Figure 1: Rh sequence. 
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The RHD allele sequence (exon borders indicated, alternating in black and grey) and 
amino-acid sequence (localisation in the membrane indicated; where the precise topology 
of the protein in the membrane is not known, indicated by a question mark). Differences 
in the sequence for RHCE allele are shown below the RHD sequence. 
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American English Numerical 
RhD positive Ro cDe RH 1,2,-3,-4,5 
R1 CDe RH 1,2,-3,-4,5 
Rz cDE RH 1,-2,-3,-4,5 
Rz CDE RH 1,-2,-3,-4,5 
RhD negative cDe RH -1,-2,-3,4,5 
I CDe r RH -1,2,-3,-4,5 
cDE RH -1,-2,-3,4,-5 
ry CDE RH -1,2,3,-4,5 
No. CDE Rh-Hr 
RH1 004001 D Rho 
RH2 004002 c 
I 
r 
RH3 004003 E rh" 
RH4 004004 c hr
1 
RH5 004005 e hr" 
Table 2: Rh nomenclature 
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Summary 
The Rh blood group system is invloved in haemolytic disease of the new-
born, transfusion reactions and autoimmune haemolytic anaemia. The Rh 
system comprises the RhD and RhCcEe polypeptides. RhD is of most 
clinical importance, because of its high immunogenicity. The Rh polypep-
tides are encoded by two highly homologous genes: RHD and RHCE. The 
RhD-positive phenotype is determined by the presence of one or two RHD 
gene(s). The Rh polypeptides have twelve transmembrane spanning do-
mains, with the -NH2 and -COOH termini oriented to the cytoplasm. The 
Rh complex consists of a tetramer with two RhD /RhCcEe molecules and 
two RhAg (Rh-associated glycoprotein) molecules. Several membrane gly-
coproteins such as LW, CD47 and GPB are associated with the Rh complex. 
The Rh complex is attached to the RBC cytoskeleton via CD47, protein 
4.2 and band 3. The Rh-deficiency phenotype (Rhnull of the regulator type) 
lacks the expression of the complete Rh complex. The predicted membrane 
organisation of the Rh polypeptides and the genetic similarities of RH with 
ammonium transporters suggest a transport function. 
Variations in RhD expression are either qualitative or quantitative, or 
a combination of these two. RBCs with qualitatively altered RhD antigens 
(partial D) lack or gain RhD epitopes. Individuals with a partial-D pheno-
type are able to form alloantibodies when they encounter the complete RhD 
antigen. RBCs with quantitatively altered RhD antigens have an increased 
or decreased (weak D) expression ofRhD. It is supposed that the conforma-
tion of the weak-D antigen is not altered, since alloantibodies have never 
been found in individuals with the weak-D phenotype after transfusion 
with normal RhD-positive RBCs. In 1999, several mutations (intracellu-
lar and transmembrane) have been found in individuals with the weak-D 
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phenotype. Major differences were observed in the expression level of the 
various RhD epitopes, measured with 59 anti-D MoAbs by flowcytometry, 
in RBCs with the weak-D phenotype (indicated with a low Rh similarity 
index (RI)). Because of the low RI, it was assumed that RBCs with the 
weak-D phenotype express an RhD protein with an altered conformation. 
In this thesis, possible qualitative alterations of the weak-D antigen 
were examined by Scatchard plot analysis. A direct correlation between 
the mutations found in individuals with the weak-D phenotype and the 
lower expression was made, using a transfection model with K562 cells. 
The K562 cell line model was also used to investigate the processing of the 
weak-D antigens in the celL Furthermore, the role of the Rh complex in 
the transport of ammonium was investigated. 
In Chapter 1, a general introduction is given with respect to the bio-
chemical, molecular and functional aspects of the Rh system, and insights 
in protein development of the celL 
In Chapter 2, DAR, a new RhD phenotype with weak expression of 
RhD is described. This new RhD variant is encoded by an RHD gene with 
mutations in exon 4, 5 and 7. Besides the weak expression, the DAR antigen 
is also qualitatively altered. Two individuals with the DAR phenotype 
produced alloantibodies after contact with the complete RhD antigen. The 
DAR genotype is often in linkage with ceAR, a new RHce variant with 
mutations in exon 5 and 6. Both variants have only been described in 
African blacks. The frequancy of the DAR phenotype and genotype is high 
among South African blacks (1.5% and 4.9%). 
In Chapter 3, the weak RhD antigens were closely examined for qual-
itative differences, by Scatchard plot analysis. The affinitiy of all used 
anti-D antibodies was comparable between normal RhD and weak-D RBCs. 
This indicates that the epitopes tested have not been qualitatively altered. 
Affinity differences have been found among the different anti-D antibodies. 
These differences in affinity can explain the differences in the expression 
level of the RhD epitopes measured by flowcytometry (represented by a 
low RI). This suggests that the RI is not only determined by properties of 
the RhD protein but also by properties of the anti-D antibodies. 
In Chapter 4, the weak-D mutations type 1 and 3 were shown to be 
responsible for the lower expression of RhD, in K562 cells transfected with 
DNA encoding normal RhD, weak D type 1 and 3. The processing of the 
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weak-D antigens in the cell was also examined with the K562 transfection 
model. We hypothesized that the weak-D proteins, due to the intracellular 
or transmembrane mutations, were misfolded or unable to form a complex. 
Then, the misfolded or uncomplexed proteins are degraded intracellularly 
by proteasomes. The amount of RhD (and GFP) was measured before and 
after proteasome inhibition, in K562 cells expressing RhD, weak-D type 1 
and 3 and K562 cells expressing GFP-fusion proteins with RhD, weak-D 
type 1 and 3. Unfortunately, no differences in expression were observed 
after proteasome inhibition. Thus, our hypothesis could not be confirmed, 
but that could be due to the techniques we used. 
In Chapter 5, the involvement of the Rh complex in the export 
of ammonium/ ammonia was shown. The uptake and release of 14C-
methylammonium (radioactive analogue of ammonium) in RBCs with the 
Rh complex (RhD positive aud RhD negative) was compared to RBCs 
without the Rh complex (Rhnull cells of the regulator type). Rhnull cells 
accumulate significantly more 14C-methylammonium than do RBCs with 
the Rh complex. This accumulation is due to a decreased release of 14C-
methylammonium. The transport of radioactive urea in Rhnull cells was 
comparable to normal RBCs, indicating that there is no general transport 
dysfunction of the Rhnull cells. Thus, the Rh complex is specifically involved 
in the transport of ammonium/ ammonia. 
In Chapter 6, the General Discussion, the findings described in this 
thesis are considered in perspective of the current knowledge of Rh. 
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Samenvatting 
Het Rh bloedgroepsysteem is betrokken bij de hemolytische ziekte van de 
pasgeborene, bij transfusiereacties en bij autoimmuun hemolytische anemie. 
Het Rh-systeem bestaat uit het RhD-eiwit en het RhCcEe-eiwit. Van 
deze twee eiwitten is vooral RhD van klinisch belang, aangezien dit eiwit 
zeer immunogeen is. De Rh-eiwitten worden gecodeerd door twee zeer ho-
mologe genen: RHD en RHCE. Het RhD-positieve fenotype wordt (meestal) 
bepaald door de aanwezigheid van een of twee RHD genen. De Rh-eiwitten 
hebben 12 transmembraan domeinen, en zowel het NH2- als het COOH 
uiteinde zitten intracellulair. Rh wordt op de rode-bloedcelmembraan 
gepresenteerd als een complex, bestaande uit een tetrameer van twee 
RhD/RhCcEe eiwitten en twee Rh-geassocieerde glycoproteinen (RhAg). 
Ook de eiwitten LW, GPB en CD47 zijn bij dit complex betrokken. Het 
Rh-complex is via CD47 en proteine 4.2 verbonden aan band 3, een eiwit 
dat weer via ankyrine stevig aan het rode-bloedcel spectrineskelet vast zit. 
Bij het Rh-deficientie fenotype (Rhnull van het regulator-type) komt het 
gehele Rh-complex niet tot expressie. De marrier waarop Rh in de rode-
bloedcelmembraan zit en de genetische overeenkomsten van Rh met ammo-
niumtransporters doen een transportfunctie vermoeden. 
De expressie van RhD kan varieren in kwaliteit en/ of in kwantiteit. Bij 
kwalitatieve variaties zijn, door een of meerdere mutaties in het RHD gen, 
epitopen verloren gegaan of nieuwe epitopen ontstaan. Door de confor-
matieverandering van het RhD-eiwit kunnen alloantistoffen gevormd wor-
den na contact met het normale RhD-eiwit. Bij kwantitatieve variaties is 
er alleen sprake van een verlaagde of verhoogde expressie van het RhD-
eiwit. Er wordt van uitgegaan dat de conformatie van het RhD-eiwit niet 
is veranderd; dus alloantistoffen zullen niet gevormd worden na contact 
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met het normale RhD-eiwit. In 1999 werden verschillende mutaties ( alleen 
intracellulair of transmembraan) beschreven die leiden tot het zwakke-D 
fenotype. Het expressieniveau van verschillende RhD-epitopen (gemeten 
met verscheidende anti-RhD antistoffen door mid del van flowcytometrie) 
liet grote verschillen zien op rode bloedcellen met het zwakke-D fenotype 
(uitgedrukt in een lage Rh-similarity-index). Hierdoor werd gesuggereerd 
dat rode bloedcellen met het zwakke-D fenotype toch een RhD-eiwit tot 
expressie brengen, dat een conformatieverandering heeft ondergaan. 
In dit proefschrift wordt onderzoek beschreven naar het effect van de 
mutaties gevonden bij het zwakke RhD op de expressie van dit eiwit. Hier-
voor werd een transfectiemodel van K562 cellen gebruikt. Tevens werd 
onderzocht of deze mutaties naast een effect op de kwantiteit ook kwali-
tatieve veranderingen teweegbrengen. Ook werd getracht uit te zoeken op 
welke marrier de zwakke-D mutaties leiden tot zwakke expressie. Naast 
dit al wordt de betrokkenheid van het Rh-complex in het transport van 
ammonium beschreven. 
In hoofdstuk 1 wordt een algemene introductie gegeven over de bio-
chemische, moleculaire en fuctionele aspecten van Rh. Tevens wordt een 
overzicht gegeven van de posttranslationele veranderingen van een eiwit in 
een eel. 
In hoofdstuk 2 wordt een nieuw RhD fenotype met zwakke expressie 
beschreven: DAR. Deze nieuwe RhD-variant wordt gecodeerd door een 
RHD gen met mutaties in exon 4, 5 en 7 . DAR heeft niet alleen een 
verlaagde expressie, maar mist ook enkele epitopen. Bij twee individuen 
met het DAR fenotype zijn alloantistoffen gevormd na contact met het 
complete RhD-eiwit. Het DAR genotype komt veel voor samen met het 
ceAR gen, een nieuwe Rhce-variant met mutaties in exon 5 en 6. Beide 
varianten zijn tot dusver alleen beschreven bij Afrikaanse negroi:den. De 
frequentie van het DAR fenotype en genotype is hoog in de Zuidafrikaanse 
negroi:de bevolking (resp. 1,5% en 4,9%). 
Voor hoofdstuk 3 werden zwakke-D type 1 en 2 nauwkeurig onderzocht 
op kwalitatieve veranderingen door middel van Scatchard plot analyse. In 
dit hoofdstuk wordt beschreven dat de affiniteit van verschillende anti-D 
antistoffen voor het normale RhD-eiwit en de zwakke-D eiwitten vergelijk-
baar is. Hieruit blijkt dat de epitopen waar deze antistoffen tegen gericht 
zijn niet veranderd zijn bij zwakke RhD expressie. Er bestaan wel grote ver-
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schillen tussen de affiniteit van de anti-D-antistoffen onderling. De grote 
verschillen in het expressieniveau van de verschillende RhD-epitopen die 
gemeten zijn met fl.owcytometrie bij het zwakke-D fenotype (uitgedrukt 
in een lage Rh-similarity-index) worden dus mede veroorzaakt door deze 
verschillen in antistofaffiniteit. 
In hoofdstuk 4 is door middel van het transfecteren van K562 cellen 
met DNA coderend voor normaal RhD, zwakke-D type 1 of 3 bewezen dat 
de mutaties die gevonden zijn bij individuen met het zwakke-D fenotype 
ook daadwerkelijk leiden tot een zwakke expressie. Tevens is een poging 
ondernomen om de ontstaanswijze van de zwakke-D typen 1 en 3 op mole-
culair niveau te doorgronden. We formuleerden een hypothese waarbij de 
zwakke-D eiwitten door de intracellulaire of transmembraanmutatie, fout 
gevouwen worden of geen complex meer kunnen vormen en daardoor intra-
cellulair worden afgebroken. De RhD-eiwitten die wel goed gevouwen zijn, 
of een complex vormen, worden op de rode-bloedcelmembraan tot expressie 
gebracht. Dit zijn er minder dan normaal en daardoor is er een zwakke ex-
pressie. De hypothese werd getoetst door middel van transfectie met een 
fusie van het zwakke-D gen met een gen coderend voor een groen fl.uo-
rescerend eiwit (GFP). Remming van de proteasomen, die foutgevouwen 
eiwitten afbreken, zou volgens de hypothese tot een verhoging van intra-
cellulair GFP moeten leiden. Helaas kon dit niet worden waargenomen, 
hetgeen ook te wijten kan zijn aan de toegepaste technieken. 
In hoofdstuk 5 wordt de betrokkenheid van het Rh-complex bij de 
export van ammonium/ammonia over de rode-bloedcelmembraan aange-
toond. Dit werd gedaan door de opname en uitstroom van 14C-
methylammonium (een radioactieve analoog van ammonium) in rode bloed-
cellen met (RhD-positief en RhD-negatief) en zonder het Rh-complex 
(Rhnun) te meten. Rhnun-cellen namen meer 14C-methylammonium op 
dan rode bloedcellen waarbij het Rh-complex wel tot expressie kwam. 
Deze ophoping werd mede veroorzaakt door een lagere uitstroom van de 
14C-methylammonium. Aangezien het transport van radioactief ureum in 
Rhnun-cellen niet verschilde van 'normale' rode bloedcellen, kan worden 
geconcludeerd dat het hier niet een algemene transportdisfunctie van de 
Rhnun-cel betreft, maar dat het Rh-complex specifiek betrokken is bij de 
export van ammonium/ ammonia. 
In hoofdstuk 6, de Algemene Discussie, worden de bevindingen uit dit 
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proefschrift in een breder perspectief geplaatst, in het licht van de huidige 
kennis van het Rh systeem. 
Dankwoord 
You have brains in your head. 
You have feet in your shoes. 
You can steer yourself any direction you choose. 
You're on your own. And know what you know. 
And you are the one who'll decide where to go ... 
Uit: Oh the places you go (Dr Seuss). 
Maar als AIO sta je zeker niet alleen, heb je alle kennis nodig die er om 
je heen is en bepaal je gezamelijk een lijn in het onderzoek. De mensen 
hieronder zijn van essentieel belang geweest voor de tot standkoming van 
dit boekje. 
Dick van Rhenen, bij deze wil ik je bedanken voor de gelegenheid die je 
me gegeven hebt om dit onderzoek te doen. Ik vind het bijzonder je eerste 
promovendus te zijn. Ik heb zeer van deze periode genoten. 
Ellen van der Schoot, je scherpte, je gedrevenheid, je waanzinnige geheugen 
en je creativiteit zullen weinigen evenaren. Ik heb veel van je geleerd, zoals 
ook het niet onderschatten van mijn eigen mogelijkheden. 
Petra Maaskant-van Wijk, je hebt me ingewijd in Rh en was de brugfiguur 
tussen Amsterdam en Rotterdam. Later hebben we lange, nuttige en gezel-
lige telefoongesprekken gehad. 
Albert von dem Borne, wat vreselijk dat je er niet meer bent. Toen ik co-
assistent was heb jij me gewezen op IH-E. Precies op het moment dat ik het 
nodig had tijdens mijn AIO-periode was jeer met je aanstekelijke enthou-
siasme. Je wist me op een geweldige marrier te stimuleren, door het werk 
wat ik deed in een breder perspectief te plaatsen. Onze werkbesprekingen, 
waar je me vaak voor uit het lab plukte, waren kort, maar zeer leerzaam. 
Ik had dit niet willen missen. 
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Dirk Roos, ik heb veel gehad aanje biochemische kennis bij het onderzoeken 
van de functie van Rh. Je had altijd tijd als ik de resultaten van proeven 
wilde laten zien en over de daarbij behorende conclusies wilde praten. Ook 
voor het kritisch doorlezen van de manuscripten ben ik je dankbaar. Heel 
nauwkeurig nagekeken en heel snel kreeg ik ze terug. Zonder jouw hand 
zou het boekje een stuk minder makkelijk te lezen zijn geweest. 
Bengi, paranimf en lieve vriendin: met jou doe ik al 18 jaar experi-
mentele proeven. Het enige verschil is dat wij de resultaten van ons werk 
zonder enige uitzondering met smaak kunnen opeten. Je hoort zo bij me, 
dat je bijna mijn zusje bent. 
Serge, paranimf en Rh-groep bureau-maatje: na een lange tijd de enige 
AIO van de Rh groep te zijn geweest, kwamen jij en Martine bij de club. 
Onderlinge discussies over Rh en andere belangrijke zaken in het leven, 
maakte het zeer plezierig naar het werk te gaan, zelfs als de experimenten 
niet allemaal wilden lukken. 
Martine, het blijft verwarrend, ben jij nou die AIO uit Rotterdam of ben ik 
het? Onze Rh-groep AIO-bijeenkomsten waren misschien niet heel regel-
matig, maar wel nuttig om inzicht te krijgen in elkaars werk en om domme 
vragen aan elkaar te durven stellen. 
Goedele: dat was perfecte samenwerking. Met weinig woorden en veel 
kleurtjes hadden we genoeg om immense tijdsreeksen foutloos te kunnen 
pipetteren. Jij linkshandig, ik rechthandig, in de koude kamer met (bijna) 
hetzelfde jack aan waren we altijd een team. 
Martijn, als student had je de opdracht de Scatchard plot op te zetten; 
misschien een ondankbare taak, omdat niemand de bijbehorende practi-
sche know-how in huis had. Hoewel je in het begin chaotisch leek, bleek je 
super secuur. Je was ook bereid om het onderzoek, waar je aan begonnen 
was, af te maken, ook al betekende het dat je maanden na jouw laatste 
werkdag nog rond liep. Het heeft een prachtig hoofdstuk opgeleverd. 
Peter (ook al blijf je toch meer Piet): zoveel over de Rh serologie weet nie-
mand. Dank voor het klonteren, meedenken en aanhoren van mijn proeven. 
Dank ook voor de perfect georganiseerde rietjes met ery's en bakjes met 
MoAbs, waar ik altijd een greep uit mocht doen. 
Rob van Zwieten, je zat bij de bron van het onderzoek naar de functie 
van Rh, bij jou kwam ik als eerste met plannen voor -of resultaten van-
deze proeven, omdat ik zeker wist dat je me nooit zou uitlachen en altijd 
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meedacht met de volgende stappen. 
Lotte, Rene en Judith, af en toe waaide ik voorbij met een praatje over 
zwakke D's of de functie van Rh. In het begin deed ik nog wel proeven bij 
jullie; dank dat jullie me bij Rotterdam/Dordrecht lieten horen en -natuur-
lijk- voor het isoleren van DNA/RNA en het doen van de zwakke-D PCRs. 
Esther, jammer dat je naar het AMC bent gegaan. Je hebt mij ingewerkt 
op het Rh-gebied en je was een enorme motor achter het sociale gebeuren 
van de afdeling. Gelukkig gaan wij nog af en toe uit eten en houden we 
elkaar op de hoogte van het wel en wee. 
Toen ik bij de afdeling IH-E kwam werken voelde ik me er direct thuis. 
Het werk was totaal anders dan de co-schappen waar ik net uitkwam, maar 
iedereen was bereid mete helpen met alle praktische problemen. Hier een 
opsomming van een paar van hen. De lijst kan nooit volledig zijn. 
Robin en Jaap, bijna gelijktijdig zijn we begonnen met ons promotie-
onderzoek. Dat schept een band. Successen, diepe dalen, van student tot 
onderzoeker. We hebben er alles aan gedaan om deze periode te rekken, 
maar nu is er toch een eind aan gekomen. 
Claudia, Carlijn en Sonja, jullie waren allang AIO toen ik began (zo voelde 
het). Gelukkig zijn jullie niet helemaal weg nu jullie klaar zijn, want jullie 
horen er voor mij echt bij. 
En dan zijn er nog al die mensen die het lab draaiend houden, en altijd 
alles weten: Bernadette, Eloise, Elsbeth, Erik, Irma, Jan, Jup, Kirsten, 
Mar, Marion, Martin, Masja, Paula, Peter, Rob Dee, Romano, Tinie ..... 
Zander een warm nest kan je niet werken. 
Mascha: Ik zou niet weten hoe het zonder je zou zijn. Ik zou het niet 
eens willen weten. En Michel. Jullie huis voelt als thuis. Met ieder twee 
kinderen (had je me bijna in een klap ingehaald!) zullen we hopelijk net zo 
veel beleven, al zal het waarschijnlijk dichter bij huis zijn (Mexico, India en 
Nepal zijn misschien eerst niet zo geschikt voor vakanties met kinderen). 
Maarten: lekker voor elkaar koken, een film, het Vondelpark of een pop-
concert en elkaar een beetje scherp houden, leuk! 
Solveig, ik ben heel blij dat wij elkaar hebben leren kennen in het practicum-
groepje. Volgens mij hebben we bijna alle co-schappen op dezelfde plek 
gelopen (ik net iets later dan jij) en nu volg ik je weer in de huisarts-
geneeskunde. Later misschien ook onder een HOEDje werken? 
Astrid en Bircan, veel zaterdagen wil ik met jullie in een cafeetje in Haarlem 
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het nog hebben over geneeskunde, de liefde en het leven. 
Hannah, jouw toegewijde liefde en zorg voor Gaya en Tycho maakt het 
mogelijk dat ik me helemaal op mijn werk kan storten. Beter dan de Huzzel 
is niet voor te stellen! 
Bas, lieve broer, veel heb ik aan je te danken. Je directe hulp bij 
statistische vraagstukken (artsen en statistiek. ... ) was significant. We zien 
elkaar niet regelmatig omdat je in Arnhem woont met Carine en jullie lieve 
dochters, Myrthe en Rosa. Ook al wonen jullie daar, jullie blijven toch 
dichtbij. 
Akke en Piet, lieve ouders, er is zoveel waar ik jullie voor zou kunnen 
bedanken: jullie oprechte interesse, aansporing en natuurlijk praktische 
hulp zoals het oppassen op Gaya en Tycho. Het is te veel om op te noemen, 
maar misschien is het enigszins samen te vatten door jullie te bedanken voor 
wie ik nu ben. 
Lieve Onno. Mijn tijd op het CLB was levensbepalend. Dit proefschrift 
is daarin enkel bijzaak. Het zal wennen zijn niet meer samen met je 
naar werk te rijden. Ook de laatste periode waar we regelmatig avonden 
boven half-afgemaakte manuscripten zaten te discusieren, zal ik missen. 
Daarentegen is dat werk maar een fractie van dingen die we met elkaar 
gemeen hebben. Ik hou van je. 
Lieve Gaya & Tycho. De tijd dat jullie er zijn is misschien wel de meest 
vruchtbare wetenschappelijke periode van mijn AIO-schap geweest. Door 
jullie is er een duidelijk verschil tussen inspannen en ontspannen. 
Bij dag en nacht, 
in zon en regen, 
kom je leuke dingen tegen. 
(Stip naar Seuss) 
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groeide op in Amsterdam, alwaar ze in 1990 het VWO diploma behaalde 
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studie geneeskunde aan de Universiteit van Amsterdam. De doctoraalfase 
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op de afdeling Behavioural Pharmacology van de Universiteit van Hera-
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gecontinueerd als promotie onderzoek in samenwerking met het CLB en 
de Bloedbank ZWN Rotterdam ( tegenwoordig: Sanquin Research at CLB 
en Sanquin Bloedbank, regio Zuidwest) metals promotor prof.dr D.J. van 
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